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ABSTRACT
CHARACTERIZATION OF
THE DYRK1A PROTEIN-PROTEIN INTERACTION NETWORK

By
Varsha Ananthapadmanabhan
MS, Human Genetics, Virginia Commonwealth University, 2015
B. Tech., Biotechnology, D.Y Patil University, 2013

A dissertation submitted in partial fulfillment of the requirements for the degree of
Doctor of Philosophy at Virginia Commonwealth University.

Virginia Commonwealth University, 2020

Thesis Director: Larisa Litovchick, M.D., Ph.D.
Associate Professor
Division of Hematology/Oncology and Palliative Care
Department of Internal Medicine

Human Dual specificity tyrosine (Y)-Regulated Kinase 1A (DYRK1A) is a protein kinase
encoded by a dosage-dependent gene. An extra copy of DYRK1A contributes to Down syndrome
(DS) pathogenesis while loss of one allele causes severe mental retardation and autism.
DYRK1A is involved in phosphorylation of several proteins that regulate cell cycle control and
tumor suppression. However, the function and regulation of this kinase is not well understood
and current knowledge does not fully explain dosage-dependent function of this important
kinase. Our previous proteomic studies identified several novel DYRK1A interacting proteins
including RNF169, FAM117B, TROAP, LZTS1, LZTS2 and DCAF7. In this dissertation, we
report the proteomic, biochemical and functional characterization of this DYRK1A protein-

xvii

protein interaction network. Firstly, we show that DYRK1A regulates that recruitment of 53BP1
to DNA double strand breaks (DSBs) in part through its interaction with RNF169. This revealed
a novel role of DYRK1A in DSB repair pathway choice. Secondly, we identify LZTS1 and
LZTS2 as novel regulators of DYRK1A activity towards LIN52. Thirdly, we observed that
DCAF7 interacts with several other DYRK1A-binding proteins including RNF169, TROAP,
FAM117B, LZTS1 and LZTS2 giving rise to various multi-subunit protein complexes, but it
does not act as a scaffold for these interactions. We also observed an unexpected role of
DYRK1A in mediating the interaction between these DYRK1A-binding proteins and DCAF7,
which could explain some aspects of the dosage-dependent function of DYRK1A.
As DCAF7 was the most highly enriched DYRK1A-interacting protein, we generated and
analyzed the DCAF7 interactome in order to understand the functional significance of the
DYRK1A-DCAF7 interaction. We show that DCAF7 interacts with the components of a multisubunit Polycomb Repressive Complex 1.3/5 (PRC1.3/5) independent of DYRK1A, but
DYRK1A could influence the molecular size of the PRC1.3/5 complex. Furthermore, our data
suggest that DYRK1A and DCAF7 regulate the monoubiquitination of H2A at K119 by
PRC1.3/5. Using RNA-seq analysis, we identified a common set of genes regulated by DYRK1A
and DCAF7. Our data shows that DCAF7 requires DYRK1A for its transcriptional effect. Future
studies will be focused to determine the molecular mechanism by which DYRK1A and DCAF7
regulate the transcription of the PRC1.5 target genes.
In conclusion, DYRK1A interacting proteins could regulate the activity and function of
DYRK1A and play a role in its biological functions including tumor suppression, the DNA
damage response and transcription.

CHAPTER 1: GENERAL INTRODUCTION
1.1. The DYRK family
DYRK, or Dual specificity Tyrosine Regulated Kinases, belong to the CMGC group of
eukaryotic protein kinases that includes cyclin-dependent kinase [CDK], mitogen-activated
protein kinase [MAPK], glycogen synthase kinase [GSK3], and CDC-like kinase [CLK] (Aranda
et al., 2011; Hanks & Hunter, 1995). Based on the degree of conservation in their kinase domain,
the DYRK family can be further divided into three sub-families: 1) DYRK kinases 2) PRP4s
(pre-mRNA processing protein 4- kinases) and 3) HIPKs (Homeodomain-interacting protein
kinases) (Figure 1). Out of these, the DYRK sub-family can be further divided into three
branches including 1) yeast kinase Yak1p which has no members in animals; 2) DYRK1 and 3)
DYRK 2. DYRK1 and DYRK2 have members ranging from yeast to humans and are highly
conserved across evolution (Aranda et al., 2011) (Figure 1). Minibrain in Drosophila is the
closest homolog of mammalian DYRK1A (Aranda et al., 2011).
Based on ectopic expression of the DYRK family members in cell lines, they were also classified
as cytosolic kinases (DYRK2, DYRK3, DYRK4) and nuclear kinases (DYRK1A and DYRK1B)
(Becker et al., 1998). However, it has been observed that the endogenous expression of these
proteins varies from this classification. For example, under overexpressed conditions DYRK1A
localizes to the nuclear speckles while endogenous DYRK1A is observed both in the nucleus and
cytoplasm (Álvarez et al., 2003; Hämmerle et al., 2003; Martı́ et al., 2003; Wegiel et al., 2004).
DYRK1B has been found to be predominantly nuclear in some cell lines while it is mostly
cytoplasmic in muscle fibers as well as in rhabdomyosarcoma and pancreatic ductal carcinoma
cells (Friedman, 2007).
1

DYRK1A is the most ubiquitously expressed member in tissues of adult and fetal origin
(Guimera et al., 1999; Okui et al., 1999) while DYRK2, DYRK3 and DYRK4 have limited tissue
distribution (Becker et al., 1998; Sacher et al., 2007).
Structurally, DYRK family members share a conserved kinase domain and an adjacent DYRK
homology domain (DH) but differ more towards the N and C terminal regions (Aranda et al.,
2011). In addition to the conserved catalytic kinase domain, DYRK1A has two nuclear
localization signal sequences (NLSs): a classical bipartite NLS at the N-terminal region of the
protein and a complex NLS within the catalytic domain (Aranda et al., 2011). The kinase domain
is followed by a PEST domain and then by a histidine-rich domain that targets DYRK1A to the
nuclear speckles compartment where it may co-localize with splicing machinery (Figure 2)
(Álvarez et al., 2003; Aranda et al., 2011).
DYRKs phosphorylate themselves on tyrosine (Y) and serine/threonine (S/T) residues but
phosphorylate their substrates only on serine and threonine residues. This is why they are
referred to as dual specificity tyrosine regulated kinases. The Y autophosphorylation in the
activation loop on all DYRKs occurs in cis with translation. Specifically, the phosphorylation on
the second tyrosine (Y) in the YxY motif is required for the activity of all DYRK members
(Himpel et al., 2001; Li et al., 2002; Lochhead et al., 2003). This phosphorylation on DYRK
seems to be constitutive unlike the regulatory phosphorylation on the mitogen-activated protein
kinases (MAPK) (Glenewinkel et al., 2016). Interestingly, in contrast to former observations, it
has been observed that DYRK1A retains its Y phosphorylation ability even after translation
(Walte et al., 2013).

2

Figure 1: The DYRK kinase family.
A) An unrooted phylogenetic tree depicting the evolutionary divergence of the kinase domain in
the DYRK family members. The DYRK sub family has members ranging from yeast to humans.
B) The DYRK sub family members can be classified as Class I and Class II DYRKs. The
percentage of conservation at the protein level between orthologues is indicated above the arrows
and between 2 paralogues is indicated in parentheses within the boxes [Adopted from (Aranda et
al., 2011)].

Figure 2: Schematic representation of the domain structure of the 5 mammalian DYRKs.
Different functional motifs are indicated. Red lines indicate regions of the protein affected by
alternate splicing events [Adopted from (Aranda et al., 2011)].

3

1.2. DYRK1A is a dosage sensitive gene
In humans, DYRK1A protein is encoded by the DYRK1A gene which is located in the ‘Down
syndrome Critical Region’ on chromosome 21 (Korbel et al., 2009; Ohira et al., 1997). Trisomy
of this critical region results in Down syndrome (Korbel et al., 2009; Ohira et al., 1997). It was
suggested that DYRK1A overexpression could contribute to the depletion of neurons in the
developing brain of the DS fetuses either due to the precocious onset of neurogenesis in
progenitors leading to the concomitant depletion of the proliferating progenitor pool or by
inducing a premature cell cycle arrest of the neurogenic progenitors leading to a decrease in the
number of neurons generated by each progenitor (F. J. Tejedor & Hämmerle, 2011). On the other
hand, intragenic deletion or loss of one copy of DYRK1A gene has also been recognized as a
syndrome with characteristic features such as microcephaly, severe mental retardation and
speech impairment (Bronicki et al., 2015; Ji et al., 2015). As both gain and loss of one allele of
DYRK1A results in developmental abnormalities, this gene is highly dosage sensitive. This
dependence on optimum dosage of DYRK1A is conserved across evolution. Mini brain (Mnb) in
Drosophila is the closest homolog of mammalian DYRK1A (Figure 1b) and is involved in neural
proliferation and differentiation in Drosophila. It was observed that flies with a Mnb loss of
function developed a smaller adult brain (Tejedor et al., 1995). Furthermore, in mice,
homozygous deletion of Dyrk1a is embryonically lethal, whereas mice having only one copy of
Dyrk1a have reduced brain size and display specific neurological and behavioral defects and
febrile seizures (Fotaki et al., 2002; Raveau et al., 2018). Moreover, mouse models of Dyrk1a
trisomy recapitulate some of the DS phenotypes (Ahn et al., 2006; Altafaj et al., 2001; F. J.
Tejedor & Hämmerle, 2011). DYRK1A also plays a role in neural stem development and is
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necessary for neurogenesis, neural differentiation, cell death and synaptic plasticity across
different species (Dierssen & de Lagrán, 2006; F. J. Tejedor & Hämmerle, 2011).
1.3. DYRK1A in other neurological diseases
DYRK1A is also implicated in several other neurological diseases like dementia, Alzheimer’s
disease, Parkinson’s disease and Pick’s disease. DYRK1A is one of the kinases responsible for
phosphorylation of α-synuclein which is a candidate biomarker of Parkinson’s disease (PD) (E. J.
Kim et al., 2006; Spillantini et al., 1997). An increase of α-synuclein in the brain, leading to
aggregation and subsequently sequestration in Lewy Bodies, is a hallmark of PD.
Alzheimer’s disease pathology includes amyloid‐β (Aβ) accumulation and hyperphosphorylation
of the microtubule binding protein -Tau (Querfurth & LaFerla, 2010). Hyperphosphorylated Tau
is pathologic and has lesser affinity to microtubules. Pathological Tau forms neurofibrillary
tangles (NFTs) and insoluble inclusions which is a feature of Alzheimer’s disease and other
Tauopathies (Medina et al., 2016). DYRK1A is about 1.5 fold overexpressed in DS (Becker et
al., 2014). Early onset AD is common in DS patients and one possible reason is the
hyperphosphorylation of Tau by DYRK1A (F. Liu et al., 2008; Wegiel et al., 2011). Indeed,
DYRK1A phosphorylates Tau at multiple serine and threonine residues (Azorsa et al., 2010;
Ryoo et al., 2008). Interestingly, mice overexpressing DYRK1A have increased phosphorylated
Tau in the brain and crossing the DYRK1A heterozygous mice with DS mice regulates
phosphorylated Tau and amyloid load (García-Cerro et al., 2017). Furthermore, overexpression
of DYRK1A was observed in postmortem brains of AD patients, supporting the contribution of
DYRK1A to tau hyperphosphorylation and accumulation of NFTs (Ferrer et al., 2005). Thus,
inhibition of DYRK1A is being considered to alleviate problems caused by Tau phosphorylation
in AD. Furthermore, studies in AD mice models or transgenic mice with Tau pathology have
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further supported that DYRK1A can be a potential target for AD and other Tauopathies (Branca
et al., 2017; Melchior et al., 2019).
1.4. Some of the known DYRK1A substrates
Several reported substrates of DYRK1A harbor a consensus sequence that includes the RX(XX)-S/T-P motif. Analysis of in-vitro phosphorylated synthetic peptide substrates established
DYRK1A’s preference for arginine residue in the -2 or -3 position and for a proline at the +1
position (Himpel et al., 2001; Himpel et al., 2000).
Depending on its cellular localization, DYRK1A is responsible for the phosphorylation of
several proteins involved in important signaling pathways, such as the cell cycle and
transcription (Duchon & Herault, 2016; Kaczmarski et al., 2014; Martı́ et al., 2003; Park et al.,
2012). Apart from the substrates already mentioned above, DYRK1A phosphorylates Nuclear
Factor of Activated T cells (NFAT), cAMP Response Element Binding protein (CREB), Signal
Transducer and Activator of Transcription 3 (STAT3), Glioblastoma associated oncogene
protein (GLI1), splicing factors (cyclin L2, SF2, SF3), a translation factor (eIF2Be),
miscellaneous proteins (glycogen synthase, caspase-9, Notch) and synaptic proteins (dynamin I,
amphiphysin I, synaptojanin) (Duchon & Herault, 2016). Additional DYRK1A substrates
include cyclin D1, p53, p27, RNA polymerase II and the LIN52 subunit of the DREAM
repressor complex, as well as Caspase 9 ((J.-Y. Chen et al., 2013; Di Vona et al., 2015;
Litovchick et al., 2011; Najas et al., 2015; Park et al., 2009, 2010; Soppa et al., 2014). In addition
to these substrates, DYRK1A interacts with several proteins that may regulate its function or
subcellular localization including DCAF7 and 14-3-3 (Alvarez et al., 2007; Glenewinkel et al.,
2016; D. Kim et al., 2004; Miyata & Nishida, 2011; Ritterhoff et al., 2010).
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1.5. DYRK1A’s role in DREAM complex assembly and cancer
The activity of E2F transcription factors is regulated by the retinoblastoma (RB) family of
proteins which includes pRB, p107 and p130 (Cobrinik, 2005). The RB family proteins act as
tumor suppressors in a hypo-phosphorylated form when they bind E2F transcription factors and
inhibit E2F mediated transcription. Phosphorylation of RB family members by cyclin-dependent
kinases (CDKs) in the G-1 phase of the cell cycle relieves the binding and inhibition of E2Fs
(Cobrinik, 2005; Malumbres & Barbacid, 2009). In cells entering quiescence, p130 accumulates
in response to serum starvation, confluency or pINK4a expression (Cam et al., 2004; E. J. Smith
et al., 1996). Furthermore, p130 was found to be the predominant RB family member that
interacts with MuvB core protein complex consisting of RBBP4, LIN9, LIN37, LIN52 and
LIN54. Mass spectroscopy proteomic analysis and biochemical validation in human cell lines
revealed that p130 interacts with E2F4, DP1 and the MuvB core, forming the DREAM complex
in G0/G1 but not in the S-phase, and subsequently causes repression of DREAM target genes
(Litovchick et al., 2007; Schmit et al., 2007). In S phase, the MuvB core dissociates from the
p130-DREAM complex and binds BMYB in order to promote transcription of the MMB (MYBMuvB) target genes (Litovchick et al., 2007; Schmit et al., 2007). DYRK1A specifically
phosphorylates the serine 28 (S28) residue on LIN52 (Figure 3) (Litovchick et al., 2011). This
phosphorylation of LIN52 at S28 was found to be required for DREAM assembly. Furthermore,
DYRK1A overexpression was found to inhibit proliferation of several human cancer cell lines
including T98G, U-2 OS, but not HEK 293T (Figure 3) (Litovchick et al., 2011).
Further, point mutation of LIN52 at S28 or inhibition of DYRK1A activity disrupts DREAM
assembly and reduces the ability of cells to enter quiescence or undergo Ras-induced senescence
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(Litovchick et al., 2011). Thus, DYRK1A has been found to play an important role in the
regulation of DREAM activity and entry into quiescence.

Figure 3: Schematic representation depicting how DYRK1A promotes DREAM complex
assembly, G0/G1 arrest and senescence. [Adopted from (Litovchick et al., 2007)].
Interestingly, DS patients have a lower risk of solid tumors but DS children specifically carry a
higher risk for developing leukemias (Hasle et al., 2000). DYRK1A is known to influence both
tumor suppressive and tumorigenic activities by regulating its substrates and hence it has been
termed as a double edged kinase (Fernández-Martínez et al., 2015). DYRK1A substrates can
function as pro- or anti-oncogenic factors (Figure 4).
1.6. DYRK1A inhibitors
Due to DYRK1As role in human disease, its pharmacological inhibition has been a focus of
research for several years. Potent plant derived inhibitors of DYRK1A include Harmine and
Epigallocatechin‐gallate (EGCG), the poly phenolic compound in green tea. Synthetic DYRK1A
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inhibitors include INDY, proINDY, roscovitine, purvalanol A, pyrazolidine-diones, aminoquinazolines, meridianins, pyridine and pyrazines, and chromenoidole with varying potencies
towards DYRK1A (H. Kim et al., 2016; B. Smith et al., 2012). DYRK1A inhibitors can further
be divided into three major classes. The type I inhibitors bind the ATP binding site in the kinase
domain of DYRKs and type II and type III inhibitors are non-ATP mimetics. Harmine, an ATP
competitive inhibitor of DYRK1A, is a plant alkaloid derivative, whereas EGCG is a noncompetitive ATP inhibitor of DYRK1A (Adayev et al., 2006; Bain et al., 2003; Duchon &
Herault, 2016; Göckler et al., 2009). The use of EGCG has been limited due to poor
pharmacokinetic properties and limited bioavailability (Duchon & Herault, 2016). Along with
effectively inhibiting DYRK1A mediated substrate phosphorylation, Harmine has been found to
inhibit the autophosphorylation of DYRK1A (Walte et al., 2013). Although very potent, clinical
use of Harmine is limited because it is also a monoamine oxidase inhibitor (Duchon & Herault,
2016). Other potent inhibitors of DYRK1A include INDY or proINDY but their use has also
been limited (Duchon & Herault, 2016). Recently, the well-known ATP competitive casein
kinase II and CLK inhibitor CX4945 was also found to be a potent inhibitor of DYRK1A (H.
Kim et al., 2016). This drug has already been successful in clinical trials for cancer treatment
(Siddiqui-Jain et al., 2010). It has also proven efficient in Drosophila and mouse models of
DYRK1A overexpression and hence holds promise (H. Kim et al., 2016). Additional novel
DYRK1A inhibitors have been identified that can induce DYRK1A degradation and are
supposed to be more potent than the current inhibitors, but further research is required to
evaluate their potential for therapeutic use (Branca et al., 2017; Melchior et al., 2019; Velazquez
et al., 2019).
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Figure 4: Pro and anticancer functions of DYRK1A.
DYRK1A has been associated with pro-tumoral activity (green boxes) by activating (green
arrows) known oncogenes or by inhibiting (red lines) tumor suppressors (red boxes) [Adopted
from (Fernández-Martínez et al., 2015)].

1.7. Understanding the function and regulation of DYRK1A through its interacting
proteins
Even though DYRK1A is such an important kinase, its function and regulation is poorly
understood. Hence, multiple groups have recently studied the proteomic landscape of DYRK1A.
The BioGrid protein interaction network database lists 90 unique proteins that interact with
human DYRK1A (thebiogrid.org). Most of these interactors have been identified by highthroughput affinity-capture mass spectrometric analyzes performed in HEK293T cells. The
glioblastoma cell line T98G, but not HEK293T, was one of the cell lines whose proliferation was
suppressed with ectopic expression of DYRK1A (Litovchick et al., 2011). Therefore, we used
the sensitive MudPIT proteomic approach (Florens & Washburn, 2006; Swanson et al., 2009) to
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detect DYRK1A interacting proteins in T98G cells. We identified 120 proteins specifically
detected in at least two out of four biological replicate analyses of DYRK1A
immunoprecipitates, including 98 novel interactors not reported to bind DYRK1A in the BioGrid
protein interaction database (Figure 5) (Menon et al., 2019).
Furthermore, our analysis detected 51 proteins in 3 out of 4 DYRK1A pull-down repeats and 7
proteins including DYRK1A, DCAF7, FAM117A, FAM117B, LZTS2, RNF169 and TROAP,
were identified in all 4 biological replicates (Menon et al., 2019). These interacting proteins
were also the most enriched in the samples and their interaction with DYRK1A was confirmed
using reciprocal pull-down assays (Menon et al., 2019). Of note, average enrichment of DCAF7
in the immunoprecipitated samples (as shown by Normalized Spectrum Abundance Factor, or
dNSAF (Sardiu et al., 2008), was comparable to that of DYRK1A itself, indicating a potentially
stoichiometric interaction. Further, bioinformatic analysis of the 51 DYRK1A-binding proteins
revealed a complex network of interactions of factors involved in different cellular processes,
with notable enrichment of the mRNA processing, transcription and DNA damage response
functional categories (Menon et al., 2019). Previous proteomic analysis of DYRK1A in
HEK293T cells identified 24 interacting proteins, 14 of which were also detected in our study
(Menon et al., 2019; Varjosalo et al., 2013). Two other groups also subsequently reported the
DYRK1A interactome in HeLa cells. Interestingly, even with different cell types, there is a
considerable overlap of DYRK1A interacting proteins found in our study with the proteins
reported in these studies (Guard et al., 2019; Menon et al., 2019; Roewenstrunk et al., 2019;
Varjosalo et al., 2013), including DCAF7, RNF169, FAM117B, LZTS2 and TROAP.
In this thesis, we have focused on characterizing some of the novel DYRK1A protein-protein
interactions, and an introduction to each of these is included in subsequent chapters 2 and 3.
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Figure 5: Analysis of the DYRK1A-interacting protein network.
(A). Purification of DYRK1A for MudPIT proteomic analysis. Top: representative western blot
showing levels of DYRK1A in T98G cells expressing HA-Flag-tagged DYRK1A (DYRK1AFH) and DYRK1A band density relative to Actin (control). Bottom: representative silver stained
gel containing 10% of HA-peptide eluted control or DYRK1A-FH IP samples analyzed by
MudPIT. Green arrow indicates DYRK1A. (B) Graph shows relative enrichment (dNSAF) of
proteins detected in two, three or all four DYRK1A MudPIT experiments. DYRK1A is shown as
a green circle whereas red and blue circles correspond to interacting proteins either listed in the
BioGrid database, or new DYRK1A-binding proteins, respectively. (C) dNSAF (corresponds to
relative enrichment) and molecular weight (MW) of seven proteins specifically detected in four
DYRK1A-FH MudPIT replicate experiments. (D) Hierarchical network of interactions
(CytoScape) involving DYRK1A-binding proteins identified in this study, constructed using
MetaScape analysis tool. Larger nodes correspond to proteins detected in all four replicates,
smaller nodes correspond to proteins detected in three replicates. Unconnected nodes are not
known to interact with other factors. Colors, as in panel B (E) Molecular Signature Database
(MSigDB) annotation of the genes encoding DYRK1A-interacting proteins reveals significantly
enriched functional gene ontology (GO) categories. Proteins detected in at least 3 DYRK1A
MudPIT repeats were analyzed using Molecular Signature Database annotation tool to compute
overlaps with GO Biological Process (GO_BP) and GO Cellular Component (GO_CC) gene sets
[Adopted from (Menon et al., 2019)].
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CHAPTER 2: CHARACTERIZATION OF THE DYRK1A-RNF169 INTERACTION
AND ITS FUNCTION IN THE DNA DAMAGE RESPONSE PATHWAY
(Adapted from Menon V, Ananthapadmanabhan V et al., 2019)

2.1. INTRODUCTION TO THE CHAPTER
MudPIT analysis carried out to identify DYRK1A interacting proteins detected RNF169 (Ring
Finger protein 169) in all four biological replicates (Figure 5) (Menon et al., 2019). RNF169
plays a role in the DNA damage response (An et al., 2018; Poulsen et al., 2012) while DYRK1A
had no known role in this process. We therefore carried out a functional characterization of the
DYRK1A-RNF169 interaction in this chapter.
2.1.1. The DNA damage response
Cellular exposure to various DNA damaging agents, be it environmental or endogenous, is
harmful and leads to impaired DNA integrity and genomic instability leading to disease. Of the
many types of DNA lesions, DNA double strand breaks (DSBs) are considered the most harmful.
This is because a single DSB is sufficient to cause growth arrest and cell death (Bennett et al.,
1993; Panier & Boulton, 2014; Sandell & Zakian, 1993). Whenever there is a DNA DSB, the
MRE-11-RAD 50-NBS1 (MRN) complex senses the break. This leads to recruitment of the
serine/threonine kinase Ataxia Telangiectasia Mutated (ATM) which phosphorylates itself and
becomes activated (Panier & Boulton, 2014; Paull, 2015). At the break site, ATM in turn
phosphorylates H2A.X at ser 139 (γH2AX) (Panier & Boulton, 2014; Rogakou et al., 1998).
γH2AX is used as an early marker of the DNA DSB response. γH2AX is recognized by Mediator
of DNA Damage Checkpoint protein 1 (MDC1), leading to the sequential recruitment of E3
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ubiquitin ligases RNF8 and RNF168. RNF8, RNF168 and an E2 conjugating enzyme UBC13
together regulate the ubiquitination of histones surrounding the DSB sites. One of the outcomes
of RNF8 and RNF168-mediated chromatin ubiquitylation is a stable recruitment of oligomerized
p53-binding protein 1 (53BP1), which directly binds to RNF168-ubiquitylated H2AK15 and to
mono- and di-methylated H4K20 (Panier & Boulton, 2014). 53BP1 is a key factor that can
influence pathway choice during the repair process. Specifically, 53BP1 phosphorylation by
ATM leads to recruitment of RIF1, and the 53BP1-RIF1 complex promotes the DNA repair via
the Non-Homologous End Joining pathway or NHEJ (Escribano-Díaz et al., 2013). This pathway
can introduce errors in the genome as it involves minor processing of the DNA ends prior to the
direct ligation of the DSB. In the S-G2 phase of the cell cycle, BRCA1 antagonizes the 53BP1RIF1 complex and promotes the more accurate HRR (Homologous Recombination Repair)
facilitated by end resection via Mre11 and C-terminal binding protein-interacting protein (CtIP)
(Escribano-Díaz et al., 2013).

Figure 6: The complexity of signal transduction pathway following a DNA DSB break.
DNA damage response elicits a sequential cascade leading to accumulation of 53BP1 at the
damage sites [Adopted from (Panier & Boulton, 2014)].
RNF169 has been reported to be a negative regulator of 53BP1 accumulation at the sites of DNA
DSBs (Poulsen et al., 2012). RNF169 binding thereby promotes cells to favor HR repair instead
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of NHEJ (An et al., 2018). The role of DYRK1A in the DNA damage response was poorly
studied and this chapter will highlight our findings on the role of the DYRK1A-RNF169
interaction in the DNA DSB response pathways. Notably, post the publication of our study, two
other groups also reported the DYRK1A-RNF169 interaction and its role in the DNA damage
response (Guard et al., 2019; Roewenstrunk et al., 2019).
2.2. RESULTS
2.2.1. DYRK1A and RNF169 interact at the endogenous level and co-fractionate together
First, we confirmed the interaction between exogenously expressed HA-tagged RNF169 and
endogenous DYRK1A in T98G cells using immunoprecipitation and Western blot analysis
(IP/WB) (Figure 7A). Using reciprocal IP/WB analysis, interaction between DYRK1A and
RNF169 was also confirmed at the endogenous level in both T98G and U-2 OS cell lines (Figure
7B, C). We also observed that the kinase activity of DYRK1A was not required for the
DYRK1A-RNF169 interaction (Figure 7D). Furthermore, we found that DYRK1A and RNF169
co-fractionated together in T98G cell lysates subjected to glycerol gradient ultracentrifugation,
and the estimated approximate size of the DYRK1A-RNF169 complex was 280 kDa (Figure 7E).
2.2.2. DYRK1A and RNF169 regulate the recruitment of 53BP1 at sites of DNA DSBs
U-2 OS cells retain wild type p53 making this cell line a common model for DNA damagefocused studies. Moreover, these cells have also been used to characterize the regulatory role of
RNF169 towards 53BP1 recruitment into γ-irradiation induced foci (IRIF). In preliminary
experiments, we observed that U-2 OS cells displayed the maximum number of distinct 53BP1
IRIF at 3h post γ-irradiation (5Gy, data not shown). We therefore decided to induce DNA
damage using γ-irradiation followed by analysis of foci accumulation 3 hours post irradiation in
our subsequent experiments. We used U-2 OS cell lines stably expressing either wild type or
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kinase inactive DYRK1A-K188R mutant under control of a doxycycline (dox)-inducible
promoter to analyze the role of DYRK1A in the regulation of 53BP1 upon DNA damage
(Himpel et al., 2001; Litovchick et al., 2011). Interestingly, induced expression of WT but not
kinase-inactive DYRK1A resulted in significantly decreased number of cells displaying more
than 10 53BP1 IRIF compared to the un-induced control (Figure 8A, B and 9A). In order to
analyze if RNF169 was required for this effect, we transiently knocked down RNF169 and
observed that recruitment of 53BP1 into IRIFs in the WT DYRK1A overexpressing cells was
rescued to the control cell levels (Figure 8C, D and 9B).
We further investigated the role of DYRK1A kinase activity by using the DYRK1A inhibitor
Harmine. U-2 OS cells were treated with 10μM of Harmine for 16 hours prior to γ-irradiation
and the accumulation of 53BP1 IRIFs was quantified. Interestingly, recruitment of 53BP1 to foci
was increased with Harmine pre-treatment as compared to vehicle treated controls (Figure 10A,
B). For most accurate quantification of our observations, we calculated both the percentage of
cells containing more than ten IRIF, as well as an average number of IRIF per nucleus, using
ImageJ software (Schneider et al., 2012). Consistent with previous reports, with stable HARNF169 overexpression, we also observed a 50% reduction in the number of cells with more
than 10 53BP1 IRIFs as well as fewer IRIFs per nucleus (compare grey bars, figure 10C).
Harmine treatment of HA-RNF169- expressing cells resulted in increase in 53BP1 foci formation
although it was not fully rescued to the control levels (red bars and graph on the right Y-axis).
Interestingly, in the cells treated with Harmine, HA-RNF169 foci formation was reduced by
approximately 30% as compared to controls (compare green bars, figure 10C). This could
explain the increase in 53BP1 IRIFs with Harmine treatment. We also analyzed the binding
between DYRK1A and RNF169 after the cells were treated with Harmine. Similar to kinase-
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dead DYRK1A, RNF169 from Harmine treated cells also bound endogenous DYRK1A
efficiently (Figure 10D). These results demonstrate that RNF169 and DYRK1A interact at the
endogenous level in human cells and that DYRK1A facilitates RNF169’s limiting function
towards 53BP1 IRIF recruitment.

Figure 7: DYRK1A and RNF169 interact at the endogenous level and co-fractionate
together.
(A) IP/WB assay shows binding between transiently expressed HA-tagged RNF169 and
endogenous DYRK1A in T98G cells. (B, C) IP/WB analyzes of the interaction between the
endogenous RNF169 and DYRK1A in T98G and U-2 OS cells. RNF169-depleted cell extract
(siRNF169) is included to identify the RNF169-specific protein band. IgG, negative control. (D)
IP/WB assay shows interaction between the wildtype and the kinase-inactive DYRK1A (Y321F)
and the endogenous RNF169 in U-2 OS cells. (E) WB of the U-2 OS cell extract separated by
5–45% glycerol gradient ultracentrifugation shows co-fractionation of RNF169 and DYRK1A.
Black arrows indicate the positions of the molecular weight markers. Red arrow indicates
estimated size of the DYRK1A-RNF169 complex.
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Figure 8: DYRK1A and RNF169 regulate 53BP1 recruitment at DNA DSB.
(A) WB shows the DYRK1A levels in the inducible U-2 OS cell lines under un-irradiated
conditions before and after doxycycline (Dox) treatment for 12h. Actin is shown as loading
control. (B) The inducible U-2 OS cell lines were pre-incubated with or without Dox for 12h,
treated with radiation (5 Gy) and processed for 53BP1 staining after 3h. Induced expression of
active but not kinase-inactive (KD) DYRK1A (K188R) inhibits 53BP1 IRIF formation. Graph
shows quantification of cells with 53BP1 foci in cell lines with (+) or without (-) Dox induction
of 3 biological replicate experiments. Error bars show standard deviation. Red and black dots
indicate quantifications by two independent observers. p-values were calculated using Student’s
two-tailed t-test and are indicated on the graphs. (C, D) Knockdown of RNF169 rescues
DYRK1A-mediated inhibition of 53BP1 foci formation. Inducible U-2 OS cell lines were
transfected with non-targeting (siControl) or RNF169-specific siRNA and treated with
doxycycline as in panels A, B to induce expression of DYRK1A. WB in panel C shows
expression of proteins of interest. Panel D shows quantification of the 53BP1 foci in cells.
Samples were processed in the same way as in B. Graph shows average of 3 biological
replicates. Error bars show standard deviation. Red and black dots same as in B and p-values
calculated using Student’s two-tailed t-test are indicated on the graphs.
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Figure 9: Induced expression of DYRK1A inhibits 53BP1 accumulation at the DSB sites.
(A) Representative images of inducible U-2 OS cell lines expressing wild-type DYRK1A (WT)
or kinase inactive mutant (KD), with or without treatment with doxycycline for 16h. Cells were
γ-irradiated (5Gy) and incubated for 3h before staining with anti-53BP1antibody and DAPI. (B)
Representative images of U-2 OS cells with induced expression of the wild-type DYRK1A,
transfected with either non-targeting (siControl) or RNF169-specific siRNA, γ-irradiated (5Gy)
and incubated for 3h before staining with anti-53BP1antibody and DAPI. See Figure 8 for
representative WB showing expression of proteins of interest in the cell lines used.
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Figure 10: Inhibition of DYRK1A increases 53BP1 recruitment to IRIF.
(A) Representative images of HA-RNF169 and 53BP1 irradiation induced foci in U-2 OS cells
stably expressing HA-RNF169 that were either untreated (Mock), or pre-treated with 10 μM
Harmine or DMSO (vehicle) for 16h before irradiation (5 Gy) and processed for staining after
3h. (B, C) Graphs show quantification of the 53BP1 or HA-RNF169 IRIF from 4 biological
replicate experiments. Error bars show standard deviation. p-values were calculated using
Student’s two-tailed t-test and are indicated on the graphs in panels B and C. (D) IP/WB shows
that DYRK1A-RNF169 interaction is unaffected by Harmine treatment.
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2.2.3. DYRK1A phosphorylates RNF169 at functionally important Ser368 and Ser403
residues
By scanning through the RNF169 protein sequence, we found that RNF169 contains two
predicted DYRK1A consensus phosphorylation sites (Menon et al., 2019). These sites were
identified at positions S386 and S403 in the human RNF169 protein sequence. The region in
RNF169 encompassing these sites was found to be highly conserved but had no known function.
Both of these sites were reported in Phosphosite plus database as detected in several high
throughput phosphoproteomic studies (Hornbeck et al., 2012). Using stable cell lines expressing
mutants of RNF169, and in-vitro kinase assays with recombinant DYRK1A, we found that
DYRK1A indeed phosphorylates RNF169 at both the predicted sites - S386 and S403 (Menon et
al., 2019).
To characterize the functional significance of DYRK1A phosphorylation sites in RNF169, we
analyzed accumulation of 53BP1 and RNF169 after induction of DNA damage by γ-irradiation
in U-2 OS cell lines stably expressing either wild type HA-RNF 169, non-phosphorylatable
S368A/S340A (RNF169-AA) mutant, or phospho-mimetic S368D/S340D (RNF169-DD) mutant
(Figure 11). Interestingly, there was approximately two-fold higher number of cells with more
than ten 53BP1 foci in either RNF169-AA or RNF169-DD-expressing cells compared to the wild
type HA-RNF169 cell line (Figure 11A, B). As compared to the wild-type expressing cells, there
was a modest but significant increase in the number of 53BP1 foci per nucleus in the cells
expressing mutant RNF169 alleles, indicating that phospho-site mutant RNF169 proteins inhibit
accumulation of 53BP1 at DSB sites to a significantly lesser extent than the wild type RNF169
(Figure 11A, B). This result is consistent with the effect of Harmine, supporting the contribution
of DYRK1A to the RNF169-mediated inhibition of 53BP1 accumulation at the DSB sites.
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Next, we analyzed the recruitment of the HA RNF169-AA and DD mutants to DSB sites in γ
irradiated U-2 OS cell lines. Interestingly, there was a slight but significant decrease in the
number of HA positive foci in the cells expressing the mutant proteins as compared to the wild
type RNF169 (Figure 11A, C). Despite the differences observed with accumulation of 53BP1
and HA-RNF169 at IRIF between the wild type and RNF169 mutant expressing cell lines, the
expression levels of the respective HA-RNF169 or 53BP1 proteins were similar across the cell
lines (Figure 11E). We also observed that IRIF formed by the mutant HA-RNF169 proteins
appeared to be larger in size than in case of the wild type protein (Figure 11D). Indeed, analysis
of the foci size using ImageJ software revealed a significant increase of the mean size of the
RNF169- AA and DD foci compared to the wild type control. Of note that the phenotype we
observed with the phosphomimetic mutant of RNF169 (RNF169-DD) was very similar to that of
the phospho deficient (RNF169-AA) mutant. This could mean that the phosphomimetic mutant
of RNF169 does not accurately represent a constitutively phosphorylated state of the protein. It
appears that it instead disrupts the same function. Therefore, it was important to test the impact
of the mutation of DYRK1A phosphorylation sites on some other known function of RNF169.
The ubiquitin-binding MIU domain of RNF169 recognizes RNF168-polyubiquitylated histones.
This recognition has been found to be required for the recruitment of RNF169 at the DSB sites
and for the displacement of 53BP1 (J. Chen et al., 2012; Panier & Boulton, 2014; Poulsen et al.,
2012). Interestingly, we observed that RNF169-AA and RNF169-DD mutants were able to bind
polyubiquitin chains similar to the wild type RNF169, further supporting our conclusion that
S368 and S403 sites do not play a significant role in RNF169’s accumulation at the DSB sites
(Menon et al., 2019). USP7 (Ubiquitin Specific protease 7) has been reported to be important for
RNF169 function in DNA repair (An et al., 2018). We found that mutations of DYRK1A
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phosphorylation sites on RNF169 did not affect the interaction between RNF169 and USP7
(Menon et al., 2019). However, we found that both mutants showed a dramatically reduced
binding to DYRK1A, both in the un-irradiated controls or post treatment with γ-irradiation
(Menon et al., 2019). Therefore, these RNF169 mutants not only lack DYRK1A mediated
phosphorylation but also bind less to DYRK1A. We were therefore able to support the
conclusion that DYRK1A binding and phosphorylation of RNF169 increases its ability to limit
the recruitment of 53BP1 at the DSB sites after γ-irradiation.
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Figure 11: The functional significance of S368 and S403 residues in RNF169.
(A) Representative images of the HA-RNF169 (green) and 53BP1 (red) foci 3h after γ-radiation
(5 Gy). U-2 OS stable cell lines expressing HA-RNF169 (WT), or the S368A/S403A (AA), or
S368D/S403D (DD) mutants were stained using anti-HA and 53BP1 antibodies, and DAPI. (B)
Graph shows quantification of the 53BP1 IRIF from 4 biological replicate experiments shown in
panel A. All cells were scored in the control U-2 OS cells (Mock, shown as reference) whereas
only HA-positive cells were scored in the HA-RNF169, RNF169-AA or RNF169-DD expressing
cell lines. Here and below, error bars show standard deviation and p-values calculated using
Student’s two-tailed t-test are shown on the graphs. (C) Graph shows quantification of HARNF169 IRIF from 4 experiments in A. Red and black dots indicate values scored by two
independent observers. (D) Quantification (average foci sizes, left Y-axis and size distribution,
right Y-axis) of HA-RNF169 foci sizes measured in 4 biological replicate experiments. (E) WB
shows expression of proteins of interest in the cell lines used in panels A-D.
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2.2.4. Loss of DYRK1A causes a decreased DSB recruitment of RNF169 and 53BP1
In order to investigate the effects of loss of DYRK1A on 53BP1 and RNF169 IRIF, we
generated U-2 OS cell lines with CRISPR Cas-9 mediated KO of DYRK1A in the lab [(Menon
et al., 2019)., and the Methods section]. The KO clones were analyzed for DYRK1A protein
expression using WB with DYRK1A antibodies targeting different regions of the protein [Figure
12A (Menon et al., 2019)]. Two independent U-2 OS DYRK1A-KO clones were expanded and
further validated by WB and genomic DNA sequencing (Menon et al., 2019). We have
developed an in-vitro kinase assay in the lab to analyze DYRK1A activity in cell extracts.
Purified LIN52 is used as a substrate and incubated with cell lysates with or without DYRK1A
(Menon et al., 2019). Using this assay, we confirmed that there was a significant loss of
DYRK1A kinase activity in the U-2 OS DYRK1A- KO cell lines (Menon et al., 2019).
Therefore, we chose to use these DYRK1A KO cell lines in our subsequent assays because
transient siRNA knockdown or stable shRNA knockdown of DYRK1A resulted in significantly
higher residual LIN52 kinase activity (data not shown).
Using transiently transfected HA-RNF169 or GFP-RNF169, we compared the recruitment of
RNF169 into the IRIF in the control and the DYRK1A-KO U-2 OS cells. Similar to the
phenotype observed with Harmine treatment, both HA-RNF169 and GFP-RNF169 displayed a
modest but significant decrease in DSB recruitment in γ-irradiated U-2 OS DYRK1A-KO cell
lines compared to controls (Figure 12B, C). However, unlike Harmine-treated cells, DYRK1AKO cell lines showed significantly reduced 53BP1 IRIF formation at 3h post γ-irradiation when
compared to control cell lines, nor did accumulation of 53BP1 at the DSB sites in the DYRK1AKO cell lines increase at 6h post γ-irradiation, as both DYRK1A-KO cell lines continued to
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display a significantly decreased 53BP1 IRIF recruitment compared to controls (Figure 12D, E,
F).
U-2 OS cell lines have only one copy of DYRK1A (Menon et al., 2019). It is possible that these
cell lines have intrinsically reduced DYRK1A expression resulting from loss of one copy of
the DYRK1A gene. Therefore, we further validated our findings described above using mouse
NIH-3T3 fibroblasts in which Dyrk1a was similarly knocked out using a CRISPR-Cas9
approach. In the case of NIH-3T3 cells, accumulation of 53BP1 foci reaches its peak at 1h post
γ-irradiation (3Gy), and then starts to decrease at 3h (data not shown). Using these experimental
conditions, we again observed a decreased 53BP1 IRIF formation in two independent, clonal
NIH-3T3 Dyrk1a-KO cell lines compared to control cells. Indeed, while a majority of the control
and Dyrk1a-KO NIH-3T3 cells contained more than ten 53BP1 foci at 1h post γ-irradiation, the
average number of 53BP1 IRIF per nucleus was significantly lower in the Dyrk1a-KO cells
compared to control (Menon et al., 2019). Moreover, at 3h post γ-irradiation, the number of
53BP1 foci per nucleus decreased by approximately 50% in both the control and Dyrk1a-KO cell
lines, indicative of a similar rate of resolving the lesions and removal of 53BP1 foci in these cells
lines (Menon et al., 2019).
To further confirm that the phenotype of the DYRK1A-KO U-2 OS cells was specific to a loss of
DYRK1A protein and kinase activity, we re-introduced either active DYRK1A or kinaseinactive K188R-DYRK1A (KD) mutant into one of our knockout clones and created stable cell
lines. Indeed, we observed that expression of wild-type DYRK1A, but not the kinase inactive
mutant, resulted in a complete rescue of the 53BP1 IRIF defect in these cells (Figure 13A, B).
These results strongly support the role of DYRK1A in regulation of 53BP1 recruitment to the
DNA double strand breaks caused by γ-irradiation.
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Figure 12: DYRK1A-deficient cells have impaired recruitment of RNF169 and 53BP1 to
the DSBs.
(A) WB confirms absence of the full length DYRK1A protein expression in two different U-2
OS DYRK1A-KO clones. (B, C) Quantification of HA-RNF169 IRIF in U-2OS cells transiently
expressing HA-RNF169 or GFP-RNF169 after 3h post-irradiation (5Gy) of the parental, control
(non-targeting sgRNA clone) or DYRK1A-KO U-2 OS cell lines from three biological
replicates. Red and black dots indicate counts by two independent observers. Here and below,
the error bars show standard deviation. For statistical analysis, cell lines were compared to the
parental U-2 OS cells using a Student’s two tailed t-test; p-values are shown on the graphs. (D,
E, F) Representative images 3h post γ-irradiation and graphs show quantification of 53BP1 IRIF
from the cell lines processed for staining 3h or 6h post γ-irradiation (5Gy). Graph show values
obtained from three biological replicates. For statistical analysis, each cell line was compared to
parental U-2 OS line (gray bars) as above.
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Figure 13: Rescue of the 53BP1 foci formation in DYRK1A-KO cells by re-expression of
active DYRK1A.
(A) Representative images of the 53BP1 staining in parental U-2 OS cells, control sgRNA clone,
the DYRK1A-KO clone #1 (KO), and the KO clone #1 before or after stable re-expression of the
wild type (KO + WT) or kinase-inactive mutant (K188R) DYRK1A (KO + KD). Scale bar, 10
μm. (B) Quantification of the 53BP1 IRIF from three independent experiments using cell lines
described in A. For statistical analysis, each cell line was compared to the parental U-2 OS line
(gray bars) using a Student’s t-test and p-values are shown on the graphs. Error bars indicate
standard deviation. Lower Panel: WB shows levels of DYRK1A in the cell lines used in this
experiment. Slower gel migration of the recombinant DYRK1A alleles is due to the presence of
dual Flag-HA tag. Actin serves as loading control.
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Further, we investigated if DYRK1A was required for overexpressed RNF169 to displace 53BP1
from IRIF. Overexpression of GFP-RNF169 in the DYRK1A-KO U-2 OS cells also resulted in
inhibition of the 53BP1 recruitment to DSBs. The differences between the GFP and GFPRNF169-expressing cells were highly significant in all cell lines, p- value < 0.001 (Figure 14AC). This result was consistent with our findings that RNF169 was able to inhibit 53BP1 IRIF
formation in cells treated with DYRK1A inhibitor Harmine. Furthermore, recruitment of 53BP1
foci was significantly lower in both the GFP- and GFP-RNF169-transfected DYRK1A-KO cells
compared to the corresponding control cell lines (Figure 14A-C). This suggested that knockout
of DYRK1A in U-2 OS cells could impair 53BP1 IRIF formation independent of RNF169.
2.2.5. Depletion of RNF169 does not fully rescue the 53BP1 recruitment defect in
DYRK1A-KO cells
To determine whether the effect of DYRK1A loss on 53BP1 is mediated by RNF169 or not, we
depleted RNF169 in U-2 OS cell lines using siRNA transfection. Interestingly, RNF169 depleted
DYRK1A KO cells still had a reduced recruitment of 53BP1 as compared to their respective
controls. The 53BP1 was not completely rescued with RNF169 depletion (Figure 14D, E). This
phenotype was unlike what we observed with DYRK1A overexpressing cells. This result
suggests that the 53BP1 recruitment defect in the absence of DYRK1A is not likely due to a
more efficient displacement by RNF169. Together, our data support the conclusion that
DYRK1A regulates the recruitment of 53BP1 to damaged chromatin in an RNF169-dependent as
well as independent manner.
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Figure 14: Impaired 53BP1 IRIF formation in DYRK1A-KO cells is RNF169 independent.
(A, B) Representative images and quantification of GFP-RNF169 (green) and 53BP1 (red) foci
3h after γ-radiation (5 Gy). Indicated U-2 OS cell lines were transiently transfected with GFP or
GFP-RNF169 and stained using 53BP1 antibody and DAPI. Graphs show values from 3
biological replicates. Red and black dots indicate counts by two independent observers. Here and
below, the error bars indicate standard deviation. Data were analyzed using ANOVA with
Dunnett’s multiple comparisons test (p-values shown). All comparisons between the
corresponding GFP-transfected and GFP-RNF169-transfected samples were significant (p <
0.01, indicated by an asterisk). (C) WB showing the expression levels of RNF169 and DYRK1A
in the representative experiment analyzed in panels (D) and (E). (D, E) Quantification of the
53BP1 IRIF in control or DYRK1A-KO U-2 OS cell lines after siRNA knockdown of RNF169
from three biological replicates. Statistical significance was calculated using Student’s two tailed
t-test and p-values are indicated on the graphs.
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To address the mechanism of the 53BP1 recruitment defect in DYRK1A-KO cells, we analyzed
the expression of several DNA damage response markers during DNA repair. First, we looked at
the early markers of the DNA damage response by WB analysis. There was no change in the
induction of p53 or γH2AX in the DYRK1A-KO cells compared to control (Menon et al., 2019).
Analysis of the ubiquitylation of histones and accumulation of γH2AX and at the DNA damage
sites also appeared to be unchanged in the DYRK1A-KO cells compared to controls (Menon et
al., 2019). This suggests that the initial DNA damage response was similar in control and
DYRK1A KO cells. Furthermore, we analyzed if loss of DYRK1A in U-2 OS affected the DNA
damage checkpoint. Cell cycle analysis revealed accumulation of cells in G1 and G2 phases after
γ-irradiation indicating that loss of DYRK1A in U-2 OS cells did not affect the DNA damage
checkpoint (Menon et al., 2019). An increase in 53BP1 and BRCA1 protein levels was observed
in the DYRK1A KO cells with or without induction of DNA damage (Menon et al., 2019). Since
accumulation of both 53BP1 and BRCA1 at the DSB sites requires the activity of RNF168 and
RNF8 E3 ubiquitin ligases, we also analyzed the recruitment of BRCA1 in these cells and found
it was unchanged in the DYRK1A-KO cells (Menon et al., 2019). Therefore, we were able to
conclude that decreased recruitment of 53BP1 to the damage sites was likely not because of
abnormal DNA damage signaling or histone ubiquitylation in the DYRK1A-KO cells.
2.2.6. Loss of DYRK1A promotes HRR and DNA repair
There is evidence that 53BP1 suppresses HR-mediated DNA repair by blocking end resection
(Canny et al., 2018; Durocher & Pelletier, 2016). Since loss of DYRK1A decreased
accumulation of 53BP1 at DSB sites, we investigated the effect of DYRK1A loss on DNA repair
pathway choice, using control and DYRK1A-KO U-2 OS cell lines stably expressing the direct
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repeat (DR) GFP reporter for the HR repair pathway (Pierce et al., 1999). In this model system,
I-SceI restriction nuclease is used to generate a DSB by cleavage of the non-functional GFP gene
fragment. If the generated DSB is repaired by NHEJ, there would be no GFP protein expression.
However, if the DSB is repaired by HRR, using the downstream GFP sequence, a GFP protein is
expressed (Menon et al., 2019). Consistent with reduced recruitment of 53BP1 to DSBs in the
DYRK1A-KO cells, we observed an approximately two-fold increase in the percentage of GFPpositive cells after I-SceI expression (Menon et al., 2019). The same trend was observed with
both DYRK1A-KO clones. As compared to the control U-2 OS cells, this result was statistically
significant with one of the DYRK1A-KO clones but not with the second U-2 OS DYRK1A-KO
clone because of high variability between biological replicates.
2.3. DISCUSSION AND FUTURE DIRECTIONS
Through the results discussed in this chapter, we provide functional characterization of the
DYRK1A-RNF169 interaction. Our study revealed the role of DYRK1A in the DNA damage
pathway by regulating one of the key response factors to DNA DSB lesions - 53BP1 (Panier &
Boulton, 2014). Overexpression of RNF169 prevents the accumulation of 53BP1 at DSBs,
resulting in increased HR-mediated DNA repair efficiency due to a more efficient resection of
the DNA ends (J. Chen et al., 2012; Poulsen et al., 2012). However, the mechanism by which
RNF169 regulates 53BP1 accumulation, as well as the factors that regulate RNF169 recruitment
and dissociation from the DSB sites are still not known. Our study not only validated the role of
RNF169 as a negative regulator of 53BP1 accumulation but also supported the role of DYRK1A
as an RNF169 effector that positively regulates its activity through both direct and indirect
mechanisms. Since the publication of our study, two other groups also reported the DYRK1A-
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RNF169 interaction and its role in the DNA damage response (Guard et al., 2019; Roewenstrunk
et al., 2019).
Previous studies found that a high-affinity ubiquitin-binding MIU domain in RNF169 is required
for its ability to inhibit 53BP1 accumulation at the damage sites (J. Chen et al., 2012; Q. Hu et
al., 2017; Poulsen et al., 2012). Our study shows that the binding of RNF169 to ubiquitin may be
necessary, but not sufficient, to fully prevent the accumulation of 53BP1 at DSB sites. Indeed,
the phosphorylation-deficient RNF169 mutants show reduced ability to displace 53BP1 from the
DSBs despite almost normal recruitment to these sites. Interestingly, several ATM-regulated
phosphorylation sites in 53BP1 are required for interaction with its key effector RIF1 but
dispensable for its recruitment to the damage sites (Escribano-Díaz et al., 2013; Isono et al.,
2017). It is possible that DYRK1A phosphorylation of RNF169 serves to recruit an additional
factor that is essential for displacing 53BP1, or for stabilizing the binding of RNF169 to
ubiquitylated chromatin. The phosphomimetic DD mutant of RNF169 also showed a reduced
ability to displace 53BP1 from DSBs. One possibility is that this mutant does not accurately
represent the constitutively active form of RNF169. Another possibility is that the RNF169 DD
mutant causes a dominant negative effect. An RNF169 dimer could be responsible for inhibiting
53BP1 foci formation, wherein one molecule of RNF169 is in the phosphorylated form and the
other is not phosphorylated. Thus, when the AA mutant is expressed, there is an excess of unphosphorylated RNF169, which may dimerize and cause inhibition of 53BP1 recruitment. When
the phosphomimetic mutant is present in excess, a possibility is that there is not enough
unphosphorylated RNF169 to form the active dimer and therefore, there is reduced 53BP1
recruitment. Moreover, the constitutive presence of the DYRK1A-RNF169 complex both in the
intact cells and after damage, as well as the estimated size of the DYRK1A-RNF169 complex
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also indicate that other factor(s) is/are likely present in this complex that could be regulated by
DNA damage signaling. Further proteomic studies of the RNF169-DYRK1A complex in the
cells before and after DNA damage will help to identify such a factor. Of note, our analysis of
the DYRK1A interactome detected an interaction with USP7, a ubiquitin-specific protease that
has been recently shown to bind directly to RNF169 and increase the stability of 53BP1,
RNF169 and RNF168 (An et al., 2018; X. Liu et al., 2016; Zhu et al., 2015). Although disruption
of the DYRK1A phosphorylation sites in RNF169 did not influence its interaction with USP7,
the role of USP7 in the DYRK1A-RNF 169 mediated regulation of 53BP1 should be further
investigated.
In our study, DYRK1A overexpression or depletion both caused a decrease in 53BP1 IRIF.
Interestingly, while increased expression of DYRK1A appears to attenuate the displacement of
53BP1 from the DSBs by RNF169, the 53BP1 DSB recruitment defect in DYRK1A-depleted
cells appears to be, at least in part, RNF169-independent. This is because 53BP1 IRIF
accumulation was not completely rescued with RNF169 depletion in DYRK1A-KO cells.
Indeed, DYRK1A-KO cell lines displayed decreased RNF169 IRIF formation. Recent studies
have revealed that in addition to the histone H2A-K15ub mark, 53BP1 recognizes and binds to
the H4K20Me2 mark via its conserved Tudor domain, and this process is regulated by several
factors including histone methyltransferases SETD8 and MMSET, as well as Polycomb proteins
L3MBTL1 and JMJD2A that occupy these marks in the absence of DNA damage [reviewed in
(Panier & Boulton, 2014)]. Furthermore, in S/G2 phases of the cell cycle, BRCA1 plays an
active role in removing 53BP1 from chromatin around damage sites by a mechanism that is not
fully understood, requiring CDK activity and CtIP (Chapman et al., 2012; Escribano-Díaz et al.,
2013; Isono et al., 2017). It will be interesting to investigate in the future whether changes in
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these 53BP1-regulating factors are responsible for the phenotypes observed in the DYRK1A-KO
cells.
There is also a possibility that there is another kinase capable of phosphorylating RNF169 at the
same sites as DYRK1A, and this kinase is inhibited when DYRK1A is present in optimum
amounts. When DYRK1A is present in excess, there could be an increased phosphorylation of
RNF169 leading to decreased 53BP1 recruitment. On the other hand, when DYRK1A is
depleted, the alternate kinase may phosphorylate RNF169 leading to decreased 53BP1
recruitment. Although further studies will be needed to determine if this is true, it is important to
note that there are several examples of redundant kinases phosphorylating a single substrate in
the DNA damage response, such as ATM and DNA-PK kinases that are both capable of
phosphorylating H2AX (Stiff et al., 2004).
Since BRCA1 gene expression could be regulated by DYRK1A through recruitment of the
DREAM repressor complex (Litovchick et al., 2011; Yakovlev, 2013), the relationship between
DYRK1A expression levels and the outcomes of the DNA damaging therapy in cancer should be
further investigated. Importantly, loss of 53BP1 can rescue the HR defects associated with
inactivation of BRCA1, and is one of the factors responsible for the acquired resistance of the
BRCA1-mutant tumors to PARP inhibitor therapy (Jaspers et al., 2013). Therefore, future studies
will be needed to establish the exact role of DYRK1A in the context of cellular processes that
regulate the recruitment of 53BP1 to the DSBs, and to validate the significance of DYRK1A as a
factor that can influence the outcomes of cancer therapy.
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CHAPTER 3: CHARACTERIZATION OF NOVEL DYRK1A INTERACTING
PROTEINS

3.1 INTRODUCTION TO THE CHAPTER
Of the DYRK1A interacting proteins we reported earlier, we validated its interaction with
DCAF7, LZTS1, LZTS2, FAM117B, RNF169 and TROAP (Menon et al., 2019) in human cells.
Although we did not validate the interaction of LZTS3 with DYRK1A, its close relationship with
LZTS1 and 2 lead us to review the literature on LZTS3 as well. In this chapter we will focus on
the biochemical and functional characterization of all of these DYRK1A interactors.
Below is a review of current literature on each of these DYRK1A interacting proteins except
RNF169 (described in detail in Chapter 2).
3.1.1. DCAF7
Similar to DYRK1A, the DCAF7 gene is conserved in evolution. DYRK family of protein kinases
includes members from yeast to humans. Interestingly, out of all the top human DYRK1A
interacting proteins in our study only DCAF7 has an orthologue in yeast- Saccharomyces
cerevisiae (genecards.org) and according to the BioGrid database, an interacting partner of the
founding member of the DYRK sub-family member Yak1 includes the yeast DCAF7 orthologue
YPL-247. The DCAF7 orthologue in plants, AN11 was originally identified as a gene in petunia
located in a locus that controls the pigmentation of flowers by stimulating the transcription of
anthocyanin biosynthetic genes (de Vetten et al., 1997) The orthologues of this gene have been
identified in many species, including humans (Jin et al., 2006). In vertebrates this gene is also
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known as WDR68 (WD-repeat protein 68) or DCAF7 (DDB1 and Cullin Associated Factor 7)
(Lee & Zhou, 2007).
The DCAF7 ortholog in Drosophila, CG14614 (official gene symbol wap, wings apart, also
called riq, riquiqui), is essential for normal wing-vein patterning and development of the adult
jump muscle (Morriss et al., 2013).. Interestingly, CG14614 associates with MNB in Drosophila,
and both genes were shown to control normal wing and leg growth by modulating the SalvadorWart-Hippo (SWH) pathway (Degoutin et al., 2013). Thus, there is evidence of the importance
of the DYRK1A-DCAF7 interaction for development in different organisms. DCAF7 is also
involved in craniofacial development in zebrafish where it plays a role upstream of the EDN1
(Endothelin-1) pathway (Nissen et al., 2006). This is of particular interest as DYRK1A itself is
involved in development and DS patients have certain craniofacial abnormalities. Interestingly,
nuclear access of DCAF7 is required for normal craniofacial development in zebrafish (B. Wang
et al., 2013). This is important as DCAF7 is mainly a cytosolic protein. However, DCAF7 binds
DYRK1A and this binding induces the nuclear translocation of DCAF7 (Miyata & Nishida,
2011). On the other hand, the localization of DYRK1A has not been found to be dependent on
DCAF7 binding (Glenewinkel et al., 2016; Miyata & Nishida, 2011).
Structurally, DCAF7 and its orthologues all encode a protein with several WD40 domains. These
domains are characterized by tryptophan-aspartate (WD) dipeptide repeats that are 44-60 amino
acids in length (Stirnimann et al., 2010; Wu et al., 2012). These WD40 repeats fold and organize
into circularized β- propeller structures and can facilitate protein-protein interactions (Stirnimann
et al., 2010; Wu et al., 2012). DCAF7 is predicted to act as a substrate receptor for the DDB1Cullin complexes although this function has not been experimentally demonstrated till date (Jin
et al., 2006; Lee & Zhou, 2007). Interestingly, DCAF7 acts as a scaffold receptor to control
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HIPK2 and MEKK1 kinase functions (Ritterhoff et al., 2010). DCAF7 is also required for
efficient binding of E1A to DYRK1A, DYRK1B and HIPK2 (Glenewinkel et al., 2016; Skurat &
Dietrich, 2004).
There is evidence that DCAF7 could be required for cellular proliferation (Miyata & Nishida,
2011; Ritterhoff et al., 2010). Both DYRK1A and DCAF7 bind to the C-terminal region of
oncoprotein E1A (Komorek et al., 2010; Zemke & Berk, 2017). This region of E1A is
responsible for restraining its oncogenic and transforming abilities. It was found that an E1A
mutant defective in binding DYRK1A and DCAF7 showed a robust increase in proliferation,
transformation and tumor formation as compared to wildtype E1A (Komorek et al., 2010). This
suggests that E1A interaction with DYRK1A and DCAF7 could inhibit cell proliferation.
DCAF7 is also required to maintain normal levels of DYRK1A and DYRK1B in C2C12 and
HeLa cell lines (Yousefelahiyeh et al., 2018).
We and others have detected DCAF7 as a binding partner of DYRK1A (Glenewinkel et al.,
2016; Guard et al., 2019; Komorek et al., 2010; Menon et al., 2019; Miyata & Nishida, 2011;
Morita et al., 2006; Roewenstrunk et al., 2019; Skurat & Dietrich, 2004; Varjosalo et al., 2013).
Furthermore, it was found that the interaction between DYRK1A and DCAF7 is evolutionarily
conserved (Glenewinkel et al., 2016), as shown in Figure 15. Interestingly, WD40 repeats of
DCAF7 alone are not sufficient for the binding of DCAF7 to DYRK1A but the N- and Ctermini of DCAF7 are also required (Miyata & Nishida, 2011). It was determined that the
minimal region in DYRK1A required for DCAF7 binding is located in the N-terminus and spans
amino acids 93-104 of human DYRK1A (Glenewinkel et al., 2016; Miyata & Nishida, 2011).
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Additional functions of DCAF7 include a role in the osmotic stress response (Ritterhoff et al.,
2010) and control of GLI1 transcriptional activity through interaction with mDia1 (DIAPH1)
(Morita et al., 2006). Additionally, it has been reported that DCAF7 is required for nucleotide
excision repair by maintaining the cellular levels of ERCC1-XPF (Kawara et al., 2019). This is
the first report suggesting a direct role of DCAF7 in regulation of a DNA repair pathway and is
interesting given the role of DYRK1A in DNA repair (Guard et al., 2019; Menon et al., 2019;
Roewenstrunk et al., 2019). DCAF7 was also recently shown to regulate stability of DNA ligase
I (LIG1), one of the key enzymes in the DNA replication and repair of DNA DSBs (Z. Peng et
al., 2016). Another DCAF7 interacting protein detected in multiple studies is the molecular
chaperone TRiC/CCT. It was shown that molecular chaperone TRiC/CCT binds to DCAF7 and
promotes its folding, binding to DYRK1A and nuclear accumulation (Miyata et al., 2014).
Finally, DCAF7 has also been reported to have functions in transcription that will be discussed in
detail in Chapter 4.
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Figure 15: The DYRK1A-DCAF7 interaction is conserved across evolution.
(A) Consensus sequence of the DCAF7 binding motif in class 1 DYRKs created by analyzing 19
representative sequences from Class I DYRKs from the animal kingdom. (B) Phylogenetic
relationship of the DYRKs and HIPKs that interact with DCAF7 [Adopted from (Glenewinkel et
al., 2016)].
3.1.2. LZTS proteins
In our MudPIT analysis of DYRK1A, we identified PSD-Zip70 (or LZTS1), LAPSER1 (or
LZTS2) and ProSAPiP1 (LZTS3), which all belong to a ‘Fezzin’ family of proteins (Wendholt et
al., 2006). Along with the characteristic Fez1 domain/s, LZTS1 and LZTS2 also have a coiledcoil region with an internal leucine zipper motif in the center part of the protein and a PDZ
domain at their C-terminus (Wendholt et al., 2006). These proteins can form homo or heterooligomers (Schmeisser et al., 2009; Wendholt et al., 2006). Note that LZTS1 is also referred to as
FEZ1 in some studies. The function of this family of proteins is not fully understood.
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Interestingly, LZTS1, LZTS2 and LZTS3 were identified as Post Synaptic Density (PSD)
proteins (Dolnik et al., 2016; Schmeisser et al., 2009; Wendholt et al., 2006), and they all bind
directly to the signal-induced proliferation associated (SIPA) family of proteins that includes
SIPA1, 2, and 3, also known as SPARs or spine-associated RapGAPs. SPARs are GTPase
activating proteins (GAPs) in the brain (Dolnik et al., 2016; Reim et al., 2016; Wendholt et al.,
2006). The expression profile of LZTS1 detected in mouse and chick embryos revealed that it is
localized to regions involved in neuronal development (Kropp & Wilson, 2012). LZTS1 knock
out mice show cognitive and behavioral defects due to abnormal Rap2 activity (Mayanagi et al.,
2015), suggesting that the LZTS proteins may be associated with behavioral disorders. A recent
publication suggests a previously unknown role of LZTS1 during mammalian cerebral
development. This study showed that LZTS1 controls neuronal delamination and outer radial
glial-like cell generation (Kawaue et al., 2019). Furthermore, LZTS2 could serve as a negative
regulator in regulation of β-catenin localization from the synapse to nucleus, leading to decreased
transcription of β-catenin target genes (Schmeisser et al., 2009).
It is not known if there is a functional connection between DYRK1A and the LZTS family in
neurological disorders. Interestingly, DYRK1A also phosphorylates proteins that bind to clathrin
coated vesicles and inhibits clathrin-mediated endocytosis in neurons (Murakami et al., 2009,
2012). Moreover, DYRK1A may also be regulated by Wnt signaling (Granno et al., 2019).
Hence DYRK1A-LZTS interactions in this regard will be an interesting avenue of study.
3.1.3. Role of LZTS proteins in cancer
As suggested by the name (LZTS stands for Leucine Zipper Tumor Suppressor), LZTS1, LZTS2
and LZTS3 have tumor suppressive functions. Indeed, Lzts1-/- mice develop tumors with diverse
histogenetic backgrounds and LZTS1 expression is frequently lost in various types of cancers
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(Ishii et al., 1999; Vecchione et al., 2007) suggesting that it acts as a major tumor suppressor
gene in multiple cell types. Reintroduction of LZTS1 into cancer cells that lack its expression
suppresses cell proliferation by cell cycle arrest at the G2/M phase of the cell cycle, and this
effect is thought to be mediated by its interaction with mitotic kinase CDK1 (Ishii et al., 1999;
Vecchione et al., 2007). LZTS1 expression is reduced in hepatocellular carcinoma (Y. He & Liu,
2015; Zhang et al., 2015), and there is evidence of LZTS mediated suppression of proliferation
by impairing the PI3K/Akt pathway in hepatocellular carcinoma (Y. He & Liu, 2015). Down
regulation of LZTS1 is associated with poor prognosis and causes increased metastasis in breast
cancer (L. Chen et al., 2009; W. Chen et al., 2007; Lovat et al., 2014; X.-X. Wang et al., 2011,
2015). LZTS1 is lost or silenced in various other cancers including uveal melanoma (Onken et
al., 2008), prostate cancer (Cabeza-Arvelaiz et al., 2001; Ishii et al., 1999), squamous cell
carcinoma (Olasz et al., 2015), lung cancer (Lin et al., 2013; Nonaka et al., 2005; Toyooka et al.,
2002) and ovarian cancer (Arnold et al., 2006; Califano et al., 2010; Ishii et al., 1999).
Similar to LZTS1, LZTS2 is also frequently deleted in cancer. LZTS2 has been mapped to a subregion of human chromosome 10q24.3, near the PTEN locus (Cabeza-Arvelaiz et al., 2001;
Wendholt et al., 2006). In laryngeal squamous cell carcinoma, LZTS2 promoter methylation has
been reported (Z. Shen et al., 2018). Loss of LZTS2 in mice leads to renal abnormalities and an
increased incidence of cancer (Johnson et al., 2013; Y. Peng et al., 2011). Overexpression of
LZTS2 cDNA strongly inhibits cell proliferation and the colony forming efficiencies of some
cancer cell lines (Cabeza-Arvelaiz et al., 2001). Increased nuclear localization of β-catenin due to
aberrant activation of the Wnt pathway contributes to cancer, and LZTS2 binds to β-catenin and
promotes its nuclear exclusion, thus increasing the cytosolic pool of β-catenin (Thyssen et al.,
2006). It was recently demonstrated that PTEN and LZTS2 both control β-catenin mediated
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transcription (E.-J. Yu et al., 2017). Interestingly, a connection between DYRK1A and β-catenin
was recently reported where activation of Wnt signaling altered the sub-cellular localization of
DYRK1A by an unknown mechanism (Granno et al., 2019). Furthermore, LZTS2 was seen to
inhibit cell proliferation and regulate Lef/Tcf-dependent transcription through the Akt/GSK3β
signaling pathway in lung cancer (Cui et al., 2013). LZTS2 inhibits PI3K/AKT activation in
nasopharyngeal carcinoma as well (Xu et al., 2018). Finally, the protein interaction network of
the mammalian Hippo pathway revealed interaction of LZTS2 with LATS2 (Couzens et al.,
2013). Thus, this particular DYRK1A-interacting protein found through the proteomic analysis
could provide a connection between cancer-related cellular signaling pathways and DYRK1A.
The role of LZTS3 in cancer has been studied to a lesser extent. Like LZTS1 and LZTS2, it is
thought to have a tumor suppressive function (J. He et al., 2018; Teufel et al., 2005).
3.1.4. FAM117B
FAM117B (Family with sequence similarity 117, member B) is a poorly studied but potentially
important DYRK1A interacting protein. A study conducted in 215 individuals with either
Autism spectrum disorder (ASD) or intellectual disability reported the presence of several gene
copy number changes. In this study, FAM117B was one of the 46 genes located in a region of 7.8
Mb chromosomal deletion at 2q33.1 to q34. This suggests that FAM117B could also be involved
in ASD or intellectual disability and it will be interesting to see if it has a link with the
involvement of DYRK1A in neurological conditions (Roberts et al., 2014). Interestingly, a
GWAS study recently found that FAM117B was one of the genes associated with cerebral small
vessel disease. Further, using two independent single cell RNA sequencing datasets from the
anterior temporal lobe of adult human brains and cerebrovascular cells of adult mouse brains,
researchers found that FAM117B was expressed in various cell types that included astrocytes,
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neurons and oligodendrocytes (Chung et al., 2019). This further suggests that FAM117B could
play an important role in neurological processes and since it is a DYRK1A-interacting protein,
FAM117B could be dependent on or influence DYRK1A’s function in neurological conditions.
3.1.5. TROAP
Tastin was initially described as a protein that forms a complex with trophinin and bystin, hence
it was renamed as TROphinin Associated Protein or TROAP. The TROAP-trophonin-bystin
complex is required for the initial adhesion of the blastocyst to uterine epithelial cells at the time
of embryo implantation (Fukuda & Nozawa, 1999). Although TROAP expression is absent in
most adult tissues (Nadano et. al., 2002), higher levels of expression are observed in testis, bone
marrow and thymus, as well as human cancer cell lines such as HeLa and Jurkat cells (Genomics
Institute of the Novartis Research Foundation [GNF] database). In mammalian cells, TROAP is
thought to associate with microtubules (Nadano et al., 2002). Levels of TROAP increase in the
G2/M phase of the cell cycle and it has been found to be required for maintaining bipolar
spindles and the integrity of the centrosome during mitosis (Yang et al., 2008). Ectopically
expressed TROAP in COS7 cells forms fibers that localize to the microtubular cytoskeleton and
binds to cytoplasmic dynein in HEK293T cells (Nadano et al., 2002). The role of TROAP in
cancer has been studied by several groups. TROAP was found to be pro-tumorigenic in lung
adenocarcinoma (Z. Chen et al., 2019), non-small cell lung cancer (Huang et al., 2019), breast
cancer (Kai Li et al., 2019), ovarian cancer (Godoy et al., 2013), colorectal cancer (X. Ye & Lv,
2018), gastric cancers (Jing et al., 2018) and prostate cancer (J. Ye et al., 2019). In breast cancer,
lung adenocarcinoma and gastric cancers, higher expression of TROAP was found to correlate
with lower survival (Z. Chen et al., 2019; Jing et al., 2018; Kai Li et al., 2019). However,
TROAP may play a dual role and both promote and suppress tumorigenesis in hepatocellular
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carcinoma (H. Hu et al., 2019; Jiao et al., 2019; Lian et al., 2018). In breast cancer cells, TROAP
depletion was found to cause cell cycle arrest in the G1/S phase of the cell cycle (Kai Li et al.,
2019). Depletion of TROAP in gastric and colorectal cancer cells also leads to an arrest in the
G0/G1 phase of the cell cycle (Jing et al., 2018; X. Ye & Lv, 2018). In NSCLC, expression of
TROAP along with certain other genes was found to be deregulated in pre-cancerous lesions and
was gradually altered with disease progression suggesting that TROAP may be involved during
tumorigenesis (Huang et al., 2019). These findings suggest that TROAP could be a therapeutic
target in several cancer types, and provide the rationale for further research.
3.2. RESULTS
3.2.1. MudPIT proteomic analysis of DYRK1A interacting proteins
In our earlier study, we reported the interaction of DYRK1A with RNF169, FAM117B, LZTS1,
LZTS2 and TROAP. MudPIT proteomic analysis of DYRK1A revealed that DCAF7 interacts
stoichiometrically with DYRK1A, suggesting that it is a major DYRK1A interacting protein.
Since DCAF7 is a known scaffolding protein, we hypothesized that some of these proteins could
form multi-protein complexes, which could be important for understanding the function of
DYRK1A. We also hypothesized that DCAF7 acts as a scaffold to bring all these proteins
together. In order to identify multi-protein complexes, we decided to first analyze the
interactome of DCAF7 in T98G cells in a similar way as we did for analyzing the DYRK1A
interactome. We detected 55 proteins that reproducibly bound DCAF7 in at least 2 out of 3
replicate experiments. Unexpectedly, we found only a small overlap with DYRK1A interacting
proteins (indicated by a black outline, Figure 16). Several known interactors of DCAF7 were
also detected, including components of PRC1.3/5 (will be discussed in Chapter 4) and the
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chaperone TRiC/CCT complex that binds to DCAF7 and promotes its folding (Miyata et al.,
2014).
Next, we similarly analyzed the interactomes of other novel DYRK1A interacting proteins to see
if there is any overlap with DYRK1A and DCAF7 interactomes. RNF169, FAM117B, LZTS2,
LZTS1 and TROAP reproducibly pulled down 28, 113, 183, 678 and 17 proteins respectively in
at least 2 out of 3 biological replicates (Appendix tables and Figure 17A-E), including known, as
well as novel, interactors for each of these proteins. As LZTS2, LZTS1 and FAM117B bound a
large number of proteins, we sorted these reproducible interactors by their dNSAF score (relative
abundance compared to all proteins detected), to identify the top enriched 50 interacting proteins
detected in at least 2 biological replicates. We observed that, except for of RNF169, the
interactomes of FAM117B, LZTS1, LZTS2 and TROAP did not show major overlap with
DYRK1A (Appendix tables and Figure 17). Interestingly, all these proteins did pull down
DCAF7 (Figures 17 and 18). Only a few proteins detected in these analyses also bound DCAF7
(shown by yellow labels in Figures 17 A-E and indicated in bold in Appendix tables). In
summary, our MudPIT proteomic analysis revealed that while there were no apparent multisubunit complexes with our novel DYRK1A interacting proteins, all of these proteins bound both
DYRK1A and DCAF7 (Figures 17 and 18). This could support a model that DCAF7 plays a
scaffolding role to promote these interactions.
3.2.2. DYRK1A interacting proteins bind DCAF7
Next, we wanted to validate if the DYRK1A binding proteins bound DCAF7. Using T98G cell
lysates we carried out IP/WB analysis with antibodies against RNF169, FAM117B, LZTS2,
LZTS1 and TROAP. Consistent with our previously observed result, all of these proteins bound
DYRK1A. Furthermore, consistent with our new mass spec data, all of these DYRK1A
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interacting proteins also bound DCAF7 (Figure 19, A-E). Next, we wanted to confirm our
finding that these proteins apparently do not form a multi-subunit complex. Therefore, using
T98G cells we carried out IP analysis of RNF169, FAM117B, LZTS1, LZTS2, TROAP and
DYRK1A followed by WB analysis with DCAF7, DYRK1A and each bait protein. Indeed, we
detected both DYRK1A and DCAF7 in all immunoprecipitates, but did not find interaction
between most of the pulled-down proteins, thus confirming our results obtained by MudPIT
proteomic analysis, suggesting that these proteins were not all present in a single complex
(Figure 19F). One exception to this was previously reported binding between LZTS1 and LZTS2
(Figure 19F). Although our LZTS1 MudPIT analysis detected TROAP, we were unable to
confirm this interaction by IP/WB (Figure 18, 19F).
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Figure 16: Analysis of the DCAF7-interacting protein network.
(A) Purification of DCAF7 for MudPIT proteomic analysis. Top: Representative western blot
showing levels of DCAF7 in T98G cells expressing HA- Flag tagged GFP (GFP-FH) or HAFlag-tagged DCAF7 (DCAF7-FH). Arrow indicates epitope tagged DCAF7. Values show band
density relative to Vinculin (control). Bottom: representative silver stained gel containing 10% of
HA-peptide eluted control (GFP) or DCAF7-FH IP samples analyzed by MudPIT. Green arrow
indicates DCAF7 (B) Graph shows relative enrichment (dNSAF) of proteins detected in two or
all three DCAF7 MudPIT experiments. DCAF7 is shown as a green circle whereas red and blue
circles correspond to interacting proteins either listed in the BioGrid database, or new DCAF7binding proteins, respectively. Black arrow points to DYRK1A. (C) Hierarchical network of
interactions (CytoScape) involving DCAF7-binding proteins identified in this study was
constructed using MetaScape analysis tool. Colors, same as in (B). Larger nodes correspond to
proteins detected in all three replicates and smaller nodes correspond to proteins detected in two
biological replicates. Unconnected nodes are not known to interact with other factors. Black
outline indicates an overlap with our previous DYRK1A dataset (detected in at least 2 out of 4
biological DYRK1A pull down experiments).

48

49

Figure 17: Analysis of protein networks of DYRK1A interacting proteins.
Hierarchical networks of interactions (CytoScape) for (A) LZTS2, (B) LZTS1, (C) FAM117B,
(D) RNF169 and (E) TROAP were constructed using MetaScape analysis tool. Larger nodes
correspond to proteins detected in all three replicates while smaller nodes correspond to proteins
detected in two biological replicates. Unconnected nodes are not known to interact with other
factors. Bait protein is shown in green whereas red and blue circles correspond to interacting
proteins either listed in the BioGrid database, or new-RNF169 binding proteins, respectively.
Black outline indicates an overlap with our previous DYRK1A dataset (detected in at least 2 out
of 4 biological DYRK1A pull down experiments). Yellow label indicates an overlap with our
DCAF7 dataset (Detected in at least 2 out of 4 biological DCAF7 pull down experiments). Note:
Overlap with BioGrid database was analyzed in May 2019, which was before the inclusion of
our DYRK1A dataset into the BioGrid.
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Figure 18: Summary of MudPIT proteomic analysis for our novel DYRK1A interacting
proteins.
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Figure 19: DYRK1A interacting proteins bind DCAF7 but do not form a single complex.
(A-F) T98G lysates were used to perform immunoprecipitation analysis with the indicated
antibodies or with non-reactive IgG control antibody followed by WB analysis for detection of
the indicated proteins. As RNF169, FAM117B, TROAP and LZTS2 have similar molecular
weights, Figure 21F is a composite figure made from 4 independent IP/WB experiments in order
to avoid any residual overlapping signal from different antibodies during the WB analysis.
DCAF7 and DYRK1A were detected in each IP/WB experiment as controls, and looked identical
for all four independent experiments, therefore representative panels are shown.
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In order to identify if these complexes were mainly present in the nucleus or in the cytoplasm,
we carried out cyto-nuclear fractionation of T98G cells and subjected the cytoplasmic and
nuclear extracts to IP/WB analysis (Figure 20). Consistent with its role in DNA damage repair,
we found that RNF169 is mainly a nuclear protein and that the RNF169-DYRK1A-DCAF7
complex is also mainly nuclear in the cell [Figure 20A, (An et al., 2018; J. Chen et al., 2012;
Guard et al., 2019; Menon et al., 2019; Poulsen et al., 2012; Roewenstrunk et al., 2019)].
Interestingly we also observed that the cytoplasmic RNF169 also binds both DYRK1A and
DCAF7 (Figure 20A). We also observed that nuclear RNF169 migrates slower as compared to
the cytoplasmic form, which could indicate the presence of a post translational modification in
the nuclear compartment. Unlike the RNF169-DYRK1A-DCAF7 complex, FAM117B, LZTS2
and LZTS1 complexes were mainly cytoplasmic (Figure 20A-D). Interestingly, we observed that
two isoforms of TROAP are present in the cytoplasm whereas only the longer isoform is present
in the nucleus, and that the TROAP-DYRK1A-DCAF7 complex was detected mainly in the
cytoplasm, but is also present in the nucleus (Figure 20E).
3.2.3. DCAF7 is not a scaffolding protein for DYRK1A tertiary complexes
Next, we investigated if DCAF7 is required for the interaction of DYRK1A with RNF169,
FAM117B, LZTS2, LZTS1 and TROAP (Figure 21 A-E). We carried out IP/WB analysis in U-2
OS control or shDCAF7 cell lines in which DCAF7 was depleted by two different shRNA
hairpins. Interestingly, we observed that depletion of DCAF7 reduced the levels of DYRK1A.
This is consistent with a previous report suggesting that DCAF7 is required to maintain levels of
DYRK1A (Yousefelahiyeh et al., 2018). Furthermore, it was found that DCAF7 is not required
for RNF169, FAM117B or TROAP to bind DYRK1A but it might be needed for LZTS1/2DYRK1A binding.
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Figure 20: Nucleo-cytoplasmic distribution of the tertiary complexes including DYRK1A
and DCAF7.
(A-E): T98G cells were fractionated into nuclear and cytoplasmic compartments followed by IP/
WB analysis with the indicated antibodies. Tubulin and Lamin were used to confirm the
cytoplasmic and nuclear fractions, respectively.
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Figure 21: DCAF7 is not required for RNF169, FAM117B, TROAP to bind DYRK1A but it
might be needed for LZTS1/2-DYRK1A binding.
(A-E) Lysates from U-2 OS control or shDCAF7 cells were subjected to IP/WB analysis with
indicated antibodies. IgG represents non-specific, control antibody. Arrows point to bands of
interest and asterisk indicates non-specific band. DYRK1A band density in the IP lanes was
quantified relative to bait protein using ImageJ analysis. Numbers indicate DYRK1A band
density values relative to input.
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Next, we sought to analyze if DYRK1A is required for mediating the interaction of RNF169,
FAM117B, LZTS1, LZTS2 or TROAP with DCAF7 (Figure 22). We used U-2 OS control or U2 OS cell line in which DYRK1A has been knocked out using the CRISPR-Cas9 approach (KO
#1 used in Chapter 2). As an additional control, we used a rescue DYRK1A KO cell line in
which recombinant DYRK1A was stably re-expressed (same cell line used in Chapter 2).
Interestingly, we found that the interaction of RNF169, FAM117B, LZTS1, LZTS2 and TROAP
with DCAF7 was reduced in the absence of DYRK1A, but restored in the rescue cell line (Figure
22A-E). Therefore, we can conclude that DYRK1A is required for the interaction of RNF169,
FAM117B, LZTS1, LZTS2 and TROAP with DCAF7. Of note, we have consistently observed
that FAM117B migrates higher in the presence of DYRK1A than in DYRK1A-KO cells
indicating the presence of a post-translational modification. This difference was recapitulated
using siRNA knockdown of DYRK1A in T98G cells. Using λ-phosphatase treatment in cell
lysates from U-2 OS cells, we were able to confirm that this modification was indeed due to
phosphorylation (Figure 23A, B).
It has been reported that the amino acids 93-104 of DYRK1A are required for its interaction with
DCAF7 (Glenewinkel et al., 2016). We wanted to determine if the DCAF7 binding site in
DYRK1A was also required for its interaction with RNF169, FAM117B, LZTS2 and TROAP
(Figure 24). We transiently transfected either GFP (negative control) or GFP-DYRK1A Nterminal deletion constructs or rescue constructs expressing only certain N-terminal regions of
DYRK1A (Figure 24A), followed by a GFP-pull down and WB analysis of DYRK1A interacting
proteins (Figure 24B). We confirmed that DCAF7 bound to DYRK1A through the 93-104 amino
acids (Figure 24A-B; indicated with red boxes), and found that RNF169, LZTS2 or FAM117B
were not able to bind DYRK1A when the DCAF7 binding domain was deleted. This suggests
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that the DCAF7 binding domain in DYRK1A is required for its interaction with RNF169,
LZTS2 and FAM117B. Further, as previously shown, a GFP-DYRK1A fragment comprised of
the first 103 amino acids was sufficient for DCAF7 binding (Figure 24A-B; indicated with red
boxes). However, this construct did not bind RNF169, FAM117B, or LZTS2. This suggested that
the DCAF7 binding region in DYRK1A was necessary but not sufficient for its interaction with
RNF169, FAM117B or LZTS2. Interestingly, the minimal region of DYRK1A that binds
RNF169, FAM117B and LZTS2 was found to encompass amino acids 77-136 of DYRK1A. Of
note, RNF169, FAM117B and LZTS2 bound DYRK1A 77-136 more strongly than DYRK1A 1176, which also harbors the minimal binding region within it (Figure 24 A-B; indicated with red
boxes). Interestingly, a different pattern of binding was observed for TROAP, which bound
DYRK1A Δ93-104 even in the absence of DCAF7 binding. However, the deletion of the first
134 amino acids at the N-terminus of DYRK1A was also able to abolish its binding with TROAP
while none of the DYRK1A N-terminal rescue fragments were able to bind to TROAP. We
therefore used DYRK1A C-terminal constructs and carried out a similar experiment in order to
further map the TROAP binding region (Figure 25A-B). Deletion of most of the kinase domain
of DYRK1A (DYRK1A Δ174-487) reduced the binding of TROAP to DYRK1A, while a kinase
inactive mutant DYRK1A Y321F was able to bind TROAP indicating that the kinase domain but
not activity of DYRK1A is required for this interaction (Figure 25A-B).
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Figure 22: DYRK1A is required for DCAF7 interaction with RNF169, FAM117B, LZTS2,
LZTS1 and TROAP.
(A-E) Lysates from U-2 OS control, DYRK1A KO or DYRK1A KO rescue cell line with
expression of recombinant DYRK1A were used for IP/WB analysis for indicated proteins. IgG
represents a control antibody. Arrows point to bands of interest.
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Figure 23: DYRK1A phosphorylates FAM117B.
(A) T98G cell lysates were treated with non-targeting siRNA or siRNA against DYRK1A
followed by WB analysis for indicated proteins. (B) Indicated T98G cell lysates were incubated
with or without λ-phosphatase followed by WB analysis.
3.2.4. Effect of DYRK1A on localization of its interacting proteins
Since binding to DYRK1A was required for novel DYRK1A interacting proteins to bind
DCAF7, we wanted to investigate whether loss of binding was due to a change in sub-cellular
localization in DYRK1A-KO cells. We used U-2 OS cells stably expressing epitope-tagged
RNF169, FAM117B, LZTS2, LZTS1 or TROAP, followed by immunofluorescence staining
using anti-HA antibody and confocal microscopy. Consistent with our cyto-nuclear fractionation,
we observed RNF169 to be nuclear, however, its localization did not change in the absence of
DYRK1A. All the other DYRK1A interacting proteins were cytoplasmic both in the presence
and in the absence of DYRK1A. However, we observed increased FAM117B accumulation in
the peri-nuclear space in the absence of DYRK1A. Further studies will be required to confirm
this and to analyze the mechanisms that regulate these proteins in the cell (Figure 26, A-F).
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Figure 24: DCAF7 binding domain in DYRK1A is necessary but not sufficient for
interaction with RNF169, FAM117B, LZTS2 and is not involved in binding TROAP.
(A) Schema of GFP-DYRK1A constructs used in B. (B) T98G cells were transfected with
indicated DYRK1A constructs and used for IP with GFP-trap beads followed by a WB for
proteins of interest. A composite figure was created from four different IP/WB experiments in
order to avoid any overlapping signals from residual antibodies. The GFP and DCAF7 pull
downs were identical in each experiment, and representative panels are shown.
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Figure 25: TROAP binding requires the kinase domain of DYRK1A.
(A) Schema of GFP-DYRK1A constructs used in B. (B) T98G cells were transfected with
indicated DYRK1A constructs and used for IP with GFP-TRAP beads followed by a WB
analysis for proteins of interest. (C) Schema depicting the regions of DYRK1A required for
binding DCAF7, RNF169, FAM117B, LZTS2 and TROAP.
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Figure 26: Localization of DYRK1A interacting proteins in the presence or absence of
DYRK1A
U-2 OS control or DYRK1A KO cells stably expressing (A) HA-RNF169, (B) FAM117B-FH,
(C) FH-LZTS2, (D) FH-LZTS1, (E) FH-DCAF7 and (F) FH- TROAP were plated on coverslips,
fixed and stained with an anti-HA antibody followed by immunofluorescence analysis. Left WB
panel indicates cell lines used and immunofluorescence images are on the right. Scale bar is
10μm.
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3.2.5. Effect of DCAF7 on DYRK1A mediated growth suppression
Overexpression of DYRK1A causes inhibition of cell proliferation and G0/G1 cell cycle arrest in
several cell lines, including U-2 OS (Litovchick et al., 2011). Since DCAF7 is a major DYRK1A
interacting protein that also binds other DYRK1A interactors, we first analyzed if DCAF7 is
involved into DYRK1A mediated growth suppression. We transiently transfected U-2 OS cells
with either full length or DYRK1A deletion mutant deficient in binding DCAF7 (GFPDYRK1A Δ93-104), or GFP alone as a control. This was followed by fixing and staining the
cells with anti- Ki67 antibody. Ki67 is a protein that is present in all active phases of the cell
cycle but absent in the resting G0 phase. Therefore, it is an excellent marker for measuring the
percentage of actively cycling cells (Scholzen & Gerdes, 2000). U-2 OS cells transfected with
GFP-DYRK1A had a significantly reduced fraction of Ki67-positive cells as compared to cells
transfected with GFP alone (Figure 27B). Cells transfected with GFP- DYRK1A Δ93-104 also
had significantly reduced Ki67 positive cells as compared to the GFP alone (Figure 27). This
suggests that DYRK1A is able to inhibit proliferation of cells even when unable to bind DCAF7.
Moreover, GFP-DYRK1A or GFP-DYRK1A Δ93-104 similarly suppressed proliferation of U-2
OS cell lines stably overexpressing DCAF7 (Figure 27B). This suggests that even when DCAF7
is present in excess, it does not overcome the growth suppressive function of DYRK1A (Figure
27A-B). Overexpression of DYRK1A leads to cell cycle arrest in the G0/G1 phase of the cell
cycle (Litovchick et al., 2011). Therefore, we wanted to characterize the cell cycle profile of the
cells arrested upon expression of the DYRK1A mutant deficient in binding DCAF7.

For

additional confirmation, we also used another mutant that lacked the N- terminus of DYRK1A
(DYRK1A Δ1-134). We used the GFP-negative cells within each sample as our control. As
compared to GFP negative cells in the same samples, cells transfected with GFP-DYRK1A or
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GFP-DYRK1A deletion mutants were able to cause a G0/G1 cell cycle arrest (compare orange
bars in Figure 28A). Further, DYRK1A overexpression in shDCAF7 cell lines also led to a
G0/G1 cell cycle arrest (Figure 28B). These data collectively suggest that DYRK1A does not
require DCAF7 for its ability to induce G0/G1 arrest (Figures 27,28). Since RNF169, LZTS2,
FAM117B also bind through the N-terminus of DYRK1A, it is likely that they do not play a role
in the growth suppressive function of DYRK1A.

Figure 27: Role of DCAF7 in DYRK1A-mediated inhibition of proliferation.
(A) WB indicating U-2 OS parental and DCAF7-FH cell lines transfected with GFP or GFPDYRK1A constructs. (B) Graph shows a fraction of GFP (+)/Ki67 (+) cells in the indicated cell
lines measured by FACS analysis. Graph indicates average of 3 biological replicates and error
bars indicate standard deviation. p-values were obtained using two tailed Student’s t-test and are
shown on the graphs.
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Figure 28: Role of DCAF7 in DYRK1A-mediated growth arrest.
U-2 OS cells or derivatives expressing sh control or sh DCAF7 were transfected with indicated
GFP-DYRK1A constructs followed by cell cycle analysis using PI staining of DNA. (A) Left
panel shows representative WB indicating expression of GFP or GFP-DYRK1A in U-2 OS
parental cells. Graph shows average distribution of GFP DYRK1A (-) or GFP-DYRK1A (+)
cells in each cell cycle phase from 2 biological repeats. Here and below, the error bars indicate
standard deviation. (B) Left panel shows representative WB indicating expression of DCAF7 in
sh control or DCAF7 knockdown (two independent clones) cell lines used for cell cycle analysis.
Right panel indicates average counts of cells in each cell cycle phase from GFP DYRK1A (-) or
GFP-DYRK1A (+) cells from 3 biological repeats.
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The experiments described above analyzed the growth suppressive function of DYRK1A after a
transient transfection. We wanted to determine whether DCAF7 could influence the growth
suppressive effect of DYRK1A overexpression for an extended time period. We used U-2 OS
cells capable of inducible expression of wild type or kinase dead DYRK1A (DYRK1A K188R)
under the control of a doxycycline responsive promoter (Himpel et al., 2001; Litovchick et al.,
2011), with and without overexpression of DCAF7 in the same background (Figure 29C). We
induced DYRK1A expression using doxycycline in U-2 OS control or DCAF7-overexpressing
cells for a period of 8 days, and analyzed cell proliferation using crystal violet assay (Figure
29A-B). Consistent with published results, a significant reduction in cellular proliferation was
observed with extended overexpression of wildtype DYRK1A but not the kinase dead mutant, as
compared to their uninduced controls (Litovchick et al., 2011). However, this effect was
observed to a lesser extent in cells over expressing DCAF7 (Figure 29A-B). This suggests that
DCAF7 and DYRK1A can have opposing effects on maintenance of cell cycle arrested state.
3.2.6. Effect of DYRK1A interacting proteins on DYRK1A activity towards LIN52
DYRK1A is required for phosphorylation of the LIN52 subunit of the MuvB core leading to the
assembly of the DREAM complex (Litovchick et al., 2011). We therefore wanted to analyze if
DCAF7 and other DYRK1A-interacting proteins affected DYRK1A activity towards LIN52
phosphorylation. Briefly, lysates from U-2 OS control, or DCAF7 depleted cells or
overexpressing cells were incubated with GST-LIN52 and ATP for 0, 30 or 60 minutes.
Consistent with lack of effect on G0/G1 arrest function, knockdown or overexpression of
DCAF7 did not influence DYRK1A activity towards LIN52 (Figure 30 A, B, C).
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Figure 29: Role of DCAF7 in DYRK1A-mediated growth arrest
U-2 OS control or DCAF7 overexpressing cells were induced with Doxycycline to express
DYRK1A WT or DYRK1A KR followed by crystal violet staining, dissolving the dye and
colorimetric quantification. (A) Representative images of crystal violet stained plates (B) Graph
indicating proliferation of Doxycycline-treated cells relative to untreated control from three
biological replicates. Statistical significance was calculated using two-tailed Student’s t-test and
significant p-values are shown on the graph. (C) Representative WB with cell lines used in this
experiment.
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Figure 30: DCAF7 does not influence DYRK1A activity towards LIN52
(A) Cell lysates from U-2 OS control or shDCAF7 cell lines were incubated with GST-LIN52,
kinase buffer and ATP for an in-vitro kinase assay for different time points, and analyzed by WB
Representative WB from one experiment is shown. (B) U-2 OS GFP-FH or DCAF7-FH cell
lysates were used for an in-vitro kinase assay as in (A) and analyzed by WB. Representative WB
from one experiment is shown. (C) Graphs depict ImageJ densitometry analysis of p-LIN52
signal relative to GST (average from three independent experiments). Error bars show standard
deviation. No statistically significant differences were found using 2-way ANOVA.
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Next, we used the same approach to analyze if any of the other DYRK1A interacting proteins
including RNF169, FAM117B, TROAP, LZTS1 or LZTS2 regulated the activity of DYRK1A
towards LIN52. Transient depletion or overexpression of RNF169, FAM117B and TROAP did
not have an effect on LIN52 phosphorylation (Figure 31 A-C). Since there was no significant
effect, we only report here the quantifications of data for these assays. On the other hand,
knockdown of either LZTS1 or LZTS2 led to a decrease in DYRK1A-mediated LIN52
phosphorylation (Figure 33A and 32A). We confirmed this result using an additional siRNA
against LZTS1 (Figure 33B), and two different shRNA clones against LZTS2 (Figure 32B). Note
that the extent of decrease in LIN52 phosphorylation correlated with the level of LZTS2
knockdown [compare shLZTS2 (1) to shLZTS2 (2) in Figure 32B].
From our biochemical experiments, we know that LZTS1 and LZTS2 bind each other. Therefore,
we wanted to analyze if LZTS1 and LZTS2 have a combined effect towards LIN52
phosphorylation or if they have redundant functions. We transiently knocked down LZTS1 in U2 OS control or the two shLZTS2 cell lines and analyzed the effect on DYRK1A mediated
LIN52 phosphorylation (Figure 34). Like in Figures 32 and 33, single knockdown of LZTS1 or
LZTS2 did lead to a reduction in LIN52 phosphorylation. However, combined knockdown of
LZTS1 and LZTS2 failed to completely inhibit DYRK1A activity towards LIN52. Of note,
knocking down LZTS1 in the cell line expressing shLZTS2 (2) gives a better inhibition of
DYRK1A activity as compared to the control but it was still not a complete inhibition.
Therefore, we can conclude that LZTS1 and LZTS2 regulate DYRK1A activity together and not
redundantly. Of note that knock down of LZTS1 in shLZTS2 cell lines tends to further reduce
LZTS2 levels suggesting that LZTS1 could be required for optimal LZTS2 levels.
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Figure 31: Depletion of RNF169, FAM117B or TROAP does not influence DYRK1A
activity towards LIN52
(A-C) Cell lysates from U-2 OS control or indicated siRNA depleted proteins or overexpressed
proteins were used for an in-vitro kinase assay as explained in Figure 30 and analyzed by WB
with LIN52 S28-phospho specific antibody as described in- (Litovchick et al., 2011). GSTLIN52 signal was quantified using ImageJ analysis. Graphs show average p-LIN52 band density
relative to GST band density from three independent experiments. Error bars indicate standard
deviation. No statistically significant differences were found using 2-way ANOVA to compare
test groups to controls.
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Figure 32: Depletion of LZTS2 decreases DYRK1A activity towards LIN52
(A, B) Cell lysates from U-2 OS control or siRNA/shRNA mediated LZTS2 depleted cell lines
or were used for an in-vitro kinase assay as described in Figure 30. Representative WB’s from
one experiment are shown. Graphs show average p-LIN52 band density relative to GST band
density from three independent experiments. Error bars indicate standard deviation. Statistical
significance was calculated using 2-way ANOVA to compare test groups to untransfected (A) or
shControl (B) group and significant p-values are indicated on the graphs.
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Figure 33: Depletion of LZTS1 decreases DYRK1A activity towards LIN52.
(A, B) Cell lysates from U-2 OS control or two different siRNA mediated LZTS1 depleted cell
lines were used for an in-vitro kinase assay as described in Figure 30. Representative WB from
one experiment are shown. Graphs show average p-LIN52 band density relative to GST band
density from three independent experiments. Error bars indicate standard deviation. Statistical
significance was calculated using 2-way ANOVA to compare test groups to untransfected
controls. Significant p-values are indicated on the graphs.
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Figure 34: Depletion of both LZTS1 and LZTS2 does not completely abolish DYRK1A
activity towards LIN52.
(A) Cell lysates from U-2 OS control or shLZTS2 cell lines treated with control siRNA or
siRNA against LZTS1 were used for an in-vitro kinase assay for 60 minutes as described earlier.
Graphs show average p-LIN52 band density relative to GST band density from three
independent experiments. Error bars indicate standard deviation. Statistical significance was
calculated using a two tailed Student’s t-test and p-values are indicated on the graph.
Next, we analyzed if transient knockdown of LZTS1, LZTS2 or both had an effect on GFPDYRK1A mediated inhibition of proliferation. We analyzed this by transiently knocking down
LZTS1, LZTS2 or both in U-2 OS cells followed by GFP or GFP DYRK1A transfection (Figure
35A). The number of GFP (+)/Ki67 (+) cells were scored after immunostaining for Ki67. We
observed that as compared to the GFP controls, GFP-DYRK1A was able to inhibit proliferation
to a similar extent even with depletion of LZTS1 or LZTS2 or both. Therefore, LZTS1 or LZTS2
do not significantly contribute to the growth suppressive function of DYRK1A under
overexpressed conditions (Figure 35 A-B). Note that the levels of LZTS1 and LZTS2 are higher
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when GFP-DYRK1A is overexpressed, suggesting that DYRK1A regulates the levels of
LZTS1/2.

Figure 35: Effect of LZTS1 and LZTS2 on DYRK1A mediated inhibition of proliferation.
(A) Representative WB indicating knockdown of LZTS1 or LZTS2 or both in U-2 OS cell lines
expressing GFP or GFP-DYRK1A. These cells were fixed and immunostained with anti-Ki67
antibody. (B) Manual quantification of at least 100 GFP+/Ki67+ cells was performed for each
repeat. Graphs show average values obtained from 3 biological replicates. Error bars indicate
standard deviation. Statistical significance was calculated using a two tailed Student’s t-test and
significant p-values are shown on the graph.
Next, we investigated the effect of overexpression of LZTS1 or LZTS2 on DYRK1A activity in
cell extracts, and found that neither protein affected DYRK1A activity towards LIN52 (Figure
36B). However, we noticed that the migration of both DYRK1A and LZTS2 was altered with
time in LZTS2 overexpressing cells, suggesting that these proteins were post translationally
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modified (Figure 36A). Interestingly, such changes were not observed in LZTS1- overexpressing
cells (Figure 36B).

Figure 36: Effect of LZTS2 or LZTS1 overexpression on DYRK1A activity towards LIN52.
(A and B) Cell lysates from control or from cells overexpressing LZTS2 (A) or LZTS1 (B) were
used for an in-vitro kinase assay as in Figure 30 followed by WB analysis for the indicated
proteins. WB shown is from one experiment (Left panels). Graphs depict average values
obtained following ImageJ densitometry analysis of p-LIN52 signal relative to GST signal from
three independent experiments. Error bars indicate standard deviation (Right panels). No
statistically significant differences were found using 2-way ANOVA.

77

3.2.7. Post translational modification of DYRK1A in LZTS2 overexpressing cells is a
phosphorylation
Next, we explored if the modification of DYRK1A and LZTS2 in LZTS2-overexpressing cells
was due to phosphorylation. We carried out immunoprecipitation of DYRK1A from control or
LZTS2 overexpressing cells followed by treatment of the beads with λ-phosphatase. WB
analysis indicated that as compared to the untreated control, λ-phosphatase treatment abrogated
the gel shift of DYRK1A in LZTS2 overexpressing cells, suggesting that it was indeed a
phosphorylation (Figure 37A). This was also confirmed by WB analysis using a PhosTag gel
(Figure 37B). This experiment also revealed that LZTS2 itself was also phosphorylated (Figure
37A).

Figure 37: DYRK1A and LZTS2 in LZTS2 overexpressing cells are modified by
phosphorylation.
(A) Immunoprecipitation of DYRK1A from U-2 OS GFP-FH (control) or LZTS2-FH cell lysates
was performed followed by incubation of the indicated sample with λ-phosphatase and WB
analysis. Inputs and 1/3rd of IP samples were loaded in (A). (B) The remaining IP samples were
loaded on a PhosTag gel followed by WB detection of DYRK1A.
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Next, we investigated if DYRK1A phosphorylation in LZTS2 overexpressing U-2 OS cells is
caused by autophosphorylation. We treated cell lysates with Harmine or with another DYRK1A
inhibitor CX4945, before performing an in-vitro kinase assay (Göckler et al., 2009; H. Kim et
al., 2016; Walte et al., 2013). Untreated lysates or lysates treated with DMSO were used as a
control. The gel shift of DYRK1A or LZTS2 was not abolished by inhibition of the kinase
activity of DYRK1A, while LIN52 phosphorylation was completely blocked in the same assay
(Figure 38A). Moreover, HA-tagged LZTS2 migrated in a similar way in control and DYRK1AKO cell lines (Figure 38B). Thus, DYRK1A and LZTS2 are phosphorylated by a kinase other
than DYRK1A itself in U-2 OS cells overexpressing LZTS2 (Figure 38A, B).
3.2.8. Summary
Through biochemical experiments carried out in this chapter we found that DYRK1A, along with
DCAF7, exists in several hetero trimeric complexes rather than a single multi-protein complex.
We also identified that DYRK1A, and not DCAF7, is required for the formation of these
different complexes. We have also mapped the region of DYRK1A to which its interacting
proteins bind. Through the functional characterization carried out in this chapter, we have
identified LZTS1 and LZTS2 as two novel regulators of DYRK1A activity.
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Figure 38: Effect of DYRK1A loss on DYRK1A or LZTS2 phosphorylation.
(A) Lysates from U-2 OS GFP-FH cells (control) or U-2 OS LZTS2-FH cells were treated with
DMSO, Harmine or CX4945 followed by in-vitro kinase assay and WB analysis of indicated
proteins. (B). Lysates from U-2 OS control FH-LZTS2 or U-2 OS DYRK1A KO FH-LZTS2
were incubated with ATP followed by WB analysis of indicated proteins.

3.3 DISCUSSION AND FUTURE DIRECTIONS
3.3.1 MudPIT proteomic analysis of DYRK1A interacting proteins reveals novel
interactors that could help understand the regulation and substrates of DYRK1A
Except DCAF7 and RNF169, the interactome of other DYRK1A interacting proteins was not
characterized in previous studies. Importantly, this study characterized the interactome of
DYRK1A-interacting proteins in the T98G cell line derived from human glioblastoma, which is
not transformed by viral oncoproteins that could influence protein interaction networks. Apart
from DCAF7, our MudPIT proteomic analysis also provided several potential directions to
elucidate and understand the function of DYRK1A in the future studies. For example, the LZTS2
interactome shows the presence of known LZTS interactors belonging to the signal-induced
proliferation associated family of proteins (SIPA), including SIPAL1, 2 and 3, also known as
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SPARs, which in turn regulate RAP1 signaling. It is not known if DYRK1A contributes to the
function of SPARs or is regulated by RAP1. Furthermore, MudPIT proteomic analysis of
FAM117B shows the presence of proteins involved in the splicing machinery like SRSF2 and
SRSF3, as well as ribosomal proteins RPS15, RPL24, RPL31, RPL37A and eukaryotic
translation initiation factors EIF2S1, EIF2S2 and EIF3G, suggesting that FAM117B could be
involved in translation. Interestingly, five of the mitochondrial ribosomal proteins (for example:
MRPS31, MRPS38) were also found in our FAM117B pull-down analysis. As we have shown
that DYRK1A phosphorylates FAM117B, it will be interesting to determine if FAM117B plays a
role in mitochondrial ribosomal function, translation or RNA splicing, and if DYRK1A mediated
phosphorylation of FAM117B regulates these functions.
RNF169 did pull down several DNA binding proteins, which could point us towards further
understanding the mechanism of DYRK1A and RNF169 mediated regulation of DNA repair.
Interestingly RNF169 also pulled down some proteins that could be involved in transcription and
translation. These include RPL10A, ILF2, LARP1 and ELAVL1. This suggests that DYRK1A
and RNF169 could have roles in the cell apart from DNA repair.
The TROAP interactome contained the smallest number of proteins as compared to all the other
DYRK1A interacting proteins, possibly because of the cell type used. Therefore, characterization
of the TROAP interactome in a physiologically-relevant cell type, including breast or ovarian
cancer cells, will help elucidate the function of the TROAP-DYRK1A complex.
In contrast to this, both LZTS1 and LZTS2 pulled down multiple proteins, in fact more than
usually expected. This could be because of the high abundance of LZTS1 and LZTS2 in our cell
lines or because of LZTS binding to a cellular compartment such as intracellular vesicles. We
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also analyzed if there are any mutations in the construct used for LZTS1 and LZTS2 expression,
but this was ruled out. Like DYRK1A, the interactomes of DCAF7, LZTS1, LZTS2 and
FAM117B also show the presence of certain 14-3-3 proteins. Since it has been shown that
DYRK1A activity can be regulated by 14-3-3 protein (Alvarez et al., 2007; D. Kim et al., 2004),
it will be interesting to analyze if DCAF7, LZTS1, LZTS2 or FAM117B play a role in this
function of the 14-3-3 proteins towards DYRK1A.
3.3.2 DYRK1A interacting proteins exist in different protein complexes
Through this study we have shown that although the DYRK1A interacting proteins bind DCAF7,
they do not form larger multiprotein complexes. Our data so far also indicates that only a fraction
of DCAF7 in the cell is bound to RNF169, LZTS1, LZTS2, FAM117B and TROAP. However,
since all of these proteins bind both DYRK1A and DCAF7, it is important to study these
complexes separately because they could be responsible for specific functions of DYRK1A.
Moreover, unlike the RNF169-DYRK1A-DCAF7 complex that is observed in the nucleus, other
proteins form a complex with DYRK1A and DCAF7 in the cytoplasm. This finding indicates
that understanding the function of these different complexes of DYRK1A and DCAF7 will help
in better understanding the nuclear and cytoplasmic functions of DYRK1A or the functions of
DYRK1A in different sub-cellular compartments.
3.3.3 DYRK1A is required for the interaction of DCAF7 with DYRK1A binding partners
It is known that DCAF7 acts as a scaffold receptor to control HIPK2 and MEKK1 kinase
functions (Ritterhoff et al., 2010). We therefore analyzed if DCAF7 is required for RNF169,
FAM117B, LZTS1, LZTS2 or TROAP to bind DYRK1A. In contrast, our study demonstrated a
role of DYRK1A as a scaffolding protein. In part, the requirement of DYRK1A for these
proteins to bind DCAF7 could be explained by the region of DYRK1A that these proteins bind to
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which is different from the DCAF7 binding region in DYRK1A. Although we have observed
this role in both U-2 OS and T98G cells (T98G data not shown), it is still unknown if
overexpression of DYRK1A causes more binding of these proteins to DCAF7.
An interesting result we observed was that amino acid residues 77-136 of DYRK1A were
sufficient for LZTS2, FAM117B and RNF169 binding. In fact, the 77-136 fragment bound
LZTS2, FAM117B and RNF169 much more tightly than the 1-176 fragment. Both of these
polypeptides have an intact nuclear localization sequence. However, if the DYRK1A 1-176 is
more localized in the nucleus than DYRK1A 77-136 in the cell, it is possible that DYRK1A 1176 also binds other nuclear proteins, which interfere with binding of primarily cytoplasmic
proteins LZTS2 and FAM117B to DYRK1A 1-176. In case of RNF169 which is nuclear, the
nuclear proteins that bind DYRK1A 1-176 may be binding close to the RNF169 binding region
in DYRK1A, causing lower binding. Another possibility is that the 1-176 fragment may fold in a
different way than 77-136 fragment, leading to masking of certain epitopes required for
DYRK1A interactions.
Finally, it has been shown that DYRK1A binds to DCAF7 and induces its nuclear localization
(Miyata & Nishida, 2011). Interestingly, in our study DYRK1A did not dramatically influence
the localization of its interactors, including DCAF7.
3.3.4 DCAF7 does not affect DYRK1A mediated growth suppression
Though DCAF7 is a major DYRK1A interacting protein, it does not appear to affect DYRK1A’s
activity towards LIN52 or its ability to induce growth arrest. However, we observed that when
DYRK1A is induced in DCAF7 overexpressing cells for a longer time, its ability to maintain
growth arrest was lower compared to that in control cells. This indicates that DCAF7 could

83

oppose DYRK1A in this function. TCGA analysis of DCAF7 by Dr. Mikhail Dozmorov
(Appendix Figure 1) revealed that high expression of DCAF7 correlates with lower survival in
breast cancer. It could be possible that DCAF7 can sequester DYRK1A, thus reducing the pool
of available DYRK1A that is involved in the growth suppression function.
On screening several breast cancer cell lines for DCAF7 expression, we were able to determine
that DCAF7 indeed is overexpressed in multiple breast cancer cell lines (Appendix figure 1). It
would be interesting to determine if DCAF7 is required for proliferation and metastasis of these
breast cancer cells and if all of DYRK1A in these cells is bound to DCAF7, thus inhibiting the
tumor suppressive function of DYRK1A.
3.3.5 LZTS1 and LZTS2 are novel regulators of DYRK1A
Our study identified two novel DYRK1A interacting proteins LZTS1 and LZTS2 that could
regulate DYRK1A activity. We observed that knockdown of LZTS1 or LZTS2 caused a
reduction in DYRK1A kinase activity towards LIN52. However, depletion of both LZTS1 and
LZTS2 did not completely abolish DYRK1A activity towards LIN52, suggesting that their
functions are not redundant. Our results indicate that the LZTS proteins could be working
together as a part of the same complex and influence DYRK1A activity. In support of this model,
LZTS proteins form heterodimers (Schmeisser et al., 2009; Wendholt et al., 2006), and we have
also confirmed that LZTS1 and LZTS2 bind to each other. Further studies will be required to
analyze if disruption of the binding between LZTS1 and LZTS2 also causes the same effect on
LIN52 phosphorylation. Another point to note is that we have not analyzed the effect of another
DYRK1A interacting protein LZTS3 on DYRK1A activity. The residual activity of DYRK1A
after LZTS1 or LZTS2 knockdown may be due to the presence of LZTS3, or some other protein
which may function independent of the LZTS proteins to regulate DYRK1A activity.
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Alternatively, LZTS could regulate DYRK1A in a certain subcellular compartment, for example,
only in the cytoplasm.
DYRK1A mediated LIN52 phosphorylation is required for the formation of the DREAM
complex, which in turn causes growth suppression (Litovchick et al., 2011). However, depletion
of LZTS1/2 did not affect the ability of DYRK1A to cause growth arrest. This apparent
discrepancy could be due to the specifics of the in-vitro kinase assay used in our study. This
assay measures the ability of DYRK1A to phosphorylate a substrate, in whole cell extracts, and
in this case the substrate was LIN52. This result need not necessarily match the effect of LZTS
on endogenous LIN52 phosphorylation. Moreover, this result could indicate that LZTS1/2 does
not affect the function of DYRK1A in the nucleus. Since LZTS1/2 bind DYRK1A in the
cytoplasm, fractionating cells and carrying out in-vitro kinase assays will be helpful. If LZTS1/2
depletion only reduces DYRK1A kinase activity in cytoplasmic lysates but not in the nuclear
lysates, this would support this model. It would also be interesting to analyze if inhibition of
LZTS1/2 in the cytoplasm is able to completely inhibit DYRK1A activity as opposed to the
partial inhibition observed with the whole cell lysates. The effect of LZTS proteins on DYRK1A
activity can further be validated using cell lines, which have lost LZTS1 or LZTS2. We analyzed
a panel of ovarian cancer cell lines for changes in LZTS2 or LZTS1 expression (Appendix
Figure 2). Several cell lines had losses in LZTS1 expression (including TOV112D, SKOV3,
TOV21G, OVCA420) and a few cell lines had slightly lower expression of LZTS2 (Appendix
Figure 2). A DYRK1A kinase activity screen using these cell lines will be essential to validate
our model.
We also observed that the overexpression of LZTS2 leads to phosphorylation of DYRK1A. It is
possible that DYRK1A is required to maintain normal levels of LZTS1 and LZTS2 in the cell.
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When LZTS2 is overexpressed, there may be a feed-back loop that triggers phosphorylation of
DYRK1A by another kinase (our experiments have ruled out autophosphorylation). Future
experiments will be needed to determine the kinase that phosphorylates DYRK1A when LZTS2
is overexpressed and to determine the functional significance of this.
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CHAPTER 4: UNDERSTANDING THE ROLE OF DYRK1A and DCAF7 IN
TRANSCRIPTION

A closer look at the DCAF7 interactome shown in Figure 16, Chapter 2 of the dissertation,
revealed the presence of several Polycomb complex subunit proteins. These proteins were not
present in our previously identified DYRK1A interactome [Chapter 1, Figure 5 and (Menon et
al., 2019)]. Moreover, using an exhaustive immunoprecipitation experiment, we had identified
that not all DCAF7 in the cell is bound to DYRK1A (Appendix Figure 3) suggesting that
DCAF7 could have functions towards this complex independent of DYRK1A. Since we were
able to detect the DYRK1A-DCAF7 complexes with other proteins both in the cytoplasm and
nucleus (Chapter 2, Figure 20), we wanted to analyze if DYRK1A-DCAF7 together play a role
in this complex formation or regulation. Before proceeding to the results obtained in this chapter,
the following introduction to the chapter explains the Polycomb repressive complexes and gives
a brief account about the known roles of DYRK1A and DCAF7 in transcription.
4.1 INTRODUCTION TO THE CHAPTER
4.1.1 Polycomb group proteins and repressive complexes
Polycomb group proteins (PcG) were first identified in Drosophila as regulators of appropriate
body segmentation through Hox gene repression (Kennison, 1995; Lewis, 1978; Struhl, 1981).
PcG are essential for many biological processes in mammals, including development, stem cell
maintenance and differentiation, and tumor suppression (Jaenisch & Young, 2008; Margueron &
Reinberg, 2011; Morey & Helin, 2010; Müller & Verrijzer, 2009; Rajasekhar & Begemann,
2007; Schuettengruber & Cavalli, 2009; Schwartz & Pirrotta, 2007; Simon & Kingston, 2013;
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Sparmann & van Lohuizen, 2006; Q. Wang et al., 2018). PcG proteins assemble into multisubunit nuclear complexes with various biochemical functions, including recognition and
modification of histone posttranslational modifications (PTMs) and chromatin compaction
(Simon & Kingston, 2013).

The two well studied types of complexes are the Polycomb

Repressive Complex 1 (PRC1) and Polycomb Repressive Complex 2 (PRC2) (Jaenisch &
Young, 2008; Raphaël Margueron & Reinberg, 2011; Morey & Helin, 2010; Müller & Verrijzer,
2009; Rajasekhar & Begemann, 2007; Schuettengruber & Cavalli, 2009; Schwartz & Pirrotta,
2007; Simon & Kingston, 2013; Sparmann & van Lohuizen, 2006) As their names suggest, these
complexes are required to maintain repressive chromatin through epigenetic mechanisms and/or
chromatin compacting (Cao et al., 2002; de Napoles et al., 2004; Müller et al., 2002; H. Wang et
al., 2004) The PRC 1 and 2 complexes exhibit distinct enzymatic activities: PRC2 is responsible
for di- and tri-methylation of histone H3 at lysine 27 catalyzed by the EZH1/2 methyltransferases
(Ferrari et al., 2014; Raphael Margueron et al., 2008; X. Shen et al., 2008), whereas PRC1 is
responsible for monoubiquitination of histone H2A at lysine 119 (H2AK119ub1) catalyzed by
the E3 ligase RING1A or RING1B (de Napoles et al., 2004; Endoh et al., 2008). For the purpose
of this thesis, we concentrated on the PRC1 complex because of its relevance to DYRK1A and
DCAF7 that will be discussed below.
The core PRC1 complex in Drosophila contains Polycomb (Pc) (Saurin et al., 2001; Shao et al.,
1999), a chromodomain-containing protein that binds to H3K27me3 (Fischle et al., 2003; Min et
al., 2003); Posterior sex combs (Psc), responsible for chromatin compaction in-vitro (Francis et
al., 2004); Polyhomeotic (Ph) and dRing, the enzyme responsible for H2A ubiquitination (H.
Wang et al., 2004). Mammalian PRC1 complexes are very heterogeneous compared to
Drosophila because each subunit has several homologues in the human genome and they can
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associate in a combinatorial fashion (Gao et al., 2012). In mammals, several chromodomain
proteins (CBX) are homologous to Pc, RING1A and RING1B are enzymes similar to dRing,
several Ph homologs (PHC1-3) exist, and six Psc homologs, collectively known as Polycomb
group RING fingers (PCGFs) are present (Simon & Kingston, 2013). Different combinations of
these homologues in addition to other factors give rise to several distinct mammalian PRC1
complexes.
Proteomic and functional studies have enhanced the understanding of these complexes and
characterized at least six distinct groups of mammalian PRC1 complexes, PRC1.1–1.6, each
comprising one of six Polycomb group RING fingers (PCGFs), and the E3 ligase
RING1A/B (Gao et al., 2012; Hauri et al., 2016; Kloet et al., 2016; Sanchez-Pulido et al.,
2008). These PRC1 subtypes can be grouped into canonical and non-canonical complexes.
PRC1.2 and PRC1.4 containing CBX proteins with chromodomains fall under canonical PRC1
complexes based on H3K27me3 recognition deposited by PRC2 (Cao et al., 2002; Fischle et al.,
2003; Gao et al., 2012; Min et al., 2003; Scelfo et al., 2015), and Figure 39. The other complexes
are termed as non-canonical (Figure 39). How the non-canonical sub-complexes are recruited to
chromatin is not understood, but RYBP containing-PRC1 complexes adopt a PRC2/H3K27me3independent mechanism for targeting chromatin. There are two molecular functions attributed to
PRC1, including chromatin compaction (Levine et al., 2002; Shao et al., 1999) and
monoubiquitination of histone H2A at Lysine 119 (H. Wang et al., 2004).
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Figure 39: Schematic representation of the different PRC1 complexes.
[Adopted from (Gao et al., 2012)]. The PRC1.3/5 complex is highlighted with a pink outline.

4.1.2 PRC1.3/5
PCGF3 and PCGF5 form a distinct type of PRC1 complex which contain AUTS2 (Gao et al.,
2012). From here on in the thesis, we will refer to this complex as PRC1.3/5. In contrast to the
repressive functions of canonical PRC1, it has been found that PRC1.3/5 could mediate
transcriptional activation (Gao et al., 2014). This conversion from repressive to activating
function is mediated by AUTS2 (Gao et al., 2014).
Autism susceptibility candidate 2 (AUTS2) maps to chromosome 7q11.2 and encodes a nuclear
protein (Bedogni et al., 2010). Studies in mice revealed that AUTS2 localizes to regions of the
brain both during development and in adults (Bedogni et al., 2010). In mice, homozygous
neuron-specific deletion of the full-length Auts2 isoform display abnormalities in motor skills
(Gao et al., 2014). Furthermore, mice with heterozygous disruption of Auts2 display impaired
emotional control and cognitive memory (Hori et al., 2015). Loss of function studies of
zebrafish auts2 using morpholinos showed that auts2 knockdown leads to abnormalities
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including microcephaly, reduction of neural cells and movement disorders, as well as
craniofacial dysmorphisms (Beunders et al., 2013; Oksenberg & Ahituv, 2013). Furthermore, the
gene AUTS2 is reportedly disrupted in individuals with neurological disorders, including autism
spectrum disorders (ASD) (Hori et al., 2015; Oksenberg & Ahituv, 2013; Sultana et al., 2002).
Similar involvement of AUTS2 and DYRK1A in neurological diseases makes the PRC1.3/5
complex especially interesting for our study. Molecular studies have revealed that AUTS2
interacts with the promoters/enhancers of various genes that are involved in brain development
and/or associated with neurological disorders (Oksenberg & Ahituv, 2013). AUTS2 is
responsible for the recruitment of histone acetyl transferase p300 which turns the complex into a
transcriptional activator, and CK2 protein kinase which inhibits the repressive function of PRC1
(Gao et al., 2014; Hori et al., 2015). However, the exact molecular mechanisms that mediate the
function of PRC1.3/5 are not well known.
4.1.3 DCAF7 and PRC1.3/5
Proteins with WD40 repeats have been shown to associate with chromatin modifying complexes
that include the polycomb repressive complex 1 and complex 2 (Gao et al., 2014; Stirnimann et
al., 2010). Using proteomic studies, Gao et al., showed that both AUTS2 and PCGF5; two of the
components of the PRC1.3/5 complex, pulled down DCAF7 (Gao et al., 2014). Using
immunoprecipitation of the PRC1.3/5 component AUTS2 followed by glycerol gradient analysis
of HEK 293T cells, it has been confirmed that DCAF7 is indeed a part of the PRC1.3/5 complex
(Q. Wang et al., 2018). Furthermore, using a GAL4-luciferase reporter system, DCAF7 was
found to be required for PRC1.3/5 mediated transcriptional activation (Q. Wang et al., 2018).
Indeed, loss of DCAF7 led to a decreased expression of genes involved in neuronal
differentiation in mouse embryonic fibroblasts (Q. Wang et al., 2018).
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4.1.4 DYRK1A in transcription
DYRK1A is also thought to play a role in transcription. A chromatin-wide profiling of DYRK1A
revealed that DYRK1A could act as a RNA Polymerase II CTD kinase in order to facilitate
transcription of certain RNA Polymerase II target genes. DYRK1A appears to be recruited to its
target genes after recognizing the motif TCTCGCGAGA however it is not known how this
binding is mediated. This is followed by phosphorylation of the C-terminal domain (CTD) of
RNA Pol II at Ser2 and Ser5 (Di Vona et al., 2015). DCAF7 mediates the binding between RNA
Pol II and DYRK1A (D. Yu et al., 2019). DYRK1A was also found to phosphorylate histone H3
in a recent study (Jang et al., 2014). Interestingly, DYRK1A interacts with histone acetyl
transferases CBP and p300 in 293T cells, and DYRK1A overexpression hyper phosphorylates
CBP and p300 (S. Li et al., 2018). Analysis of published ChIP-seq datasets in T98G and HeLa
cells (Di Vona et al., 2015) and validation of some genes with ChIP in HEK293 cells revealed
that DYRK1A indeed localizes to regions of enhancers along with CBP and p300 (S. Li et al.,
2018).
However, the roles of DCAF7 or PRC1.3/5 in DYRK1A-mediated transcriptional responses are
not known.
4.2. RESULTS
In order to better understand the functional relationship between DYRK1A and DCAF7, we
employed MudPIT proteomic analysis of DCAF7 in T98G cells. We observed that DCAF7
immunoprecipitated several proteins that were also detected in our DYRK1A MudPIT proteomic
analysis. We also observed the presence of known DCAF7 binding proteins. Importantly, we
observed that DCAF7 co-precipitated all previously published components of PRC1.3/5
including PCGF3/5, RING1/2, AUTS2, FBRS, FBRSL1, CK2α, CK2α′, CK2β, YAF2 and

92

RYBP (Figure 40). FBRS and FBRSL1 are homologs of AUTS2. Of note, our DYRK1A
proteomic analysis did not show the presence of any of the PRC1.3/5 components (Figure 40).
4.2.1 DCAF7 is a part of PRC1.3/5 but DYRK1A does not bind components of the complex.
First, using T98G cells, we validated that DCAF7 is indeed a part of PRC1.3/5 (Figure 41). We
used an antibody against FBRS, a paralog of AUTS2 (genecards.org), for IP followed by WB
analysis. We were able to co-immunoprecipitate DCAF7, RING1B, RING1A and CK2α with
FBRS. As expected, FBRS did not bind to DYRK1A. For a reverse pull down, we used cell
lysates from T98G cells stably expressing Flag and HA tagged DCAF7 (FH-DCAF7) and we
immunoprecipitated DCAF7 using an anti-HA antibody. Indeed, FH-DCAF7 did bind to
RING1B, RING1A, CK2α, FBRS and DYRK1A (Figure 41). Using CRISPR-Cas9 technology,
we had previously generated DYRK1A KO T98G cells in the laboratory (Iness et al., 2019). In
order to analyze if DYRK1A depletion had an effect on PRC1.3/5 assembly, we carried out an
FBRS pull down in DYRK1A KO cells (Figure 41). PRC1.3/5 components were pulled down at
levels similar to those observed in the control cell line suggesting that loss of DYRK1A did not
affect the interaction between these subunits. Similar to the depletion of DYRK1A, DYRK1A
overexpression also had no effect on FBRS being able to pull down components of PRC1.3/5.
We also observed that FH-tagged DYRK1A was able co-immunoprecipitate DCAF7 but not any
of the PRC1.3/5 components (Figure 41).
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Figure 40: Summary of MudPIT proteomic analysis of DCAF7.
Proteins specifically detected in at least 2 out of 3 replicates are ranked by relative enrichment in
DCAF7 IP samples. The number of times each protein was detected in DCAF7
immunoprecipitation is indicated. Proteins with a blue color in the DCAF7 column are known
DCAF7 binding proteins (a). Comparison of DYRK1A dataset to the DCAF7 dataset resulted in
overlaps indicated with peach colored boxes in the DYRK1A column [b indicates (Menon et al.,
2019)]. DCAF7 was detected as a component of the PRC1.3/5 complex with
immunoprecipitation of PCGF5 and AUTS2 in a previous study [c indicates (Gao et al., 2014)).
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Figure 41: DCAF7 but not DYRK1A binds the components of the PRC1.3/5 complex.
IP using FBRS antibody was carried out using lysates from the indicated T98G cell lines
followed by WB analysis for indicated proteins. IP analysis with an HA antibody was used as a
control to show FH-DCAF7 and FH-DYRK1A pull downs followed by WB analysis for
indicated proteins.
4.2.2. DYRK1A could affect the molecular composition of the PRC1.5 complex
Next, we analyzed the effect of DYRK1A on the molecular size of PRC1.3/5 using sucrose
gradient ultracentrifugation. Nuclear lysates from T98G control or DYRK1A KO cell lines were
loaded on top of a 10-40% sucrose gradient with 5% glycerol added for better separation, and
subjected to ultracentrifugation. Following this, a total of twenty-two fractions were collected
from the top of the gradient and WB analysis was performed. We observed that components of
PRC1.3/5 co-fractionated together, indicating that they are present in a single complex (Figure
42). Though DYRK1A did not bind any of the PRC1.3/5 components, we observed that

95

DYRK1A also co-fractionated with the components of PRC1.3/5 in several fractions. Moreover,
we observed that in the absence of DYRK1A, PRC1.3/5 components were present in the heavier
fractions (Figure 42B compared to 42A) suggesting that DYRK1A could affect the PRC1.3/5
complex composition. Of note, we were only detecting those PRC1.3/5 components for which
we were able to obtain and validate the antibodies. PRC1.3/5 also has other components that we
did not detect in our WB analysis. Moreover, some of the components like RING1A/B are
involved in several PRC1.3/5 complexes. Thus, it is possible that DYRK1A inhibits the
formation of a more complete complex but further studies will be required to confirm this.
4.2.3. DYRK1A and DCAF7 negatively regulate the PRC1 function of monoubiquitination
of H2A at K119
The only known enzymatic function of PRC1 is monoubiquitination of histone H2A at lysine
119, which is associated with a repressive chromatin state (H. Wang et al., 2004). We thus
decided to analyze the effect of DYRK1A and DCAF7 on this monoubiquitination mark (H2AK119-Ub1). Using WB analysis, we observed that overexpression of DCAF7 resulted in
decreased H2A-K119-Ub1 in T98G cells (Figure 43A). This suggested that DCAF7 could be a
negative regulator of PRC1 function towards H2A-K119-Ub1. Though DYRK1A does not bind
PRC1.3/5 components, we evaluated the role of DYRK1A on H2A-K119-Ub1. Interestingly, we
observed that DCAF7 overexpression in T98G DYRK1A-KO cells did not inhibit H2A-K119Ub1 (Figure 43A). We further confirmed this result by transiently knocking down DYRK1A in
T98G cells overexpressing DCAF7, where we observed a similar result. Indeed, siRNAmediated DYRK1A depletion in T98G cells with DCAF7 overexpression led to an increase in
H2A-K119-Ub1 signal (Figure 43A). This could be interpreted in two ways: either DCAF7
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requires DYRK1A for the negative regulation of PRC1 function, or that DYRK1A and DCAF7
together inhibit H2A-K119-Ub1.

Figure 42: DYRK1A could affect the molecular size of the PRC1.3/5 complex
(A) Nuclear lysates from T98G control or (B) DYRK1A KO cells were loaded on top of a
sucrose gradient followed by ultracentrifugation to separate protein complexes. Fractions were
collected and analyzed using WB analysis for detection of indicated proteins. Differences in the
heaviest fractions are indicated by red lines.
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We further analyzed the effect of inhibition of DYRK1A kinase activity on PRC1 function using
the DYRK1A inhibitor Harmine. T98G cells were serum starved for 48 hours and released in
serum containing medium for 6, 12, 18 or 24 hours (Figure 43B). PRC1 is known to play a role
in chromatin compaction which could be increased in quiescent cells (Levine et al., 2002; Shao
et al., 1999). Our WB analysis of H2A-K119-Ub1 correlated with this function. An increased
signal was observed in serum starved cells compared with a lower signal in cycling cells (Figure
43B). Interestingly, we observed that inhibition of DYRK1A with Harmine resulted in an
increased H2A-K119-Ub1 signal (Figure 43B). This observation further supports that DYRK1A
could play a role in regulation of PRC1 function. Of note, monoubiquitination of H2A at K119 is
a collective function of all PRC1 complexes. With these experiments we could conclude that
DYRK1A and DCAF7 play an inhibitory role towards global PRC1 function.
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Figure 43: DYRK1A and DCAF7 regulate monoubiquitination of H2A at K119.
(A) WB analysis indicates effect of DYRK1A and DCAF7 on the known PRC1 function towards
mono ubiquitination of H2A at K119 in the indicated T98G cell lines/conditions. (B) T98G cells
were serum starved for 48hours followed by release with serum containing media for the
indicated time points. WB analysis indicates the effect of inhibition of DYRK1A using 10μM
Harmine on monoubiquitination of H2A at K119. DMSO was used as a vehicle control. (C)
Schema indicating that DYRK1A and DCAF7 could inhibit the function of PRC1 towards
H2AK119 monoubiquitination.
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4.2.4. DYRK1A is required for the transcriptional activity of DCAF7
T98G cell lines were used for our proteomic studies of DYRK1A and DCAF7 as well as for
ChIP-seq analysis by another group (Di Vona et al., 2015). The effects of DYRK1A and DCAF7
on H2A-K119 Ub1 were also observed in T98G cells. Therefore, to determine the role of
DYRK1A and DCAF7 in transcription, we performed RNA-seq analysis using T98G control and
DYRK1A KO cell lines with or without DCAF7 overexpression (Figure 44A, B). Cells
overexpressing GFP in the presence or absence of DYRK1A were used as controls (Figure 44A,
B). In order to minimize batch effects, five replicate samples were collected for each cell line at
the same time. This was followed by RNA isolation and analysis of the quality of RNA. All
twenty samples had an RNA integrity (RIN) value of greater than 9. We also analyzed
expression of DCAF7 in each sample using RT-qPCR analysis before submission, as a quality
control test (data not shown). We then submitted the samples for RNA-seq analysis. The
sequencing led to the generation of approximately 30 million, 150bp single-end reads per
sample. The data was analyzed for us by Dr. Mikhail Dozmorov (Department of Biostatistics and
Massey Cancer Center, VCU). Principal component analysis of the RNA-seq data revealed that
either loss of DYRK1A or overexpression of DCAF7 caused significant perturbations in the
transcriptome (Figure 44C, D). However, overexpression of DCAF7 in the absence of DYRK1A
caused relatively minor changes in global gene expression. This suggests that DYRK1A could be
required for the effect of DCAF7 on transcription.
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Figure 44: Summary of RNA seq analysis
(A) WB shows levels of DCAF7 and DYRK1A in the cell lines used for RNA seq analysis.
Arrow indicates Flag-HA-tagged DCAF7 (B) Design of RNA-seq experiment using T98G cells
to determine the effect of DYRK1A and DCAF7 on transcription. (C) Graph shows principal
component analysis of the RNA-seq data. (D) Venn diagram showing overlaps of significantly
up-regulated or down regulated genes
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4.2.5. DYRK1A and DCAF7 regulate a common subset of genes
First, we only looked at genes that were upregulated or down regulated when DYRK1A was
knocked out or when DCAF7 was overexpressed. There were multiple genes that were
differentially regulated in each comparison relative to GFP control (Figure 44D). The expression
of a total of 4904 genes were upregulated and 4721 were down regulated when DYRK1A was
knocked out (False Discovery Rate FDR 0.05). Overexpression of DCAF7 lead to 1726 genes
being upregulated and 1880 genes being downregulated as compared to the GFP control (FDR
0.05, Figure 44D). Comparison of these gene sets revealed a significant overlap (Figure 44). All
overlap comparisons are highly significant (Fisher t test <0.001). This suggests that DYRK1A
and DCAF7 may co-regulate a common subset of genes. Gene Set Enrichment Analysis (GSEA)
was used for a biological interpretation of DEGs between conditions. This analysis revealed that
both DYRK1A and/or DCAF7 regulated gene sets were significantly enriched in several
functional categories (Figure 45A). Some of the categories were cell proliferation, neurological
development and neurodegeneration. Furthermore, since previous studies found that DYRK1A is
required for the DREAM complex assembly, it is expected that DREAM target genes should be
up-regulated in DYRK1A KO cells. Indeed, ~800 target genes were up-regulated in the
DYRK1A-KO cells. This result further supported the role of DYRK1A in DREAM function
(Figure 45B).
In-order to confirm the RNA seq results, we used the same cell lines that we used for RNA seq
analysis and performed a RT-qPCR for some of the DREAM target genes. We were able to
validate the up-regulation of DREAM target genes including E2F2, ID3, ARHGAP11B, BUB1B
and MYBL2 in the DYRK1A-KO samples using RT-qPCR (Figure 45C). GSEA analysis also
revealed upregulation of DREAM targets with overexpression of DCAF7 (Figure 45A).
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However, we were unable to find the effect of DCAF7 on the gene set upregulated by loss of
DYRK1A. Since the DREAM complex represses the expression of several genes, it is possible
DYRK1A KO and DCAF7 overexpression regulate the expression of the different subsets of
DREAM target genes. Another possibility is that DCAF7 causes a very subtle effect on the genes
validated by RT-qPCR and therefore an effect was not observed.

Figure 45: DYRK1A and DCAF7 affect genes in different functional categories and
DREAM target genes are upregulated in DYRK1A KO samples.
(A) Table shows top functional categories identified using MSigDB Gene set enrichment
(GSEA) tool for each indicated dataset (B) Heatmap showing changes in DREAM target gene set
in DYRK1A KO data set as compared to control from four biological replicates. (C) RT-qPCR
validation of DREAM target genes from T98G GFP-FH or T98G KO GFP-FH cell lines. Graph
shows average of three biological repeats. Error bars show standard deviation. Statistical
significance was calculated using two tailed Student’s t- test. * - p value ≤0.05.
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Figure 46: DCAF7 requires DYRK1A for its effect on transcription of a subset of genes.
(A) Average RNA-seq Log Fold change (FC) values of DEGs regulated by both DYRK1A and
DCAF7 showing lack of response to DCAF7 overexpression in the absence of DYRK1A (red
boxes). (B) RT-qPCR validation of the indicated genes regulated by both DYRK1A and DCAF7
confirms the lack of response to DCAF7 overexpression in the absence of DYRK1A (compare
red boxes).
Further, we identified a set of DEGs for further validation. These genes were altered in both
DYRK1A and DCAF7 analyses with LogFC at least ± 1.0, and having a role in neurological
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disease or cancer. These genes could be divided into 4 major categories: 1) genes that were
upregulated with DYRK1A loss or DCAF7 overexpression; 2) genes that were downregulated
with DYRK1A loss or DCAF7 overexpression; 3) genes that were up regulated with DYRK1A
loss but downregulated with DCAF7 overexpression and 4) genes that were down regulated with
DYRK1A loss but upregulated with DCAF7 overexpression (Figure 47). Looking at the average
FC values obtained by RNA seq analysis for a subset of these genes, we were able to conclude
that DCAF7 requires DYRK1A for its transcriptional activity (Figure 46A). We also confirmed
this using RT-qPCR analysis for a subset of genes regulated by both DYRK1A and DCAF7
(Figure 46B).
We performed RT-qPCR analysis for the validation set to analyze the DYRK1A and DCAF7regulated expression of these genes. This was carried out in the same cell lines as the RNA seq
analysis. We were able to validate the expression of all selected DEGs (Figure 48). We were
therefore able to conclude that DYRK1A and DCAF7 could regulate gene expression in the same
as well as in the opposite direction.
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Figure 47: DYRK1A and DCAF7 co-regulate a common subset of genes.
Differentially expressed genes are shown in both DYRK1A and DCAF7 analyses that are
implicated in neurological disease or cancer. The four different expression categories are
indicated along with the gene name and disease link/function.
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Figure 48: DYRK1A and DCAF7 regulate a common subset of genes that have relevance in
disease.
RT-qPCR validations of genes indicated in Figure 47 using T98G GFP-FH, T98G DYRK1A KO
GFP-FH or T98G DCAF7-FH cell lines. Graphs indicate average of three biological replicates.
Error bars show standard deviation. Statistical significance was calculated using two tailed
Student’s t-test. P-values: *≤0.05; ** ≤ 0.01; *** ≤ 0.001; **** ≤ 0.0001 (A) Genes upregulated
in both DYRK1A KO and DCAF7 overexpression conditions. (B) Genes downregulated in
DYRK1A KO and upregulated in DCAF7 overexpression conditions. (C) Genes upregulated
with DYRK1A KO but down regulated with DCAF7 overexpression. (D) Genes down regulated
in both DYRK1A KO and DCAF7 overexpression conditions.
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4.2.6. There is an overlap between DEGs and published DYRK1A ChIP-seq datasets
DYRK1A has been shown to play a role in transcription (Di Vona et al., 2015). In this study Di
Vona et al., carried out ChIP-seq analysis in order to identify the genomic regions that DYRK1A
binds to under cycling or serum starved conditions in T98G cells. Since our RNA-seq analysis
was also carried out using T98G cells, we analyzed if there is an overlap of DYRK1A bound
genes from the ChIP-seq dataset with the DEGs identified through our RNA-seq analysis.
Indeed, there was an overlap of genes that were both up and down regulated with DYRK1A-KO
(Figure 49 and Appendix tables 7,8). Out of the ~4905 genes that were upregulated in DYRK1AKO cells, the genomic regions of 306 genes were bound by DYRK1A (Figure 49A, Appendix
table 7). Out of the ~4722 genes downregulated when DYRK1A is knocked out, 240 genes had
DYRK1A bound genomic regions (Figure 49B, Appendix table 8). This suggests that DYRK1A
binds to the genomic regions of these genes and could possibly regulate expression by direct
binding.
Interestingly, we also observed an overlap with genes that were up and down regulated with
DCAF7 overexpression (Figure 50, Appendix table 9). Out of ~1727 genes upregulated with
DCAF7 overexpression; 91 genes were directly bound by DYRK1A (Di Vona et al., 2015).
Further 106 of the ~1881 genes downregulated with DCAF7 overexpression were also directly
bound by DYRK1A. These results give us a starting point for the future ChIP validations in
order to further understand the mechanism by which DYRK1A and DCAF7 regulate the
expression of these genes.
There were also published ChIP-seq datasets available for AUTS2. However, this study was
carried out in HEK293T cells (Gao et al., 2014). Even though the cell types are different, we
observed a considerable overlap between genes bound by AUTS2 and genes bound by
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DYRK1A, and identified a total of 65 genes bound by both AUTS2 and DYRK1A (Figure 51,
Appendix table 10). Further analysis of these genes will help us understand the influence of
DYRK1A on the PRC1.3/5 regulated genes.

Figure 49: Overlap of DYRK1A regulated genes with DYRK1A ChIP-seq datasets
(A) Overlap of Genes Up in DYRK1A KO with DYRK1A bound genes under cycling and serum
starved conditions. (B) Overlap of Genes Down in DYRK1A KO with DYRK1A bound genes
under cycling and serum starved conditions [ChIP-seq dataset obtained from (Di Vona et al.,
2015)]. Refer Appendix Table 7 and 8 for the list of the overlapping genes.
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Figure 50: Overlap of DCAF7 regulated genes with DYRK1A ChIP-seq datasets
(A) Overlap of Genes Up in DCAF7 overexpression with DYRK1A bound genes under cycling
and serum starved conditions (B) Overlap of Genes down in DCAF7 overexpression with
DYRK1A bound genes under cycling and serum starved conditions [ChIP-seq dataset obtained
from (Di Vona et al., 2015)]. Refer Appendix Table 9 for the list of the overlapping genes.

110

Figure 51: Overlap of genes bound by AUTS2 and genes bound by DYRK1A under cycling
and serum starved conditions.
[DYRK1A ChIP-seq dataset obtained from (Di Vona et al., 2015); AUTS2 ChIP-seq dataset was
obtained from (Gao et al., 2014)]. Refer Appendix Table 10 for the list of the overlapping genes.

4.3. DISCUSSION AND FUTURE DIRECTIONS
4.3.1 DCAF7 is a part of PRC1.3/5 but DYRK1A does not bind components of the complex
Proteomic studies by our lab and others revealed that DCAF7 bound several proteins belonging
to the PRC1.3/5 complex (this dissertation and the BioGrid database, Figure 16). However, only
our study investigated the DCAF7 interactome in T98G cells. The presence of PRC1.3/5
components in DCAF7 proteomic analysis from different cell types across different studies
demonstrates that DCAF7 is indeed a part of this complex. Moreover, out of the several PRC1
complexes, DCAF7 only pulls down components of the non-canonical PRC1.3/5 complex,
suggesting a possible specific function of DCAF7 in this type of PRC1 complex.
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Indeed, we confirmed the interaction of DCAF7 with components of the PRC1.5-AUTS2
complex in T98G cells. Although DYRK1A and DCAF7 interact stoichiometrically, our results
indicated that DYRK1A is not a part of the PRC1.3/5 complex. Using exhaustive
immunoprecipitation to deplete DYRK1A from T98G cells lysates we have observed that not all
of the DCAF7 in the cell is bound to DYRK1A (Appendix Figure 3). This suggests that DCAF7
could have protein interactions independent of DYRK1A.
4.3.2. DYRK1A affects the molecular size of AUTS2-PRC1
Although DYRK1A did not bind PRC1.3/5 components, its absence altered the molecular size of
the complex. It is important to note that we did not detect all the components of the complex due
to limited availability of antibodies. It is possible that some of the AUTS2-PRC1 components
that we did not detect can be phosphorylated and regulated by DYRK1A. One angle to the future
studies would be to analyze if any of the AUTS2-PRC1 components are phosphorylated by
DYRK1A, leading to their degradation. This would explain the formation of a more stable and
complete complex in the absence of DYRK1A.
4.3.3. DYRK1A and DCAF7 regulate PRC1 function
The only

known function of

the PRC1.3/5

complex is

to catalyze H2A-K119

monoubiquitylation, which mediates transcriptional repression. This monoubiquitylation is
inhibited by CK2 mediated phosphorylation of RING1B, leading to transcriptional activation
(Gao et al., 2014). We observed that inhibition of DYRK1A by Harmine leads to an increase in
H2A-K119 monoubiquitylation. Since this is a readout of global PRC1 function and not AUTS2PRC1 alone, it is possible that DYRK1A phosphorylates and inhibits some component of PRC1.
It will also be important to analyze the extent of global PRC1 function that is affected by
DYRK1A. Moreover, since DYRK1A and CK2 are phylogenetically similar (Aranda et al.,
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2011; Kannan & Neuwald, 2004), it will be important to analyze if they are redundant with
respect to their function towards PRC1. Harmine inhibits only DYRK1A and DYRK1B while
CX4945 is primarily a CK2 inhibitor that was also found to potently inhibit DYRK1A (H. Kim
et al., 2016). Thus, comparing the effect of CX4945 to effect of other DYRK1A inhibitors on
PRC1 function, we can determine if inhibition of both CK2 and DYRK1A causes a further
increase in PRC1 function.
Our results also indicated that overexpression of DCAF7 led to a decrease in AUTS2-PRC1
function and this decrease was dependent on DYRK1A. This points to the possibility that
DYRK1A and DCAF7 could regulate a common subset of genes that are also regulated by
PRC1.3/5. Although the regulatory regions bound by DYRK1A are known, ChIP-seq analysis
will be needed to analyze the genomic region bound by DCAF7. Further, ChIP- seq analysis to
determine AUTS2 bound regions in the same cell type followed by an overlap of all of these
datasets would be helpful to understand the mechanism through which DYRK1A and DCAF7
regulate PRC1.3/5 function.
4.3.4. DYRK1A and DCAF7 regulate a common subset of genes
Interestingly, our RNA-seq analysis and RT-qPCR validations indicated that DYRK1A and
DCAF7 regulate a common sub-set of genes. Interestingly, several genes co-regulated by both
DYRK1A and DCAF7 are implicated in neurological disorders and cancer. This is important
because DYRK1A itself is implicated in both of these disease conditions. We have already
shown that DYRK1A is required for the transcriptional role of DCAF7 but the mechanism of this
regulation needs to be studied.
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Moreover, many of the genes regulated by DYRK1A or DCAF7, or both DYRK1A and DCAF7
overlap with genes to whose genomic regions DYRK1A is known to bind. It could be possible
that both DYRK1A and DCAF7 bind to the regulatory regions of these genes or it could be
possible that one recruits the other. Due to its WD-40 repeats, it is also possible that DCAF7 has
scaffolding functions bringing together DYRK1A and certain other transcriptional regulators.
Given a large number of genes influenced by both DYRK1A and DCAF7, it is possible that
these proteins may act as regulators of gene expression, for example as enhancers or activators.
There is a study that analyzed published DYRK1A datasets to find that DYRK1A indeed
localizes to regions of enhancers along with CBP and p300 (S. Li et al., 2018). Therefore, future
studies will be required to elucidate the mechanism of DYRK1A and DCAF7 in transcription.
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CHAPTER 5: PERSPECTIVES AND IMPACT
Although DYRK1A is implicated in human neurological conditions and in cancer, the functions
and regulation of DYRK1A in the cell are not very well understood hence making it difficult to
target DYRK1A for therapy. The findings presented in this dissertation significantly advance our
understanding of DYRK1A function by characterizing the extended network of its proteinprotein interactions and by detailed analysis of the functional interaction between DYRK1A and
its most significant partners in the cell. Significantly, we found that DYRK1A (and its
stoichiometric partner DCAF7) are involved in numerous distinct tertiary complexes that are
involved in different cellular processes both in the nucleus and in the cytoplasm. Further studies
will characterize the role of DYRK1A-DCAF7 in these cellular pathways.
In Chapter 2, we describe a novel role of DYRK1A in the DNA damage response pathway.
Genomic instability is a major hallmark of cancer, and the ability of the genome maintenance
systems to sense and repair damaged DNA is crucial for the homeostasis of the cell. Defects in
these repair systems cause an increase mutation burden, driving tumorigenesis. Indeed, some
familial cancer syndromes results from germline mutations in DNA repair genes, whereas most
cancers have acquired alterations in DNA damage and repair pathways. Moreover, development
of resistance to current chemotherapeutics is a direct function of genomic instability and is a
major therapeutic challenge that requires further research before it can be overcome. Apart from
cancer, several neurological disorders also result from defects in DNA repair genes. Our finding
that DYRK1A levels can influence DNA repair will help us better understand the DNA damage
response and DNA repair pathways and allow us to modulate these processes.
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Sustained proliferative advantage remains one of the most important and fundamental features in
cancer. The ability to regulate cell cycle progression in a controlled manner is lost in cancer cells
and as a result, this deregulation allows them to evade cell cycle checkpoints, leading to
sustained and aberrant proliferation. DYRK1A is a cell cycle regulator that prevents the
uncontrolled proliferation of cells by promoting cell cycle exit and entry into quiescence. This
important function must be considered when DYRK1A is targeted for therapy of conditions
associated with its gain-of-function, such as Down syndrome and Alzheimer’s disease. Through
the work in Chapter 3 of this dissertation, we have identified several DYRK1A-interactingproteins, and their respective protein interactomes, which could not only be utilized in future
studies to better understand the regulation and substrates of DYRK1A, but also be used to
characterize the function of the DYRK1A interacting proteins in different cellular pathways,
including regulation of cell proliferation. Understanding of the physiological role of the
DYRK1A complexes in the cell will help to design more precise inhibitors of only its desired
functions. We have also identified a previously unknown scaffolding function of DYRK1A in
the protein complexes identified in our study. If this scaffolding function of DYRK1A is
required in different cellular pathways, it could help us better understand the phenotypic effect of
DYRK1A dosage in different diseases.
We also identified LZTS1 and LZTS2 as novel regulators of DYRK1A activity. DYRK1A is a
multifunctional kinase that phosphorylates numerous substrates in the cell. Therefore, targeting
DYRK1A for therapy becomes difficult. However, if we are able to understand the mechanism
by which LZTS1 and LZTS2 regulate DYRK1A kinase activity, we could potentially target
LZTS1 and LZTS2 proteins in conditions where there is increased DYRK1A activity, like in
Down syndrome.
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Through Chapter 4 in the dissertation we have identified that DYRK1A and DCAF7 could
inhibit the function of the PRC1 complex. By understanding the mechanism through which
DYRK1A and DCAF7 affect the global PRC1 activity, we better understand the regulation of
this complex which is perturbed in several developmental disorders and cancer. Further, our
RNA-seq data has revealed that DYRK1A and DCAF7 could influence a common sub-set of
genes implicated in neurological disorders or cancer. This was previously unknown and can be
exploited further for therapy.
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CHAPTER 6: MATERIALS AND METHODS

5.1. Cell lines
Human glioblastoma T98G, osteosarcoma U-2OS, HEK293T, Phoenix cells (modified
HEK293T), were obtained from ATCC and used from early passage master stocks. Human
ovarian cancer cell lines were obtained from ATCC or were a gift from Dr. Ronny Drapkin.
Human Breast cancer cell lines were a gift from Dr. Jennifer Koblinski. All cell lines were
cultured according to ATCC specifications and regularly checked for mycoplasma contamination
using PCR assay and DAPI staining. T98G and U-2 OS cells stably expressing Flag-HA (FH)
epitope tagged DYRK1A, GFP, DCAF7, LZTS2, LZTS1, TROAP or FAM117B were
established using pMSCV retroviral vectors and puromycin selection as described in (Litovchick
et al., 2011). U-2 OS cells stably expressing shRNA’s against DCAF7 (Mission shRNA
Millipore

sigma,

Catalog#

SHCLNG-NM_005828;

clones

TRCN0000147504

and

TRCN0000149770) or LZTS2 (Mission shRNA Millipore Sigma, Catalog # SHCLNGNM_032429; clones TRCN0000419617 and TRCN0000412326) or non-targeting control (gift
from Dr. Steven Grossman) were established using pLKO1 lentiviral vectors followed by
puromycin selection. U-2 OS cell lines expressing DYRK1A in a doxycycline-inducible fashion
were also used (Himpel et al., 2001; Litovchick et al., 2011).
DYRK1A-KO U-2 OS (Menon et al., 2019) and T98G cell lines (Iness et al., 2019) were
established using GeneArt CRISPR Nuclease vector with OFP reporter (Life Technologies)
harboring human or mouse DYRK1A-specific guide sequences. The control cell line was
similarly established using a non-targeting construct provided with the kit. Briefly, cells were
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transfected with sgRNA-CRISPR plasmids, FACS-sorted for OFP expression and grown as
single-cell clones in 96-well plates that were screened for DYRK1A expression using
immunoblotting. Two independent clones lacking DYRK1A expression were expanded and
validated using antibodies against different epitopes in DYRK1A as well as genomic sequencing
of the nested PCR-amplified fragment surrounding the sgRNA-targeted region. T98G cell lines
have more than one copy of DYRK1A. Therefore, to verify that we had obtained single cell
clones of DYRK1A KO cell lines, the nested amplified genomic regions were purified, cloned
into Promega pGEM®-T Easy vector. Multiple DNA clones were sequenced to confirm the
presence of mutations and the absence of the wild type sequences.
Table 1: Sequences of guiding RNA used to create indicated DYRK1A KO cell lines
Cell line
U-2 OS
T98G

Top strand (5′-3′)
Bottom (5′-3′)
TGTAAAGGCATATGATCGTG CACGATCATATGCCTTTACA
TCAGCAACCTCTAACTAACC GGTTAGTTAGAGGTTGCTGA

5.2. MudPIT proteomic analysis
MudPIT proteomic analysis was performed as described previously in (Florens & Washburn,
2006; Litovchick et al., 2007) using Finnigan LTQ linear ion trap mass spectrometer equipped
with an electrospray ionization source. T98G cells stably expressing either Flag-HA tagged
DYRK1A, DCAF7, LZTS2, LZTS1, FAM117B, TROAP or GFP (control) were used for
immunoprecipitations

with

anti-HA

antibody

agarose

beads

(clone

HA7,

Sigma,

Catalog#A2095). For RNF169, U-2 OS cells stably expressing HA-RNF169 were used for
immunoprecipitation as described for the other proteins. Proteins were eluted from beads using
HA peptide (Sigma, Catalog #I2149), concentrated and digested with trypsin. Tryptic peptides
were resolved using Quaternary Agilent 1100 series HPLC and microcapillary multi-dimensional
C18-SCX-C18 matrix using fully automated 10-step chromatography run and electrosprayed into
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mass spectrometer. Full MS spectra were recorded on the peptides over a 400 to 1,600 m/z
range, followed by five tandem mass (MS/MS) events sequentially generated in a data-dependent
manner on the first to fifth most intense ions selected from the full MS spectrum (at 35%
collision energy). SEQUEST (Eng et al., 1994) was used to match MS/MS spectra to peptides in
a database of 58622 amino acid sequences, consisting of 29147 human proteins (non-redundant
entries from NCBI 2011-08-16 release). To estimate relative protein levels, spectral counts were
normalized using Normalized Spectral Abundance Factors (NSAFs) (Litovchick et al., 2007;
Swanson et al., 2009). Average NSAFs were calculated from four biological replicate DYRK1A
pull-down experiments. Average NSAFs for all other proteins were calculated from three
biological experiments. The analysis was carried out at the Proteomics Core at the Proteomics
center at Stowers institute (Selene Swanson, Laurence Florens and Michael Washburn).
5.3. Immunoblotting and immunoprecipitation
For immunoblotting, cells were lysed in EBC or RIPA buffers supplemented with protease
inhibitors (Millipore-Sigma catalog#539131), phosphatase inhibitors (Millipore-Sigma catalog#
524625) and β-ME for 10 min at 4°C and then centrifuged at 14,000g for 15 min at 4°C. Protein
concentrations were determined by DC protein assay (BioRad). Protein samples were resolved
using polyacrylamide gels (BioRad), transferred to a nitrocellulose membrane (GE Healthcare)
and probed by specific antibodies, as recommended by manufacturer. For immunoprecipitation,
cell extracts were incubated with appropriate antibodies (1 μg/ml) and Protein A Sepharose
beads (GE Healthcare, Catalog #17078001) overnight at 4°C, washed five times with lysis buffer
and re-suspended in 2X Laemmli sample buffer (BioRad, Catalog # 161-0737). Antibodies used
in this study are listed in Table 2.
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5.4. Cytonuclear fractionation
Cells were seeded at desired densities followed by cyto-nuclear fractionation using a
commercially available kit (Active Motif, Catalog# 40010) and following manufacturer’s
instructions followed by IP/WB analysis.
5.5. Chemicals and treatments
To induce DNA damage, cells were exposed to gamma irradiation using MDS Nordion
Gammacell 40 research irradiator with a 137Cs source (ON, Canada) as described in (Menon et
al., 2019). Harmine (Sigma; catalog No. H8646) and CX4945 (Selleckchem, Catalog no. #
S2248) dissolved in DMSO were used for cell treatments at 10 µM final concentrations.
For phosphorylation assays, λ-phosphatase (NEB, Catalog # P0753S) was used either directly on
immunoprecipitated sample or cell lysates according to manufacturer’s protocol followed by WB
analysis. PhosTag Acrylamide reagent (NARD institute limited, catalog # AAL-107) was added
to prepare 7.5% polyacrylamide gels for resolving phosphorylated forms of proteins.
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Table 2: List of antibodies used in the thesis
Antibody
DYRK1A (clone 7D10)
DYRK1A
RNF169
RNF169
FAM117B
TROAP
TROAP
DCAF7
LZTS2
LZTS2
LZTS1
LZTS1
RING1A
RING1B/RNF2
FBRS
CK2α
Ubiquityl-Histone H2A (Lys 119)
Ubiquitin (P4D1)
Ubiquitin (FK2)
USP7
BRCA1
p53
H2AX (pSer139)- 20E3
53BP1 (19/53BP1)
GFP (D5.1)
GFP-Trap agarose
HA-Tag (HA.11)
HA-Tag (C29F4)
HA-agarose
Ki67
p-LIN52
GST (B14)
Vinculin (hVIN-1)
Tubulin
Lamin
β-actin (13E5)
Normal Rabbit IgG
Anti-Mouse IgG
Anti-Rabbit IgG
Anti-Rabbit IgG Light Chain
Anti-Rabbit Alexa Fluor 488
Anti-Mouse Alexa Fluor 594
Anti-Rabbit Cy-3 conjugated IgG

Species
Mouse
Rabbit
Rabbit
Rabbit
Rabbit
Rabbit
Rabbit
Rabbit
Rabbit
Rabbit
Rabbit
Rabbit
Rabbit
Rabbit
Rabbit
Rabbit
Rabbit
Mouse
Mouse
Rabbit
Rabbit
Mouse
Rabbit
Mouse
Rabbit

Source
Purpose Catalog number
Sigma
WB
WH0001859MI
Bethyl
IP/WB A303-801A
Abcam
WB
ab188237
Bethyl
IP/WB A304-097A
Bethyl
WB
BL19741
Bethyl
IP
BL19735
Proteintech
IP/WB 13634-1-AP
Abcam
WB
ab138490
Bethyl
IP/WB BL19733
Invitrogen
IP/WB PA5-60871
Bethyl
IP/WB BL19723
Invitrogen
IP/WB PA5-52274
Bethyl
WB
A303-552A
Bethyl
WB
A302-869A
Invitrogen
IP/WB PA5-60615
Bethyl
WB
A300-198A
Cell Signaling WB
D27C4
Santacruz
WB
sc-8017
R&D Biosystems
IF
A-106
Bethyl
WB
A300-033A
Bethyl
WB
A300-000A
DO-1
WB
sc-126
Cell Signaling WB/IF 9718S
BD BiosciencesIF/WB 612523
Cell Signaling WB
3724S
Chromotek
IP
gta-20
Mouse BioLegend
WB/IF 16B12
Rabbit Cell Signaling WB/IF 3724
Mouse Sigma
IP
A2095
Rabbit Millipore
IF/FACS AB9260
Rabbit Litovchick lab WB
Mouse Santacruz
WB
sc-138
Mouse Sigma
WB
V9131
Mouse Sigma
WB
SAB1411818
Rabbit Cell Signaling WB
29565
Rabbit Cell Signaling WB
4970S
Rabbit Millipore
IP
NI01-100VG
Goat
Jackson ImmunoResearch
WB
115-035-003
Goat
Jackson ImmunoResearch
WB
111-035-003
Mouse Jackson ImmunoResearch211-032-171
Rabbit Invitrogen
IF
A-11008
Goat
Jackson ImmunoIFResearch115-585-146
Donkey Jackson ImmunoIF/FACS
Research711-166-152

122

5.6. RNAi and plasmids
siRNA oligos used in this study were from Ambion/ Thermo Fisher Scientific as indicated in
table 3. siRNA transfections were performed using Lipofectamine RNAiMAX (Invitrogen,
catalog# 13778075) according to the manufacturer’s instructions. GFP-tagged rat Dyrk1a wildtype and mutant constructs in pEGFP-C1 were a kind gift from Dr. Walter Becker (Glenewinkel
et al., 2016). GFP-tagged mouse Dyrk1a wild-type and mutant constructs in pEGFP-N1 were a
kind gift from Dr. Garriella D’Arcangelo (Yabut et al., 2010). HA-RNF169-pcDNA3 and GFPRNF169 constructs were a gift from Dr. Niels Mailand (Poulsen et al., 2012). The phosphosite
mutants of RNF169 were generated using the QuikChange II XL site directed mutagenesis kit
(Agilent Technologies, Catalog # 200521) and verified by sequencing. Plasmid transfections
were performed using either TransIT-2020 transfection reagent (Mirus Bio, Catalog# MIR5400),
BioT reagent (Bioland Scientific LLC, Catalog# B01-01) or polyethylenimine reagent
(Polysciences Inc., Catalog#23966) that was prepared according to manufacturer’s protocol.
Table 3: List of siRNAs used in the thesis
Target
RNF169
FAM117B
LZTS2
LZTS1
TROAP
DYRK1A
Negative control
Negative control

Type
Catalog
ID
Silencer select
4392420 s48512
Silencer select
4392420 s45493
Silencer select
4392420 s39013
Silencer select
4392420 s22063, s22062
Silencer
AM167908 16369
Silencer select
4390824 s4399
Silencer select
4390846 No. 2
Silencer
AM4611 No. 1
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Source
Ambion/Thermofisher
Ambion/Thermofisher
Ambion/Thermofisher
Ambion/Thermofisher
Ambion/Thermofisher
Ambion/Thermofisher
Ambion/Thermofisher
Ambion/Thermofisher

5.7. In-vitro kinase assays
Cell extracts (0.8 mg/ml) were prepared using EBC buffer, supplemented with EDTA-free
protease inhibitors (Roche Diagnostics, Catalog#11836170001), phosphatase inhibitors and βME. Cell extract from a control cell line was treated with 10μM Harmine for 30 minutes on ice.
The cell lysates and the Harmine treated control were then incubated with 1X kinase buffer (Cell
Signaling Technologies, Catalog# 9802S), 10 mM MnCl2, 200μM ATP (Cell signaling
Technologies Catalog# 9804), and incubated at 30°C with 300 ng GST-LIN52 in a 100 μL
reaction volume. The reaction was allowed to proceed for different time periods (0, 30, 45 or 60
minutes) and reaction was terminated by adding SDS-PAGE loading buffer and heating at 95°C
for 10 min. Phosphorylation of GST-LIN52 was analyzed by WB analysis.
5.8. Immunofluorescence
Cells were seeded on glass coverslips in 6-well dishes and allowed to attach for 24h. After
washing in PBS three times, cells were fixed in 4% formaldehyde for 20 min, blocked and
permeabilized with 0.2% Triton X-100 in PBS containing 5% BSA for 30 min followed by
incubation with primary and secondary antibodies. The coverslips were mounted in Fluoroshield
mounting medium with DAPI (Abcam) and viewed using Zeiss Axio AX10 Imager fluorescence
microscope for DNA damage-based assays. Images were acquired at 60x magnification using
AxioVision software. For foci counts, the images were analyzed using ImageJ FIJI software
(Schindelin et al., 2012). Briefly, images in JPEG format were processed to find the total number
of foci (maxima). A noise tolerance value of 20 or 30 was used, and it was the same for all
samples within each comparison group. For 53BP1, average foci per cell and number of cells
with greater than 10 foci were calculated. For HA-RNF169, average foci per HA-positive cell
and number of HA-positive cells with greater than 5 or 10 foci were calculated. To analyze
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53BP1 in HA-RNF169 expressing cell lines, 53BP1 foci were scored only in the HA-positive
cells. At least three biological repeats, defined as independently plated and treated series of cell
samples, were analyzed for each quantitative analysis. For each biological repeat, more than 100
cells per experimental condition were typically scored. Some experiments were analyzed by two
different observers, and all data were included in the analysis. The Zeiss Cell Observer Spinning
Disc confocal microscope was used for capturing images for localization analysis; images were
acquired at 63X magnification using ZEN 3.0 software (blue edition).
5.9. Gradient centrifugation
T98G cells were scraped using ice-cold PBS containing protease and phosphatase inhibitors,
collected by centrifugation and extracted using buffer containing 10 mM HEPES, 2 mM MgCl2,
10 mM KCl, 0.5% NP-40, 0.5 mM EDTA, 150 mM NaCl, H2O, 1 mM DTT, protease and
phosphatase inhibitors. For glycerol gradient analysis, 200 µL of clarified cell lysate containing
approximately 6 mg/ml of protein was loaded on top of a pre-formed glycerol gradient (5 ml, 5–
45% in lysis buffer made using a gradient maker). Another gradient was also loaded with protein
weight markers (25 μg each) including bovine serum albumin (Sigma, Catalog# A8531), yeast
alcohol dehydrogenase from yeast (Sigma, Catalog# A 8656), and bovine thyroglobulin (Sigma,
Catalog# T9145). The samples were then centrifuged using SW55Ti rotor at 45,000 rpm at 4°C
for 18h, after which 200 µL fractions were collected from the top of the gradient and analyzed by
Western blotting or Coomassie staining (for markers).
For sucrose gradient analysis, solutions of 45% sucrose (solution A), 5% sucrose (solution D),
2:1 – 2 parts of solution A and 1 part of solution D (solution B) and 1:2- 1 part of solution A and
2 parts of solution D were made (solution C) in lysis buffer. A volume of 1mL of solution A was
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pipetted into the centrifuge tube and frozen followed by sequential layering and freezing of
solutions B, C and D. Just before the gradients were ready to be run, the gradient was thawed at
room temperature for 30 minutes and cell lysates were loaded followed by centrifugation using
SW55Ti rotor at 40,000 rpm 4°C for 18h, and collection of fractions. WB analysis was carried
out as described for glycerol gradient analysis.
5.10. DR-GFP assay
DR-GFP reporter cell lines were established by transfecting the DR-GFP reporter construct [gift
from Dr. Maria Jasin, Addgene plasmid # 26475; (Pierce et al., 1999)] into the control or
DYRK1A-KO U-2 OS cells followed by puromycin selection as described (Yakovlev, 2013).
The cells stably expressing the DR-GFP reporter were infected with adenovirus to express I-SceI
at MOI =50. To monitor the HRR efficiency, GFP positive cells were detected 48h post-infection
using flow cytometry as described (Pierce et al., 1999; Yakovlev, 2013)
5.11. FACS analysis
Cells were grown to desired densities, transfected with indicated constructs, trypsinized,
collected by centrifugation and fixed overnight in 70% chilled ethanol.

The next day, cells

were incubated with PI (50μg/mL) and RNase A solution (100μg/ml, Sigma, Catalog #R4642)
made in PBS at room temperature for 1hour. The cells (at least 10,000 per condition) were then
analyzed using FACS Canto II flow cytometer (Becton Dickinson, San Jose, CA, USA).
For Ki67 staining, U-2 OS cells were plated followed by transfection with indicated constructs.
72 hours post transfection, cells were trypsinized and fixed in 1% formaldehyde solution by
incubating at room temperature for 20 minutes. This was followed by blocking and
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permeabilization at room temperature for 20 minutes, followed by staining with primary
antibody and secondary antibodies. FACS analysis was performed using BD LSR-Fortessa flow
cytometer (Becton Dickinson, San Jose, CA, USA) with at least 10,000 cells per condition.
5.12. Growth assay
U-2 OS control or DYRK1A inducible cell lines were seeded at a density of 3500 cells per well
of a 12 well plate. Cells were allowed to attach overnight followed by addition of Doxycyline
(Sigma, Catalog#9891-5G) containing medium such that the final concentration of Doxcycline is
1μg/mL. Cells were allowed to grow for 8 days and stained with crystal violet (Sigma, Catalog #
HT 90132). The relative cell density was quantified by dissolving the dye in 10% (v/v) glacial
acetic acid (ACROS, Cat# 64-19-7) and measuring the absorbance at 590 nm, after which the
ratio of cell density relative to the uninduced control was calculated.
5.13. RNA-seq analysis
Five replicates from each sample were collected in Trizol LS reagent (Invitrogen) followed by
isolation of RNA using Qiagen RNeasy Mini Kit (Catalog # 74104). RNA integrity was analyzed
using Agilent BioAnalyzer 2100 (Dr. Vladimir Lee, Genomics core- VCU) and samples were
sent for RNA-seq analysis (Genome Sequencing Facility, UT Health- San Antonio). Briefly,
RNA from five replicate samples were used to prepare mRNA libraries that were analyzed using
Illumina Hi-Seq 2500. Resulting files containing single end reads were assessed for quality using
FastQC tools and trimmed using Trimmomatic (Bolger et al., 2014). The reads were aligned to
the latest assembly of the human genome (GRCh38/hg38) using Subread, and DEGs were
determined using DESeq2 (Love et al., 2014) and Edge R (Robinson et al., 2010) packages using
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a False discovery rate (FDR) of 0.05. The analysis of RNA seq data was performed by Dr.
Mikhail Dosmorov.
5.14. RT-qPCR assays
RNA isolation was carried out using Trizol LS reagent (Invitrogen) followed by cDNA synthesis
using sensiFAST cDNA synthesis kit (Bioline; Catalog #BIO-65053). Thermoscientific maxima
SYBR Green/ Rox qPCR master mix (Catalog #K0222) was used for qPCR analysis along with
gene specific primers (Table 4) and the reactions were run on an Eppendorf realplex
mastercycler. Fold changes in mRNA expression were calculated relative to controls using the 2ΔΔCt

method.

5.15. Statistical analysis and bioinformatic tools
For quantitation of cell-staining based experiments including foci counts and Ki67 staining, 100
or more cells per conditions were typically scored. To calculate statistical significance, data from
at least three biological replicates was analyzed using two-tailed Student’s t-test. For kinase
assays, ImageJ quantifications from three biological replicates were analyzed using 2-way
Anova. For analysis of differential gene expression, two tailed student’s t-test was used to
calculate significance.
For protein networks analysis, list of proteins detected in at least three out of four DYRK1A
MudPIT analyzes or two out of four times for LZTS1, LZTS2, FAM117B, RNF169 and TROAP
were analyzed using MetaScape web-based software (metascape.org) that integrates data from
BioGrid (Chatr-Aryamontri et al., 2015) and other protein databases with custom datasets to
build protein-protein interaction networks. Protein-protein interaction networks were custom
formatted using Cytoscape_3.7.1 software.
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Table 4: List of qPCR primers used in the thesis
Gene (Human)
GABRQ
ADGRV1
ELAVL2
PLXNA2
GABRA3
SELENOP
KCNB1
WLS
TOX
PDK4
NETO1
FOXA2
DNER
E2F2
ID3
ARHGAP11B
BUB1B
MYBL2
DCAF7
18s rRNA
GAPDH

Forward (5'>3')
TCCGCCTGAGACCGAATTTT
TCTCATCAGGGAAAAGGGAACC
AGAAGGTATCCAGGACCGCT
ACAGGCCTGGGAACCTAATC
GTCAGACACTGACATGGAGTACA
CAGCTGATACCTGTGCATACTG
TACTGGAGAAGCCCAATTCCT
AAAGGATATCCGGTTGGTGGG
AAGATGAAGGCGATGATACCTCT
GCAGTGGTCCAAGATGCCTT
TATCCCAGCAAGTATCCCCCT
AGAGCCCGAGGGCTACTCC
ACCTCAGTCAAGATTCGGCA
GACAGGACTGAGGACAACCT
CTACAGCGCGTCATCGACTA
ACACATTCCAAGCTTTCTTGTCG
AGGGTGCAGCTGGATGTTTT
CATTGTGGATGAGGATGTGAAGC
CGCCCATGACAAAGAGGTCTA
AACCCGTTGAACCCCATT
GATGACATCAAGAAGGTGGTGAA
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Reverse (5'>3')
TCTGTTCAATGCTCGTGACA
CTGCCAGGGGGAAAGGTGATA
AAGCCATATTGAGCAGATTGTCC
ACTACCAGGCTAAGCAACCG
GGGCCATCAAATTTCAGTCTTTCA
TCCTTCTTTCTTCAGTTTTACTCGC
GCAATGGTGGAGAGGACGATG
GGTCTTCATGGCAAACCACAC
GCTCATTGGGATCCTTCTTCT
GTTCAACTGTTGCCCGCATT
CAATGCACTGTCTTGGAGCG
TCATGTACGTGTTCATGCCGT
CACTGTTGGAATCCTGTGGC
GGCACAGGTAGACTTCGATGG
CTCGGCTGTCTGGATGGGAA
TCCGAAAAAGCCCTTCGGTA
ACAATTCACCATCTTTTAGCTCAG
TGGTTGAGCAAGCTGTTGTCTTC
TGCTGTGTTCTAGATGGCGG
CCATCCAATCGGTAGTAGCG
GTCTTACTCCTTGGAGGCCATGT
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Appendix Figure 1: DCAF7 gene in human cancers
(A) High expression of DCAF7 in breast cancer (red lines) negatively affects survival (TCGA
data- Dr. Mikhail Dozmorov) (B) DCAF7 undergoes frequent amplifications in breast cancer
(cBioPortal). (C) Expression of DCAF7 and DYRK1A in human breast epithelial (MCF10A)
and human breast cancer cell lines (MCF7, T47D, MDAMB-231, BT549).
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Appendix Figure 2: WB indicating levels of LZTS1 and LZTS2 in indicated ovarian cancer
cell lines. T98G glioblastoma and U-2 OS osteosarcoma cell lines were used as controls.

Appendix Figure 3: All DCAF7 in the cell is not bound to DYRK1A.
T98G cell lysates were subjected to sequential immunoprecipitation with a non-specific control
antibody (IgG) or with an antibody specific to DYRK1A. The supernatant (indicated as Sup1,
Sup2) was collected after each round of immunoprecipitation and levels of DYRK1A and
DCAF7 were analyzed by WB analysis. GAPDH was used as a loading control.
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protein FAM53C
protein diaphanous homolog 1
probable fibrosin-1
casein kinase II subunit alpha
fibrosin-1-like protein isoform X3
polycomb group RING finger protein 3
zinc finger protein 703
autism susceptibility gene 2 protein
T-complex protein 1 subunit delta
E3 ubiquitin-protein ligase RING2
polycomb group RING finger protein 5
T-complex protein 1 subunit eta
YY1-associated factor 2
PREDICTED: tastin
14-3-3 protein gamma
dual specificity tyrosine-phosphorylation-regulated kinase 1B
RING1 and YY1-binding protein
zinc finger protein 503
protein phosphatase 1 regulatory subunit 3F
E3 ubiquitin-protein ligase RNF169
PDZ and LIM domain protein 5
T-complex protein 1 subunit theta
T-complex protein 1 subunit beta
T-complex protein 1 subunit alpha
T-complex protein 1 subunit gamma
tubulin alpha-8 chain
39S ribosomal protein L11, mitochondrial
DNA dC-_dU-editing enzyme APOBEC-3B
SRA stem-loop-interacting RNA-binding protein
histidine triad nucleotide-binding protein 1
40S ribosomal protein S15a
DNA-directed RNA polymerase II subunit RPB11-b2
ruvB-like 2
E3 ubiquitin/ISG15 ligase TRIM25
Werner syndrome ATP-dependent helicase
ruvB-like 1
mannose-1-phosphate guanyltransferase alpha
translocon-associated protein subunit delta
protein transport protein Sec23B
homeodomain-interacting protein kinase 2
sorting nexin-18
RNA-binding protein 12B
calnexin isoform X2
elongation factor 1-delta
myosin-11 isoform SM2A
dedicator of cytokinesis protein 7
unconventional myosin-VI
trinucleotide repeat-containing gene 6A protein
X-ray repair cross-complementing protein 5

DCAF7
DYRK1A
CSNK2A2
CCT6A
CSNK2B
RING1
FAM53C
DIAPH1
FBRS
CSNK2A2
FBRSL1
PCGF3
ZNF703
AUTS2
CCT4
RNF2
PCGF5
CCT7
YAF2
TROAP
YWHAG
DYRK1B
RYBP
ZNF503
PPP1R3F
RNF169
PDLIM5
CCT8
CCT2
TCP1
CCT3
TUBA8
MRPL11
APOBEC3B
SLIRP
HINT1
RPS15A
POLR2J3
RUVBL2
TRIM25
WRN
RUVBL1
GMPPA
SSR4
SEC23B
HIPK2
SNX18
RBM12B
CANX
EEF1D
MYH11
DOCK7
MYO6
TNRC6A
XRCC5

342
754
391
531
215
406
392
1272
980
350
1085
242
590
1266
539
336
236
543
138
868
247
689
228
646
798
708
596
548
535
556
545
383
192
382
109
126
130
115
463
630
1432
456
420
184
767
1198
628
1001
646
647
1938
2100
1253
1962
732

MW

38926
84557
45144
58024
24942
42429
43091
141347
103769
41213
115367
28115
58222
139763
57924
37655
27512
59367
15115
93449
28303
75127
24822
62555
82726
77194
63975
59621
57488
60344
60534
42954
20683
45951
12349
13802
14839
13074
51157
70974
162460
50228
46291
20213
86479
130965
68895
118103
73410
71422
223575
238532
145015
210296
82705
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pI

5.5
8.8
7.7
6.7
5.6
5.6
8.6
5.4
9.5
8.6
9.4
8.2
8.8
9.4
7.8
6.8
6.5
7.6
9.9
7.2
4.9
9.4
9.6
8.7
4.6
9.1
8.2
5.6
6.4
6.1
6.5
5.1
9.9
6.3
10.2
7
10.1
6.3
5.6
8.1
6.3
6.4
7.2
5.8
6.9
8.4
5.7
6.8
4.6
6.4
5.5
6.8
8.6
7
5.8

FAM117BFAM117B- FL
GFP-CTAP FAM117BFL dNSAF Detected Detected FL:GFPAVG
# Out of 3 # Out of 4 CTAP
Locus

0.237479
0.071217
0.057198
0.03839
0.031779
0.014981
0.010188
0.009108
0.008456
0.004821
0.003545
0.002811
0.002315
0.00123
0.000857
0.000771
0.000695
0.00069
0.000576
0.000536
0.000531
0.000481
0.000427
0.000383
0.000358
0.000355
0.000327
0.000283
0.000274
0.000263
0.000251
0.000246
0.000244
0.000237
0.000236
0.000219
0.000206
0.000193
0.000184
0.000183
0.000171
0.000169
0.000169
0.000164
0.000164
0.000162
0.000161
0.000156
0.000133
0.000132

3
3
3
3
3
3
3
3
3
3
3
3
2
3
2
3
3
3
3
2
3
2
3
3
2
2
2
2
2
2
3
2
3
3
2
3
3
2
2
3
2
3
2
3
3
3
2
3
3
3

1
0
0
1
2
0
1
1
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

969.302 gi|83267868|ref|NP_001032584.1|
∞
gi|254910983|ref|NP_775782.2|
∞
gi|767953588|ref|XP_011515591.1|
238.4472 gi|21328448|ref|NP_647539.1|
46.6652 gi|5803227|ref|NP_006817.1|
∞
gi|108936958|ref|NP_005819.3|
80.85714 gi|5803225|ref|NP_006752.1|
37.17551 gi|18087855|ref|NP_542408.1|
∞
gi|4507951|ref|NP_003396.1|
∞
gi|4506619|ref|NP_000977.1|
∞
gi|4506633|ref|NP_000984.1|
∞
gi|578836477|ref|XP_006724042.1|
∞
gi|4506643|ref|NP_000989.1|
∞
gi|4506901|ref|NP_003008.1|
∞
gi|4506687|ref|NP_001009.1|
∞
gi|767950480|ref|XP_011542667.1|
∞
gi|148727341|ref|NP_009109.3|
∞
gi|66346679|ref|NP_001018077.1|
∞
gi|77812674|ref|NP_001030005.1|
∞
gi|7705618|ref|NP_057134.1|
∞
gi|23503259|ref|NP_699170.1|
∞
gi|345197222|ref|NP_001230807.1|
∞
gi|22907039|ref|NP_055323.2|
∞
gi|767904731|ref|XP_011539919.1|
∞
gi|4758256|ref|NP_004085.1|
∞
gi|5922001|ref|NP_006475.1|
∞
gi|8922549|ref|NP_060624.1|
∞
gi|51317376|ref|NP_001003796.1|
∞
gi|16554616|ref|NP_115865.1|
∞
gi|521258690|ref|NP_001265585.1|
∞
gi|68160937|ref|NP_005073.2|
∞
gi|767951904|ref|XP_011515883.1|
∞
gi|768004861|ref|XP_011526754.1|
∞
gi|56118219|ref|NP_001007226.1|
∞
gi|7661730|ref|NP_054737.1|
∞
gi|15147219|ref|NP_150093.1|
∞
gi|87239981|ref|NP_003738.2|
∞
gi|306482646|ref|NP_001182356.1|
∞
gi|18139549|ref|NP_085151.1|
∞
gi|49472822|ref|NP_003746.2|
∞
gi|169636418|ref|NP_115867.2|
∞
gi|544346109|ref|NP_001269672.1|
∞
gi|530371187|ref|XP_005247022.1|
∞
gi|13994259|ref|NP_114108.1|
∞
gi|767985150|ref|XP_011520272.1|
∞
gi|767974361|ref|XP_011536692.1|
∞
gi|29826335|ref|NP_003899.2|
∞
gi|186928854|ref|NP_005821.2|
∞
gi|17402904|ref|NP_478126.1|
∞
gi|768010611|ref|XP_011525532.1|

Description

NCBI_Gen
e
Length MW

dynein light chain 1, cytoplasmic
protein FAM117B
14-3-3 protein zeta/delta
14-3-3 protein beta/alpha
14-3-3 protein theta
DDB1- and CUL4-associated factor 7
14-3-3 protein epsilon
dynein light chain 2, cytoplasmic
14-3-3 protein eta
60S ribosomal protein L24
60S ribosomal protein L31
dual specificity tyrosine-phosphorylation-regulated kinase 1A
60S ribosomal protein L37a
serine/arginine-rich splicing factor 3
40S ribosomal protein S15
paraneoplastic antigen Ma2
serine-threonine kinase receptor-associated protein
plasminogen activator inhibitor 1 RNA-binding
H/ACA ribonucleoprotein complex subunit 2
39S ribosomal protein L11, mitochondrial
tRNA pseudouridine synthase-like 1
four and a half LIM domains protein 3
DNA dC-_dU-editing enzyme APOBEC-3C
filamin-binding LIM protein
eukaryotic translation initiation factor 2 subunit 1
dual specificity tyrosine-phosphorylation-regulated kinase 1B
histone chaperone ASF1B
NHP2-like protein 1
28S ribosomal protein S6, mitochondrial
small nuclear ribonucleoprotein Sm D3
E3 ubiquitin/ISG15 ligase TRIM25
transcription elongation factor B polypeptide 1
kelch-like ECH-associated protein 1
insulin-like growth factor 2 mRNA-binding protein 2
28S ribosomal protein S28, mitochondrial
transcriptional activator protein Pur-beta
tankyrase-1
serine/arginine-rich splicing factor 2
histone-lysine N-methyltransferase SETD7
eukaryotic translation initiation factor 3 subunit G
39S ribosomal protein L38, mitochondrial
SPATS2-like protein
general transcription factor 3C polypeptide 3
28S ribosomal protein S5, mitochondrial
thrombospondin-1
nucleosome assembly protein 1-like 1
eukaryotic translation initiation factor 2 subunit 2
28S ribosomal protein S31, mitochondrial
exosome complex component MTR3
zinc finger protein 574

DYNLL1
89 10366
FAM117B
589 61968
YWHAZ
245 27745
YWHAB
246 28082
YWHAQ
245 27764
DCAF7
342 38926
YWHAE
255 29174
DYNLL2
89 10350
YWHAH
246 28219
RPL24
157 17779
RPL31
125 14463
DYRK1A
754 84557
RPL37A
92 10275
SRSF3
164 19330
RPS15
145 17040
PNMA2
364 41509
STRAP
350 38438
SERBP1
408 44965
NHP2
90 10071
MRPL11
192 20683
PUSL1
303 33233
FHL3
172 18918
APOBEC3C 190 22826
FBLIM1
373 40670
EIF2S1
315 36112
DYRK1B
601 66336
ASF1B
202 22434
SNU13
128 14174
MRPS6
125 14227
SNRPD3
126 13916
TRIM25
630 70974
TCEB1
112 12473
KEAP1
624 69666
IGF2BP2
556 61843
MRPS28
187 20843
PURB
312 33241
TNKS
1327 142039
SRSF2
221 25476
SETD7
366 40721
EIF3G
320 35611
MRPL38
380 44597
SPATS2L
498 54945
GTF3C3
494 56384
MRPS5
430 48006
THBS1
1170 129383
NAP1L1
403 46832
EIF2S2
333 38388
MRPS31
395 45319
EXOSC6
272 28235
ZNF574
896 98900
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pI

7.4
9.8
4.8
4.8
4.8
5.5
4.7
7.4
4.8
11.3
10.5
8.8
10.4
11.6
10.4
4.8
5.1
8.6
10
9.9
9.9
7.6
7.6
6
5.1
9.1
4.6
8.5
9.3
10.3
8.1
4.8
6.4
8.3
9.1
5.4
7
11.9
4.6
6.1
7.5
9.7
6.6
9.9
4.9
4.5
5.8
9.3
6.3
8.1

LZTS2
dNSAF
AVG

0.010264
0.005095
0.003806
0.002753
0.002222
0.001475
0.001429
0.001064
0.000723
0.000697
0.000598
0.000582
0.000417
0.000189
0.000109
0.038582
0.012743
0.003093
0.000641
0.002162
0.000742
0.019113
0.000594
0.042142
0.001352
0.001095
0.000964
0.000958
0.00079
0.000686
0.000651
0.000633
0.00059
0.000562
0.000528
0.000516
0.000514
0.000513
0.000478
0.000433
0.000421
0.000383
0.000377
0.000367
0.000349
0.000344
0.000329
0.000323
0.000322
0.000308

LZTS2
GFP-CTAP
Detected Detected LZTS2:GFP# Out of 3 # Out of 3 CTAP
Locus

3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2

0∞
gi|108936958|ref|NP_005819.3|
0∞
gi|578836477|ref|XP_006724042.1|
0∞
gi|767912565|ref|XP_011542546.1|
0∞
gi|767950531|ref|XP_011542689.1|
0∞
gi|768007560|ref|XP_011524959.1|
0∞
gi|545746375|ref|NP_001271175.1|
0∞
gi|122937500|ref|NP_001074002.1|
0∞
gi|768057171|ref|XP_011547115.1|
0∞
gi|21464101|ref|NP_036611.2|
0∞
gi|767935349|ref|XP_011541469.1|
0∞
gi|115511046|ref|NP_009098.3|
0∞
gi|44890068|ref|NP_005086.2|
0∞
gi|530426085|ref|XP_005260950.1|
0∞
gi|11321601|ref|NP_002618.1|
0∞
gi|4507729|ref|NP_001060.1|
1 964.55 gi|530394499|ref|XP_005270281.1|
2 81.6859 gi|283436222|ref|NP_001164006.1|
3 20.21569 gi|14389309|ref|NP_116093.1|
2 19.42424 gi|237649019|ref|NP_001153682.1|
2 19.13274 gi|217272849|ref|NP_001136067.1|
3 14.26923 gi|18105007|ref|NP_004332.2|
3 6.379506 gi|29788785|ref|NP_821133.1|
1 5.881188 gi|426214088|ref|NP_001258766.1|
3 5.084087 gi|55956899|ref|NP_000217.2|
0∞
gi|75677353|ref|NP_114127.3|
0∞
gi|4827048|ref|NP_005139.1|
0∞
gi|768037835|ref|XP_011529275.1|
0∞
gi|187830777|ref|NP_001119584.1|
0∞
gi|578810654|ref|XP_006714791.1|
0∞
gi|7657257|ref|NP_055580.1|
0∞
gi|5802968|ref|NP_006809.1|
0∞
gi|332634984|ref|NP_001091084.2|
0∞
gi|23308693|ref|NP_689948.1|
0∞
gi|530339647|ref|NP_001268861.1|
0∞
gi|66529294|ref|NP_000296.2|
0∞
gi|530426780|ref|XP_005266156.1|
0∞
gi|578823153|ref|XP_006719244.1|
0∞
gi|109689718|ref|NP_001035937.1|
0∞
gi|148368978|ref|NP_689512.2|
0∞
gi|157057543|ref|NP_443102.2|
0∞
gi|31543831|ref|NP_001061.2|
0∞
gi|767969890|ref|XP_011541020.1|
0∞
gi|5730009|ref|NP_006501.1|
0∞
gi|11386135|ref|NP_000700.1|
0∞
gi|153085461|ref|NP_001093138.1|
0∞
gi|767953588|ref|XP_011515591.1|
0∞
gi|4506189|ref|NP_002783.1|
0∞
gi|4506753|ref|NP_003698.1|
0∞
gi|187960098|ref|NP_001120800.1|
0∞
gi|194018488|ref|NP_000278.3|

Description

DDB1- and CUL4-associated factor 7
dual specificity tyrosine-phosphorylation-regulated kinase 1A
signal-induced proliferation-associated 1-like protein 2
leucine zipper putative tumor suppressor 1
signal-induced proliferation-associated 1-like protein 3
signal-induced proliferation-associated 1-like protein 1
protein unc-119 homolog B
dual specificity tyrosine-phosphorylation-regulated kinase 1B
14-3-3 protein gamma
protein Shroom1
zinc finger MYM-type protein 6
zinc finger MYM-type protein 4
leucine zipper putative tumor suppressor 3
ATP-dependent 6-phosphofructokinase, platelet type
tubulin beta-2A chain
leucine zipper putative tumor suppressor 2
ATPase family AAA domain-containing protein 3A
tubulin alpha-1C chain isoform c
calcium-binding mitochondrial carrier protein Aralar2
prolyl 4-hydroxylase subunit alpha-1
CAD protein
tubulin beta chain
reticulocalbin-2
keratin, type I cytoskeletal 9
ATPase family AAA domain-containing protein 3B
protein unc-119 homolog A
PDZ domain-containing protein 11
cellular tumor antigen p53
prolyl 4-hydroxylase subunit alpha-2
mitochondrial import receptor subunit TOM20 homolog
protein AF1q
DNA-directed RNA polymerase II subunit RPB11-b2
zinc finger and BTB domain-containing protein 9
condensin-2 complex subunit G2
serum paraoxonase/arylesterase 2
TNF receptor-associated factor 2
tastin
monoacylglycerol lipase ABHD12
condensin-2 complex subunit H2
sorting nexin-18
tubulin gamma-1 chain
condensin-2 complex subunit D3
zinc finger protein RFP
2-oxoisovalerate dehydrogenase subunit alpha, mitochondrial
HIG1 domain family member 1A, mitochondrial isoform
PREDICTED: 14-3-3 protein zeta/delta
proteasome subunit alpha type-7
ruvB-like 1
medium-chain specific acyl-CoA dehydrogenase, mitochondrial isoform
peroxisome biogenesis factor 6

NCBI_Ge
ne
Length MW
pI
DCAF7
342
38926
DYRK1A
754
84557
SIPA1L2
1722 190436
LZTS1
596
66613
SIPA1L3
1781 194608
SIPA1L1
1782 197407
UNC119B
251
28137
DYRK1B
689
75127
YWHAG
247
28303
SHROOM1
852
90786
ZMYM6
1325 148088
ZMYM4
1548 172787
LZTS3
673
71791
PFKP
784
85596
TUBB2A
445
49907
LZTS2
669
72759
ATAD3A
586
66218
TUBA1C
449
49895
SLC25A13
676
74304
P4HA1
534
61049
CAD
2225 242981
TUBB
444
49671
RCN2
335
39139
KRT9
623
62064
ATAD3B
648
72573
UNC119
240
26962
PDZD11
140
16131
TP53
393
43653
P4HA2
535
60902
TOMM20
145
16298
MLLT11
90
10061
POLR2J3
115
13074
ZBTB9
473
50602
NCAPG2
1143 130960
PON2
354
39381
TRAF2
533
59135
TROAP
868
93449
ABHD12
398
45097
NCAPH2
605
68227
SNX18
628
68895
TUBG1
451
51170
NCAPD3
1498 168890
TRIM27
513
58490
BCKDHA
445
50471
HIGD1A
107
11770
YWHAZ
245
27745
PSMA7
248
27887
RUVBL1
456
50228
ACADM
425
47020
PEX6
980 104061
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5.5
8.8
6.8
7.1
8.3
8.3
5.7
9.4
4.9
6.1
8.2
6.8
7.6
7.6
4.9
6.5
9.2
5.1
8.6
6
6.5
4.9
4.5
5.2
9.2
6.4
7.2
6.8
5.7
8.6
4.5
6.3
6.8
6.9
5.6
7.5
7.2
8.6
4.7
5.7
6.1
7.5
6.2
8.3
9.4
4.8
8.5
6.4
8.3
6.3

LZTS1
dNSAF
AVG

0.079012
0.012714
0.003781
0.003154
0.003012
0.002244
0.00222
0.002135
0.002091
0.0019
0.001899
0.001663
0.001579
0.001391
0.001244
0.001171
0.001041
0.00103
0.000998
0.000972
0.000934
0.000907
0.000864
0.000858
0.000823
0.000817
0.000782
0.000776
0.000757
0.00075
0.000727
0.0007
0.00069
0.000688
0.000679
0.000676
0.000652
0.000633
0.000605
0.000605
0.000556
0.000534
0.000527
0.000522
0.000497
0.000488
0.000483
0.000482
0.000482
0.000481

LZTS1
GFP-CTAP
Detected Detected LZTS1:GFP# Out of 3 # Out of 3 CTAP
Locus

3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3

0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

∞
∞
∞
∞
∞
∞
∞
∞
∞
∞
∞
∞
∞
∞
∞
∞
∞
∞
∞
∞
∞
∞
∞
∞
∞
∞
∞
∞
∞
∞
∞
∞
∞
∞
∞
∞
∞
∞
∞
∞
∞
∞
∞
∞
∞
∞
∞
∞
∞
∞

gi|767950531|ref|XP_011542689.1|
gi|122937500|ref|NP_001074002.1|
gi|4827048|ref|NP_005139.1|
gi|21361647|ref|NP_006612.2|
gi|314122177|ref|NP_001186600.1|
gi|21464101|ref|NP_036611.2|
gi|5730023|ref|NP_006657.1|
gi|767924420|ref|XP_011532466.1|
gi|4506753|ref|NP_003698.1|
gi|153085461|ref|NP_001093138.1|
gi|530392883|ref|XP_005269499.1|
gi|108936958|ref|NP_005819.3|
gi|66529294|ref|NP_000296.2|
gi|17388799|ref|NP_490647.1|
gi|530387549|ref|XP_005273449.1|
gi|11321601|ref|NP_002618.1|
gi|768044351|ref|XP_011544912.1|
gi|767948171|ref|XP_011514665.1|
gi|767935349|ref|XP_011541469.1|
gi|19923483|ref|NP_057406.2|
gi|5453559|ref|NP_006347.1|
gi|33239451|ref|NP_872590.1|
gi|6912430|ref|NP_036537.1|
gi|578821561|ref|XP_006718676.1|
gi|11559927|ref|NP_071383.1|
gi|13654278|ref|NP_112487.1|
gi|578836477|ref|XP_006724042.1|
gi|225543166|ref|NP_056195.3|
gi|21359867|ref|NP_001907.2|
gi|13435356|ref|NP_006109.2|
gi|767953588|ref|XP_011515591.1|
gi|31543831|ref|NP_001061.2|
gi|89903012|ref|NP_001034891.1|
gi|530407434|ref|XP_005255087.1|
gi|109689718|ref|NP_001035937.1|
gi|92110027|ref|NP_060129.2|
gi|169404009|ref|NP_003135.2|
gi|530395344|ref|XP_005252973.1|
gi|187830777|ref|NP_001119584.1|
gi|21361565|ref|NP_001679.2|
gi|4502227|ref|NP_001168.1|
gi|521258690|ref|NP_001265585.1|
gi|4506613|ref|NP_000974.1|
gi|46852178|ref|NP_064507.3|
gi|205830453|ref|NP_001128634.1|
gi|530376692|ref|XP_005248174.1|
gi|15721937|ref|NP_114403.1|
gi|20270303|ref|NP_620124.1|
gi|530419305|ref|XP_005261210.1|
gi|5453998|ref|NP_006382.1|

Description

NCBI_Gen
e
Length

leucine zipper putative tumor suppressor 1
protein unc-119 homolog B
protein unc-119 homolog A
putative adenosylhomocysteinase 2
calumenin isoform c precursor
14-3-3 protein gamma
ruvB-like 2
protein O-linked-mannose beta-1,4-N-acetylglucosaminyltransferase 2
ruvB-like 1
HIG1 domain family member 1A, mitochondrial
PREDICTED: erlin-1
DDB1- and CUL4-associated factor 7
serum paraoxonase/arylesterase 2
dnaJ homolog subfamily B member 6
erlin-2
ATP-dependent 6-phosphofructokinase, platelet type
ribonuclease inhibitor
MICOS complex subunit MIC19
protein Shroom1
ras-related protein Rab-14
ATP synthase subunit d, mitochondrial
proliferating cell nuclear antigen
protein-S-isoprenylcysteine O-methyltransferase
protein phosphatase 6 regulatory subunit 3
28S ribosomal protein S14, mitochondrial
SRA stem-loop-interacting RNA-binding protein, mitochondrial isoform
dual specificity tyrosine-phosphorylation-regulated kinase 1A
sorting and assembly machinery component 50 homolog
cytochrome c1, heme protein, mitochondrial precursor
HCLS1-associated protein X-1
14-3-3 protein zeta/delta
tubulin gamma-1 chain
cell division control protein 42 homolog
cytosolic Fe-S cluster assembly factor NUBP2
monoacylglycerol lipase ABHD12
glutaminyl-peptide cyclotransferase-like protein
translocon-associated protein subunit alpha
rho-related GTP-binding protein RhoG
cellular tumor antigen p53
ATP synthase F(0) complex subunit B1, mitochondrial precursor
ADP-ribosylation factor-like protein 1
small nuclear ribonucleoprotein Sm D3
60S ribosomal protein L22 proprotein
E3 ubiquitin-protein ligase KCMF1
catechol O-methyltransferase isoform MB-COMT
transmembrane protein 33
28S ribosomal protein S24, mitochondrial precursor
mitochondrial Rho GTPase 2
putative ribonuclease
importin-7

LZTS1
UNC119B
UNC119
AHCYL1
CALU
YWHAG
RUVBL2
POMGNT2
RUVBL1
HIGD1A
ERLIN1
DCAF7
PON2
DNAJB6
ERLIN2
PFKP
RNH1
MIC19
SHROOM1
RAB14
ATP5H
PCNA
ICMT
PPP6R3
MRPS14
SLIRP
DYRK1A
SAMM50
CYC1
HAX1
YWHAZ
TUBG1
CDC42
NUBP2
ABHD12
QPCTL
SSR1
RHOG
TP53
ATP5F1
ARL1
SNRPD3
RPL22
KCMF1
COMT
TMEM33
MRPS24
RHOT2
YBEY
IPO7

596
251
240
530
323
247
463
580
456
107
348
342
354
326
339
784
461
232
852
215
161
261
284
873
128
109
754
469
325
279
245
451
191
130
398
382
286
191
393
256
181
126
128
381
271
247
167
618
168
1038

MW

66613
28137
26962
58951
38051
28303
51157
66615
50228
11770
39171
38926
39381
36087
37840
85596
49974
26753
90786
23897
18491
28769
31938
97669
15139
12349
84557
51976
35390
31621
27745
51170
21259
13793
45097
42924
32235
21308
43653
28909
20418
13916
14787
41945
30037
27978
19015
68118
19436
119516

Appendix Table 4: List of top 50 proteins detected by MudPIT proteomic analysis of
LZTS1
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pI

7.1
5.7
6.4
6.9
4.6
4.9
5.6
8.6
6.4
9.4
7.9
5.5
5.6
9.1
5.6
7.6
4.8
7.8
6.1
6.2
5.3
4.7
8
4.6
11.4
10.2
8.8
6.9
9
4.9
4.8
6.1
6.5
5.1
8.6
9.8
4.5
8.1
6.8
9.4
5.7
10.3
9.2
5.7
5.5
9.7
9.4
5.9
8.1
4.8

RNF169
dNSAF
AVG

RNF169 Control
Detected Detected RNF169:C NCBI_Gen
# Out of 3 # Out of 3 ontrol
e
Locus

0.004144
0.002413
0.000644
0.000607
0.000344
0.000693
0.000267
0.000951
0.000239
0.000028
0.000279
0.000515
0.000333
0.000099
0.000106
0.002086
0.000051
0.00016
0.000862
0.001085
0.000869
0.000021
0.000634
0.000062
0.000397
0.000155
0.000057

3
3
3
3
3
3
3
3
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2

0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

∞
∞
∞
∞
∞
∞
∞
∞
∞
∞
∞
∞
∞
∞
∞
∞
∞
∞
∞
∞
∞
∞
∞
∞
∞
∞
∞

RNF169 gi|767967816|ref|XP_011543191.1|
USP7
gi|150378533|ref|NP_003461.2|
DCAF7 gi|108936958|ref|NP_005819.3|
DYRK1A gi|768020356|ref|XP_011527785.1|
ACTR1A gi|5031569|ref|NP_005727.1|
SLC25A5 gi|156071459|ref|NP_001143.2|
ILF2
gi|24234747|ref|NP_004506.2|
RPL10A gi|15431288|ref|NP_009035.3|
WDR6 gi|197927448|ref|NP_060501.3|
SIPA1L1 gi|545746375|ref|NP_001271175.1|
DYNLL2 gi|18087855|ref|NP_542408.1|
KPNB1 gi|19923142|ref|NP_002256.2|
PSMC2 gi|4506209|ref|NP_002794.1|
MCM7 gi|33469968|ref|NP_005907.3|
LRCH3 gi|578807822|ref|XP_006713854.1|
SRSF9
gi|4506903|ref|NP_003760.1|
TARDBP gi|6678271|ref|NP_031401.1|
ATP1A1 gi|21361181|ref|NP_000692.2|
ELAVL1 gi|38201714|ref|NP_001410.2|
RPS17
gi|4506693|ref|NP_001012.1|
TMOD1 gi|260763922|ref|NP_001159588.1|
DOCK7 gi|431822375|ref|NP_001258928.1|
FLG2
gi|62122917|ref|NP_001014364.1|
LARP1 gi|39725634|ref|NP_056130.2|
SMARCE1 gi|21264355|ref|NP_003070.3|
ZNF185 gi|530422917|ref|XP_005274794.1|
PPP1R12C gi|14149716|ref|NP_060077.1|

Description

Length

E3 ubiquitin-protein ligase RNF169
ubiquitin carboxyl-terminal hydrolase 7 isoform 1
DDB1- and CUL4-associated factor 7
dual specificity tyrosine-phosphorylation-regulated kinase 1A
alpha-centractin
ADP/ATP translocase 2
ILF2:interleukin enhancer-binding factor 2
60S ribosomal protein L10a
WD repeat-containing protein 6
signal-induced proliferation-associated 1-like protein 1
dynein light chain 2, cytoplasmic
importin subunit beta-1
26S protease regulatory subunit 7
DNA replication licensing factor MCM7
leucine-rich repeat and calponin homology domain-containing protein 3
serine/arginine-rich splicing factor 9
TAR DNA-binding protein 43
ATP1A1:sodium/potassium-transporting ATPase subunit alpha-1
ELAVL1:ELAV-like protein 1
40S ribosomal protein S17
tropomodulin-1
dedicator of cytokinesis protein 7
FLG2:filaggrin-2
LARP1:la-related protein 1
SWI/SNF-related matrix-associated actin-dependent regulator of chromatin subfamily E member 1
zinc finger protein 185
protein phosphatase 1 regulatory subunit 12C

MW

729
1102
342
763
376
298
390
217
1151
1782
89
876
433
719
777
221
414
1023
326
135
359
2129
2391
1019
411
690
782

pI

79394
128302
38926
85584
42614
32852
43062
24831
125001
197407
10350
97170
48634
81308
86083
25542
44740
112896
36092
15550
40569
241410
248072
116465
46649
73613
84881

9.1
5.6
5.5
8.7
6.6
9.7
5.3
9.9
6.9
8.3
7.4
4.8
5.9
6.5
6.7
8.6
6.2
5.5
9.2
9.8
5.1
6.8
8.3
9.1
4.9
7
5.6

Appendix Table 5: List of proteins detected by MudPIT proteomic analysis of RNF169

NTAPTROA
dNSAF
AVG

0.003868
0.001995
0.001886
0.001525
0.000997
0.014143
0.003002
0.001921
0.001204
0.001062
0.000761
0.000693
0.000574
0.000292
0.000141
0.000095

NTAPTROA
GFP-CTAP NTAPDetected Detected TROA:GFP# Out of 3 # Out of 3 CTAP
Locus

3
3
3
3
3
2
2
2
2
2
2
2
2
2
2
2

0∞
gi|578823153|ref|XP_006719244.1|
3 13.03922 gi|14389309|ref|NP_116093.1|
0∞
gi|578836477|ref|XP_006724042.1|
0∞
gi|108936958|ref|NP_005819.3|
3 6.828767 gi|32698730|ref|NP_065823.1|
3 5.849049 gi|124494247|ref|NP_001074419.1|
3 7.014019 gi|5453599|ref|NP_006127.1|
3 5.910769 gi|45359846|ref|NP_987100.1|
0∞
gi|4506633|ref|NP_000984.1|
1 27.23077 gi|13124875|ref|NP_074035.1|
3 11.19118 gi|383792189|ref|NP_059867.3|
2 10.04348 gi|227430301|ref|NP_001153059.1|
0∞
gi|16905517|ref|NP_473357.1|
0∞
gi|40807443|ref|NP_955445.1|
0∞
gi|18379349|ref|NP_006364.2|
0∞
gi|574584803|ref|NP_001276052.1|

Description

NCBI_Gene Length

tastin
tubulin alpha-1C chain
dual specificity tyrosine-phosphorylation-regulated kinase 1A
DDB1- and CUL4-associated factor 7
nuclear fragile X mental retardation-interacting protein 2
unconventional myosin-Ic
F-actin-capping protein subunit alpha-2
ras GTPase-activating protein-binding protein 2
60S ribosomal protein L31
myosin-11 isoform SM2A
ataxin-2-like protein
CD109 antigen isoform 2 preproprotein
serine/arginine-rich splicing factor 10
protein regulator of cytokinesis 1
synaptic vesicle membrane protein VAT-1 homolog
tubulin beta-4A chain

TROAP
TUBA1C
DYRK1A
DCAF7
NUFIP2
MYO1C
CAPZA2
G3BP2
RPL31
MYH11
ATXN2L
CD109
SRSF10
PRC1
VAT1
TUBB4A

868
449
754
342
695
1044
286
449
125
1938
1062
1428
262
606
393
495

MW

93449
49895
84557
38926
76121
119628
32949
50817
14463
223575
112091
159695
31301
70249
41920
54467

Appendix Table 6: List of proteins detected by MudPIT proteomic analysis of TROAP
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pI

7.2
5.1
8.8
5.5
8.7
9.5
5.8
5.4
10.5
5.5
8.7
5.8
11.3
6.7
6.3
5

Up in DYRK1A KO and overlap with DYRK1A ChIP-seq dataset
Serum starved + Cycling (135
genes)
ADAT1
EXOC8
PUF60
AHCTF1
FAM76A PXMP2
ALDH16A1 FBXL5
QRICH1
ASH2L
FBXO31 R3HDM1
ASXL1
FLNA
RAB33B
ATAD3A FOXC2
RBM15
ATF2
FUBP1
RCC1
ATF4
GAS8
RFC5
ATXN7L2 GGA3
RING1
BANP
GPATCH3 SCAMP5
BAZ2B
GRWD1
SEC22C
BCAR3
HERC1
SENP7
BRI3BP
HERPUD2 SETD5
C1orf74
HNRNPH3 SLC12A2
C2orf68
HSD17B8 SLC25A4
C6orf89
HUWE1
SMARCA5
CAND1
ILF2
SMG5
CD2AP
KIAA1191 SPDL1
CDC20
LIN7C
SPRTN
CDC25B
LUC7L2
SRCAP
CDC5L
MAD1L1 SRSF10
CENPB
MAPK14 STRIP1
CENPT
MAU2
SUV39H1
CEP350
MBTPS1 THAP11
CHAF1A MED22
TIPIN
CIAPIN1 MGME1
TMEM209
COPB2
MRM2
TMEM79
COQ9
MTHFSD TMPO
CORO7
MYO19
TRAPPC2
CSDE1
NANP
TRIM7
CYGB
NCAPG2 TTC23
DBNDD1 NDUFS7 TUBGCP5
DBR1
NFYC
UBE2D3
DCAF16
NKTR
UHRF2
DDHD2
NOL9
USP39
DDX20
NOP14
WDR6
DENR
NUDT1
WDR77
DHX37
OFD1
XPC
DNAJA3
PFKFB2 YOD1
DNAJC27 PHF12
ZCCHC14
DPP9
PIH1D1
ZFP91
EFHC1
POLDIP3 ZNF48
EHD1
POLE
ZNF500
EMD
POLG
ZNF839
ETFA
POP7
ZNF850

Cycling only (169 genes)
ABCC10
HDAC6
PLEKHA6
ABHD18
HGH1
PLEKHG2
ABTB2
HMBOX1 PMF1
ACBD4
HOMER2 PNKP
ADNP
HOXC6
POLR1C
ALKBH2
ICMT
POLR3E
AP4E1
ID1
PPM1G
ARHGAP32 IFRD1
PPOX
ARHGEF18 IGFBP3
PPP1R10
ASF1B
IL17RD
PPP1R12A
BAK1
INTS9
PRDM11
BRF1
KANK1
PRKDC
CARMIL1 KIF24
PRMT5
CDKN1B KIN
PROSER3
CENPC
KLC2
PRPF4
CFAP45
LOXL2
PRPF40B
CFDP1
LRFN3
PRR14
CHMP1A LTA4H
PRTG
CLASP1
LY6G5B PTGER4
CLTB
MAD2L1 R3HDM4
COL1A1
MCM4
RAB17
CYTH1
MDM4
RAD18
DDX19A
MED16
RGL2
DFFA
MGRN1
RIC8B
DIDO1
MPZL1
RPS15
DLX1
MRE11
SELENON
DYRK1A MRI1
SEMA3B
E2F2
MYBL2
SF1
EFHD1
NANS
SIPA1L1
EID2
NCL
SIRT5
EIF1AD
NCOA7
SLC12A9
EPOP
NFATC2IP SLC4A3
FBRS
NFIB
SLC6A9
FDPS
NMRAL1 SMARCAD1
FKBPL
NOA1
SMARCC2
FMNL1
NPTN
SMC1A
FUS
NUDT5
SMC5
GCAT
NUP37
SMG7
GDF7
PACS2
SNAP29
GDI2
PARP2
SNRNP70
GGT5
PDE12
SNRPC
GID8
PEX14
SPATA33
GOLGA8B PFDN6
SPC25
GSN
PHC2
SPTY2D1
HASPIN
PI4KA
SREK1

SRP14
SRRT
SUSD2
TAF6
TBL3
TCF3
THAP7
TIA1
TMEM183A
TMEM262
TRIP6
TROAP
TUBGCP6
UBALD1
UBXN11
UMAD1
UNG
USP21
USP54
VAMP2
VPS37C
VPS51
WDR46
WDR59
WDR90
YIPF3
ZBTB25
ZDHHC5
ZFP30
ZFPM1
ZKSCAN2
ZNF136
ZNF184
ZNF790

Serum starved
only (2 genes)
CNN2
TMEM259

Appendix table 7: Overlap of DYRK1A regulated genes (obtained by RNA-seq) with
DYRK1A ChIP-seq dataset [under Serum starved or Cycling conditions (Di Vona et al.,
2015)]. Related to Figure 49A.
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Down in DYRK1A KO and overlap with DYRK1A ChIP-seq dataset
Serum starved + Cycling (101
genes)
AKAP11
MKKS
SSR1
ASPH
MMS22L SURF2
C5orf24
MRPL57
TMCO1
C6orf120
MRPS7
TMEM245
CCDC77
MTFR1L TOPORS
CCNC
NAA35
UBC
CCNG1
NAA38
VDAC3
CCT8
NCOA4
VMP1
CDK12
NOL11
WDR27
CHST7
NPR3
ZBTB2
CNP
NRBF2
ZBTB6
COASY
NSUN3
COX11
PAXBP1
CUL5
PBLD
DCTN2
PGK1
DHFR2
PIGN
DNAJB4
PLOD2
DNTTIP2
PPP4R3B
ECHS1
PRDX1
ERGIC2
PSMB3
ETF1
PSMD5
FAM135A PTPRN2
FGFR1OP2 PTRH2
FMC1
PTTG1
GGNBP2
RBPJ
GLCE
RNF167
GP1BA
RPL10A
GPR19
RPL12
HSD17B1
RPL13A
HSPA4
RPL17
HSPH1
RPL23
IFT80
RPL26
IMP3
RPL27A
INTS13
RPL7A
IREB2
RPS6
KAZALD1 RRAGA
LAMP1
SEC62
LPXN
SFXN3
LRSAM1
SKA3
LTV1
SLC39A7
MAGOHB SLU7
MAP1LC3B SMIM10L1
MAP3K7CL SMIM27
MATR3
SPAG16
MICU2
SRP19

ACADSB
ACO2
ADGRF1
ADGRG1
AHCY
AIDA
AKT1S1
ANKRD49
ARCN1
ATG4A
B4GAT1
BCLAF1
BZW1
C11orf54
C12orf57
C20orf27
CASTOR1
CCNJ
CCR7
CD320
CDC26
CETN2
CETN3
CHUK
CHURC1
CLPX
CNPY2
COL1A2
COPS3
COQ3
COX7B
DIS3
DRG1
DSE
DZIP3
EDRF1
EIF3L
ENDOV
EXT2
F8
FAM136A
FAM216A
FASTKD2
FGF1
FOXG1

Cycling only (139 genes)
FTCD
PPP1R2
GPN3
PRDX4
GRB2
PSENEN
HARS2
PSMD10
HES7
PTPN1
HIGD2A RAB27A
HINT1
RACK1
HMGN5 RBM26
ICAM1
RICTOR
IFT74
RIN1
IKBKG
RPS15A
IKZF5
RPS7
ITGA10
RPS9
KCTD2
SACM1L
LAMTOR4 SAP18
LIN37
SBDS
LSM14A SEC63
LYRM7
SEMA7A
MAGT1
SH3BGRL
MAP3K7 SLC39A9
MDH1B
SMNDC1
MLF2
SNRPG
MOB1A
SP9
MRPL19 SPTBN4
MRPL58 SSR4
MRPS18B SUCLG1
MTHFD2L TAF1D
MTRF1L TAPBPL
MYNN
TBC1D17
NKAP
TFPT
NOP16
TFRC
NPM1
TIMM17A
NSDHL
TMEM107
NTMT1
TMEM11
NUDT19 TMEM127
NUDT2
TMEM132B
OST4
TRIM41
PCMTD1 TSEN34
PCYOX1 TSPYL1
PHB
TSPYL4
PIBF1
TTC14
PLAA
TTC30B
PLCD3
TTC32
POFUT2 TXNDC9
POLR2H UBAC1

UPF3A
ZNF286A
ZNF697
ZNF792

Appendix table 8: Overlap of DYRK1A regulated genes (obtained by RNA-seq) with
DYRK1A ChIP-seq dataset [under Serum starved or Cycling conditions (Di Vona et al.,
2015)]. Related to Figure 49B.
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Up in DCAF7 overexpression and overlap with DYRK1A ChIP-seq
dataset
Serum starved +
Cycling (38 genes)
ADAT1
MAK16
ASH2L
MAPK14
ASPH
MICU2
C1orf74
MRPL57
C6orf89
MYO19
CHAF1A NCAPG2
COPB2
NOP14
DBR1
NPR3
DCAF16 PGK1
DHX37
PIGW
EFHC1
PLOD2
FLNA
PTRH2
GMPPA SEC22C
GORASP2 SETD5
HSD17B8 SKA3
HSPH1
SLC39A7
LAMP1
SS18L2
LSM3
SSR1
MAGOHB TMEM79

Serum starved
Cycling only (51 genes)
only (2 genes)
ABCC10 KPNA2 SIRT5
CNN2
CARMIL1 LOXL2
SLC44A1 GGH
CETN2
MAD2L1 SNRPC
COL1A2 MRPS18B SPTY2D1
DHX8
MYBL2 TADA3
DIS3
NCOA7 TFRC
DZIP3
NOP16
TP53
FAM216A NUDT5
TRIM27
FGF1
PDE12
UBXN11
FKBPL
PFDN6
WDR46
FUS
PHB
WDR90
GDI2
POFUT2 ZNF697
GOLGA8B POLR1C ZNF790
HMGN5 PSMB2
IGFBP3
RAD18
INTS9
RBM26
KANK1
RFC3
KBTBD6 SAP18
KIF24
SEMA3B

Dn in DCAF7 overexpression and overlap with DYRK1A
ChIP-seq dataset
Serum starved +
Cycling (39 genes)
AGBL5
PTPRN2
ALDH16A1 RC3H2
ATF4
RIMS3
BANP
RPL13A
C2orf68
RPL27A
CDC25B
RPL4
CENPB
RPL7A
CHST7
RPS11
CYGB
RPS16
ECHS1
SFXN3
FAM135A SLC12A2
FBXO31
SLC25A11
FOXC2
SNX33
GLCE
SURF1
HERC1
SURF2
KAZALD1 YPEL4
LPXN
LRRC28
MIF4GD
PAOX
PAXBP1
PCGF2
POLDIP3

Cycling only (67 genes)
ACADSB EIF3L
RIN1
ADGRF1 EPHB3
RPS7
AIDA
FOXG1
SLC12A9
ATF7
GSN
SLC39A9
B4GAT1
HDAC10 SMARCC2
C11orf54 HDAC6
SMARCD2
C12orf57 IKZF5
SMNDC1
CAMK2D ITGA10 SNAI1
CCNJ
LRFN3
TFPT
CHUK
LSM14A TIA1
CLASP1
LY6G5C TMEM127
CNIH2
MBLAC1 TROAP
CNPY2
NFIB
TSPYL1
COL1A1
NUDT19 TSPYL4
CREBZF
P2RX6
TTC32
CTNNBIP1 PCYOX1 TUBGCP6
DLX1
PHC2
U2AF1L4
DUSP4
PLCD3
UBAC1
EBF1
PLEKHG2 VAMP1
EDRF1
PROSER3 ZFP36
EFNA5
PSENEN ZNF792
EID2
PTCH2
EID2B
RAB27A

Appendix table 9: Overlap of DCAF7 regulated genes (obtained by RNA-seq) with
DYRK1A ChIP-seq dataset [under Serum starved or Cycling conditions (Di Vona et al.,
2015)]. Related to Figure 50A and 50B.
Overlap of DYRK1A Chip-Seq dataset with AUTS2 ChIP-seq dataset

Serum starved + Cycling (31 genes)
ALDH16A1
MED1
RPL17
ARF3
MED22
RPL17-C18orf32
ATF4
METTL16
RPL7A
C18orf32
MYO19
RPS16
C5orf24
NCAPG2
RPS28
CCNG1
NDUFA7
SUPT5H
CCT8
NOL9
TAS1R1
DNTTIP2
PIGW
TMEM245
IREB2
PIH1D1
UBC
LRSAM1
PPCDC
MAP3K7CL
RPL12

Cycling only (33 genes)
ACTRT3
MTRNR2L1 RPS15
BCLAF1
MYNN
SMC5
C19orf53
NDUFA11 SNRPG
CNPY2
NUDT19
TIMM17A
DRG1
PICK1
U2AF1L4
DSE
PKLR
VMAC
FDPS
PLEKHG2 VPS8
GTF3C5
POLR1C
YIPF3
GUK1
PPM1G
ZFP36
HOXC5
PSENEN
ZNF345
LIN37
PSMB2
ZNF790

Serum starved
only (1 gene)
TRAPPC6B

Appendix table 10: Overlap of genes bound by AUTS2 and genes bound by DYRK1A
[under Cycling or Serum starved conditions (Di Vona et al., 2015)]. Related to Figure 51.
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